id	sid	tid	token	lemma	pos
ajlm-2942	1	1	abstract	abstract	ADJ
ajlm-2942	1	2	introduction	introduction	NOUN
ajlm-2942	1	3	methods	method	NOUN
ajlm-2942	1	4	results	result	VERB
ajlm-2942	1	5	discussion	discussion	NOUN
ajlm-2942	1	6	acknowledgements	acknowledgement	NOUN
ajlm-2942	1	7	references	reference	NOUN
ajlm-2942	1	8	about	about	ADP
ajlm-2942	1	9	the	the	DET
ajlm-2942	1	10	author(s	author(s	NOUN
ajlm-2942	1	11	)	)	PUNCT
ajlm-2942	1	12	promise	promise	VERB
ajlm-2942	1	13	c.	c.	PROPN
ajlm-2942	1	14	nwaejigh	nwaejigh	PROPN
ajlm-2942	1	15	department	department	PROPN
ajlm-2942	1	16	of	of	ADP
ajlm-2942	1	17	medical	medical	ADJ
ajlm-2942	1	18	laboratory	laboratory	NOUN
ajlm-2942	1	19	science	science	NOUN
ajlm-2942	1	20	,	,	PUNCT
ajlm-2942	1	21	school	school	NOUN
ajlm-2942	1	22	of	of	ADP
ajlm-2942	1	23	allied	ally	VERB
ajlm-2942	1	24	health	health	NOUN
ajlm-2942	1	25	sciences	sciences	PROPN
ajlm-2942	1	26	,	,	PUNCT
ajlm-2942	1	27	babcock	babcock	PROPN
ajlm-2942	1	28	university	university	PROPN
ajlm-2942	1	29	,	,	PUNCT
ajlm-2942	1	30	ilishan	ilishan	NOUN
ajlm-2942	1	31	-	-	PUNCT
ajlm-2942	1	32	remo	remo	NOUN
ajlm-2942	1	33	,	,	PUNCT
ajlm-2942	1	34	nigeria	nigeria	PROPN
ajlm-2942	1	35	maria	maria	PROPN
ajlm-2942	1	36	o.	o.	PROPN
ajlm-2942	2	1	ebesunun	ebesunun	PROPN
ajlm-2942	2	2	department	department	PROPN
ajlm-2942	2	3	of	of	ADP
ajlm-2942	2	4	medical	medical	ADJ
ajlm-2942	2	5	laboratory	laboratory	NOUN
ajlm-2942	2	6	science	science	NOUN
ajlm-2942	2	7	,	,	PUNCT
ajlm-2942	2	8	faculty	faculty	NOUN
ajlm-2942	2	9	of	of	ADP
ajlm-2942	2	10	basic	basic	ADJ
ajlm-2942	2	11	medical	medical	ADJ
ajlm-2942	2	12	sciences	science	NOUN
ajlm-2942	2	13	,	,	PUNCT
ajlm-2942	2	14	olabisi	olabisi	ADJ
ajlm-2942	2	15	onabanjo	onabanjo	PROPN
ajlm-2942	2	16	university	university	PROPN
ajlm-2942	2	17	,	,	PUNCT
ajlm-2942	2	18	sagamu	sagamu	PROPN
ajlm-2942	2	19	,	,	PUNCT
ajlm-2942	2	20	nigeria	nigeria	PROPN
ajlm-2942	2	21	stephen	stephen	PROPN
ajlm-2942	2	22	s.	s.	PROPN
ajlm-2942	2	23	udofia	udofia	PROPN
ajlm-2942	2	24	department	department	PROPN
ajlm-2942	2	25	of	of	ADP
ajlm-2942	2	26	medical	medical	ADJ
ajlm-2942	2	27	laboratory	laboratory	NOUN
ajlm-2942	2	28	science	science	NOUN
ajlm-2942	2	29	,	,	PUNCT
ajlm-2942	2	30	school	school	NOUN
ajlm-2942	2	31	of	of	ADP
ajlm-2942	2	32	allied	ally	VERB
ajlm-2942	2	33	health	health	NOUN
ajlm-2942	2	34	sciences	sciences	PROPN
ajlm-2942	2	35	,	,	PUNCT
ajlm-2942	2	36	babcock	babcock	PROPN
ajlm-2942	2	37	university	university	PROPN
ajlm-2942	2	38	,	,	PUNCT
ajlm-2942	2	39	ilishan	ilishan	NOUN
ajlm-2942	2	40	-	-	PUNCT
ajlm-2942	2	41	remo	remo	NOUN
ajlm-2942	2	42	,	,	PUNCT
ajlm-2942	2	43	nigeria	nigeria	PROPN
ajlm-2942	2	44	adebusola	adebusola	PROPN
ajlm-2942	2	45	a.	a.	PROPN
ajlm-2942	2	46	shakunle	shakunle	PROPN
ajlm-2942	2	47	department	department	PROPN
ajlm-2942	2	48	of	of	ADP
ajlm-2942	2	49	obstetrics	obstetric	NOUN
ajlm-2942	2	50	and	and	CCONJ
ajlm-2942	2	51	gynaecology	gynaecology	NOUN
ajlm-2942	2	52	,	,	PUNCT
ajlm-2942	2	53	lagos	lagos	NOUN
ajlm-2942	2	54	state	state	PROPN
ajlm-2942	2	55	university	university	PROPN
ajlm-2942	2	56	college	college	NOUN
ajlm-2942	2	57	of	of	ADP
ajlm-2942	2	58	medicine	medicine	NOUN
ajlm-2942	2	59	,	,	PUNCT
ajlm-2942	2	60	ikeja	ikeja	PROPN
ajlm-2942	2	61	,	,	PUNCT
ajlm-2942	2	62	nigeria	nigeria	PROPN
ajlm-2942	2	63	citation	citation	PROPN
ajlm-2942	2	64	nwaejigh	nwaejigh	PROPN
ajlm-2942	2	65	pc	pc	PROPN
ajlm-2942	2	66	,	,	PUNCT
ajlm-2942	2	67	ebesunun	ebesunun	PROPN
ajlm-2942	2	68	mo	mo	PROPN
ajlm-2942	2	69	,	,	PUNCT
ajlm-2942	2	70	udofia	udofia	PROPN
ajlm-2942	2	71	ss	ss	PROPN
ajlm-2942	2	72	,	,	PUNCT
ajlm-2942	2	73	shakunle	shakunle	PROPN
ajlm-2942	2	74	aa	aa	NOUN
ajlm-2942	2	75	.	.	PUNCT
ajlm-2942	3	1	apolipoproteins	apolipoprotein	NOUN
ajlm-2942	3	2	and	and	CCONJ
ajlm-2942	3	3	high	high	ADJ
ajlm-2942	3	4	-	-	PUNCT
ajlm-2942	3	5	density	density	NOUN
ajlm-2942	3	6	lipoprotein	lipoprotein	ADJ
ajlm-2942	3	7	phospholipids	phospholipid	NOUN
ajlm-2942	3	8	as	as	ADP
ajlm-2942	3	9	indicators	indicator	NOUN
ajlm-2942	3	10	of	of	ADP
ajlm-2942	3	11	atherosclerotic	atherosclerotic	ADJ
ajlm-2942	3	12	cardiovascular	cardiovascular	ADJ
ajlm-2942	3	13	disease	disease	NOUN
ajlm-2942	3	14	in	in	ADP
ajlm-2942	3	15	nigeria	nigeria	PROPN
ajlm-2942	3	16	.	.	PUNCT
ajlm-2942	4	1	afr	afr	PROPN
ajlm-2942	4	2	j	j	PROPN
ajlm-2942	4	3	lab	lab	PROPN
ajlm-2942	4	4	med	med	PROPN
ajlm-2942	4	5	.	.	PUNCT
ajlm-2942	5	1	2025;14(1	2025;14(1	NUM
ajlm-2942	5	2	)	)	PUNCT
ajlm-2942	5	3	,	,	PUNCT
ajlm-2942	6	1	a2942	a2942	NOUN
ajlm-2942	6	2	.	.	PUNCT
ajlm-2942	6	3	https://doi.org/10.4102/ajlm.v14i1.2942	https://doi.org/10.4102/ajlm.v14i1.2942	NUM
ajlm-2942	6	4	note	note	VERB
ajlm-2942	6	5	:	:	PUNCT
ajlm-2942	6	6	additional	additional	ADJ
ajlm-2942	6	7	supporting	support	VERB
ajlm-2942	6	8	information	information	NOUN
ajlm-2942	6	9	is	be	AUX
ajlm-2942	6	10	available	available	ADJ
ajlm-2942	6	11	for	for	ADP
ajlm-2942	6	12	download	download	NOUN
ajlm-2942	6	13	alongside	alongside	ADP
ajlm-2942	6	14	the	the	DET
ajlm-2942	6	15	online	online	ADJ
ajlm-2942	6	16	version	version	NOUN
ajlm-2942	6	17	of	of	ADP
ajlm-2942	6	18	this	this	DET
ajlm-2942	6	19	article	article	NOUN
ajlm-2942	6	20	as	as	ADP
ajlm-2942	6	21	online	online	ADJ
ajlm-2942	6	22	supplementary	supplementary	ADJ
ajlm-2942	6	23	document	document	NOUN
ajlm-2942	6	24	1	1	NUM
ajlm-2942	6	25	.	.	PUNCT
ajlm-2942	6	26	original	original	ADJ
ajlm-2942	6	27	research	research	NOUN
ajlm-2942	6	28	apolipoproteins	apolipoprotein	NOUN
ajlm-2942	6	29	and	and	CCONJ
ajlm-2942	6	30	high	high	ADJ
ajlm-2942	6	31	-	-	PUNCT
ajlm-2942	6	32	density	density	NOUN
ajlm-2942	6	33	lipoprotein	lipoprotein	ADJ
ajlm-2942	6	34	phospholipids	phospholipid	NOUN
ajlm-2942	6	35	as	as	ADP
ajlm-2942	6	36	indicators	indicator	NOUN
ajlm-2942	6	37	of	of	ADP
ajlm-2942	6	38	atherosclerotic	atherosclerotic	ADJ
ajlm-2942	6	39	cardiovascular	cardiovascular	ADJ
ajlm-2942	6	40	disease	disease	NOUN
ajlm-2942	6	41	in	in	ADP
ajlm-2942	6	42	nigeria	nigeria	PROPN
ajlm-2942	6	43	promise	promise	VERB
ajlm-2942	6	44	c.	c.	PROPN
ajlm-2942	6	45	nwaejigh	nwaejigh	PROPN
ajlm-2942	6	46	,	,	PUNCT
ajlm-2942	6	47	maria	maria	PROPN
ajlm-2942	6	48	o.	o.	PROPN
ajlm-2942	6	49	ebesunun	ebesunun	PROPN
ajlm-2942	6	50	,	,	PUNCT
ajlm-2942	6	51	stephen	stephen	PROPN
ajlm-2942	6	52	s.	s.	PROPN
ajlm-2942	6	53	udofia	udofia	PROPN
ajlm-2942	6	54	,	,	PUNCT
ajlm-2942	6	55	adebusola	adebusola	PROPN
ajlm-2942	6	56	a.	a.	PROPN
ajlm-2942	6	57	shakunle	shakunle	PROPN
ajlm-2942	6	58	received	receive	VERB
ajlm-2942	6	59	:	:	PUNCT
ajlm-2942	6	60	15	15	NUM
ajlm-2942	6	61	july	july	NOUN
ajlm-2942	6	62	2025	2025	NUM
ajlm-2942	6	63	;	;	PUNCT
ajlm-2942	6	64	accepted	accept	VERB
ajlm-2942	6	65	:	:	PUNCT
ajlm-2942	6	66	05	05	NUM
ajlm-2942	6	67	nov	nov	PROPN
ajlm-2942	6	68	.	.	PROPN
ajlm-2942	6	69	2025	2025	NUM
ajlm-2942	6	70	;	;	PUNCT
ajlm-2942	6	71	published	publish	VERB
ajlm-2942	6	72	:	:	PUNCT
ajlm-2942	6	73	17	17	NUM
ajlm-2942	6	74	dec	dec	PROPN
ajlm-2942	6	75	.	.	PROPN
ajlm-2942	7	1	2025	2025	NUM
ajlm-2942	7	2	copyright	copyright	NOUN
ajlm-2942	7	3	:	:	PUNCT
ajlm-2942	7	4	©	©	PROPN
ajlm-2942	7	5	2025	2025	NUM
ajlm-2942	7	6	.	.	PUNCT
ajlm-2942	8	1	the	the	DET
ajlm-2942	8	2	author(s	author(s	PROPN
ajlm-2942	8	3	)	)	PUNCT
ajlm-2942	8	4	.	.	PUNCT
ajlm-2942	9	1	licensee	licensee	NOUN
ajlm-2942	9	2	:	:	PUNCT
ajlm-2942	9	3	aosis	aosis	NOUN
ajlm-2942	9	4	.	.	PUNCT
ajlm-2942	10	1	this	this	DET
ajlm-2942	10	2	work	work	NOUN
ajlm-2942	10	3	is	be	AUX
ajlm-2942	10	4	licensed	license	VERB
ajlm-2942	10	5	under	under	ADP
ajlm-2942	10	6	the	the	DET
ajlm-2942	10	7	creative	creative	ADJ
ajlm-2942	10	8	commons	common	NOUN
ajlm-2942	10	9	attribution	attribution	NOUN
ajlm-2942	10	10	4.0	4.0	NUM
ajlm-2942	10	11	international	international	NOUN
ajlm-2942	10	12	(	(	PUNCT
ajlm-2942	10	13	cc	cc	NOUN
ajlm-2942	10	14	by	by	ADP
ajlm-2942	10	15	4.0	4.0	NUM
ajlm-2942	10	16	)	)	PUNCT
ajlm-2942	10	17	license	license	NOUN
ajlm-2942	10	18	(	(	PUNCT
ajlm-2942	10	19	https://creativecommons.org/licenses/by/4.0/	https://creativecommons.org/licenses/by/4.0/	PROPN
ajlm-2942	10	20	)	)	PUNCT
ajlm-2942	10	21	.	.	PUNCT
ajlm-2942	11	1	abstract	abstract	ADJ
ajlm-2942	11	2	background	background	NOUN
ajlm-2942	11	3	:	:	PUNCT
ajlm-2942	11	4	altered	alter	VERB
ajlm-2942	11	5	apolipoproteins	apolipoprotein	NOUN
ajlm-2942	11	6	and	and	CCONJ
ajlm-2942	11	7	high	high	ADJ
ajlm-2942	11	8	-	-	PUNCT
ajlm-2942	11	9	density	density	NOUN
ajlm-2942	11	10	lipoprotein	lipoprotein	ADJ
ajlm-2942	11	11	(	(	PUNCT
ajlm-2942	11	12	hdl	hdl	NOUN
ajlm-2942	11	13	)	)	PUNCT
ajlm-2942	11	14	phospholipids	phospholipid	NOUN
ajlm-2942	11	15	are	be	AUX
ajlm-2942	11	16	linked	link	VERB
ajlm-2942	11	17	to	to	ADP
ajlm-2942	11	18	premature	premature	VERB
ajlm-2942	11	19	atherosclerotic	atherosclerotic	ADJ
ajlm-2942	11	20	cardiovascular	cardiovascular	ADJ
ajlm-2942	11	21	disease	disease	NOUN
ajlm-2942	11	22	(	(	PUNCT
ajlm-2942	11	23	ascvd	ascvd	NOUN
ajlm-2942	11	24	)	)	PUNCT
ajlm-2942	11	25	.	.	PUNCT
ajlm-2942	12	1	objective	objective	NOUN
ajlm-2942	12	2	:	:	PUNCT
ajlm-2942	12	3	this	this	DET
ajlm-2942	12	4	study	study	NOUN
ajlm-2942	12	5	investigated	investigate	VERB
ajlm-2942	12	6	associations	association	NOUN
ajlm-2942	12	7	between	between	ADP
ajlm-2942	12	8	plasma	plasma	NOUN
ajlm-2942	12	9	apolipoprotein	apolipoprotein	ADJ
ajlm-2942	12	10	a1	a1	PROPN
ajlm-2942	12	11	,	,	PUNCT
ajlm-2942	12	12	apolipoprotein	apolipoprotein	ADJ
ajlm-2942	12	13	b	b	PROPN
ajlm-2942	12	14	,	,	PUNCT
ajlm-2942	12	15	hdl	hdl	PROPN
ajlm-2942	12	16	phospholipids	phospholipids	PROPN
ajlm-2942	12	17	,	,	PUNCT
ajlm-2942	12	18	and	and	CCONJ
ajlm-2942	12	19	ascvd	ascvd	VERB
ajlm-2942	12	20	risk	risk	NOUN
ajlm-2942	12	21	in	in	ADP
ajlm-2942	12	22	nigeria	nigeria	PROPN
ajlm-2942	12	23	,	,	PUNCT
ajlm-2942	12	24	assessing	assess	VERB
ajlm-2942	12	25	their	their	PRON
ajlm-2942	12	26	potential	potential	NOUN
ajlm-2942	12	27	as	as	ADP
ajlm-2942	12	28	early	early	ADJ
ajlm-2942	12	29	diagnostic	diagnostic	ADJ
ajlm-2942	12	30	markers	marker	NOUN
ajlm-2942	12	31	.	.	PUNCT
ajlm-2942	13	1	methods	method	NOUN
ajlm-2942	13	2	:	:	PUNCT
ajlm-2942	13	3	this	this	DET
ajlm-2942	13	4	cross	cross	ADJ
ajlm-2942	13	5	-	-	ADJ
ajlm-2942	13	6	sectional	sectional	ADJ
ajlm-2942	13	7	case	case	NOUN
ajlm-2942	13	8	-	-	PUNCT
ajlm-2942	13	9	control	control	NOUN
ajlm-2942	13	10	study	study	NOUN
ajlm-2942	13	11	was	be	AUX
ajlm-2942	13	12	conducted	conduct	VERB
ajlm-2942	13	13	from	from	ADP
ajlm-2942	13	14	november	november	PROPN
ajlm-2942	13	15	2021	2021	NUM
ajlm-2942	13	16	to	to	ADP
ajlm-2942	13	17	november	november	PROPN
ajlm-2942	13	18	2022	2022	NUM
ajlm-2942	13	19	at	at	ADP
ajlm-2942	13	20	lagos	lagos	PROPN
ajlm-2942	13	21	state	state	NOUN
ajlm-2942	13	22	university	university	PROPN
ajlm-2942	13	23	teaching	teaching	NOUN
ajlm-2942	13	24	hospital	hospital	NOUN
ajlm-2942	13	25	in	in	ADP
ajlm-2942	13	26	nigeria	nigeria	PROPN
ajlm-2942	13	27	.	.	PUNCT
ajlm-2942	14	1	atherosclerotic	atherosclerotic	ADJ
ajlm-2942	14	2	cardiovascular	cardiovascular	ADJ
ajlm-2942	14	3	disease	disease	NOUN
ajlm-2942	14	4	patients	patient	NOUN
ajlm-2942	14	5	and	and	CCONJ
ajlm-2942	14	6	healthy	healthy	ADJ
ajlm-2942	14	7	controls	control	NOUN
ajlm-2942	14	8	were	be	AUX
ajlm-2942	14	9	randomly	randomly	ADV
ajlm-2942	14	10	selected	select	VERB
ajlm-2942	14	11	.	.	PUNCT
ajlm-2942	15	1	the	the	DET
ajlm-2942	15	2	plasma	plasma	NOUN
ajlm-2942	15	3	apolipoprotein	apolipoprotein	VERB
ajlm-2942	15	4	a1	a1	PROPN
ajlm-2942	15	5	and	and	CCONJ
ajlm-2942	15	6	b	b	NOUN
ajlm-2942	15	7	levels	level	NOUN
ajlm-2942	15	8	were	be	AUX
ajlm-2942	15	9	determined	determine	VERB
ajlm-2942	15	10	via	via	ADP
ajlm-2942	15	11	a	a	DET
ajlm-2942	15	12	sandwich	sandwich	NOUN
ajlm-2942	15	13	enzyme	enzyme	NOUN
ajlm-2942	15	14	-	-	PUNCT
ajlm-2942	15	15	linked	link	VERB
ajlm-2942	15	16	immunosorbent	immunosorbent	NOUN
ajlm-2942	15	17	assay	assay	NOUN
ajlm-2942	15	18	,	,	PUNCT
ajlm-2942	15	19	and	and	CCONJ
ajlm-2942	15	20	the	the	DET
ajlm-2942	15	21	lipid	lipid	NOUN
ajlm-2942	15	22	profile	profile	NOUN
ajlm-2942	15	23	was	be	AUX
ajlm-2942	15	24	measured	measure	VERB
ajlm-2942	15	25	via	via	ADP
ajlm-2942	15	26	spectrophotometry	spectrophotometry	NOUN
ajlm-2942	15	27	.	.	PUNCT
ajlm-2942	16	1	statistical	statistical	ADJ
ajlm-2942	16	2	analyses	analysis	NOUN
ajlm-2942	16	3	included	include	VERB
ajlm-2942	16	4	t	t	NOUN
ajlm-2942	16	5	-	-	PUNCT
ajlm-2942	16	6	tests	test	NOUN
ajlm-2942	16	7	,	,	PUNCT
ajlm-2942	16	8	analysis	analysis	NOUN
ajlm-2942	16	9	of	of	ADP
ajlm-2942	16	10	variance	variance	NOUN
ajlm-2942	16	11	,	,	PUNCT
ajlm-2942	16	12	analysis	analysis	NOUN
ajlm-2942	16	13	of	of	ADP
ajlm-2942	16	14	covariance	covariance	NOUN
ajlm-2942	16	15	,	,	PUNCT
ajlm-2942	16	16	and	and	CCONJ
ajlm-2942	16	17	pearson	pearson	PROPN
ajlm-2942	16	18	’s	’s	PART
ajlm-2942	16	19	correlation	correlation	NOUN
ajlm-2942	16	20	.	.	PUNCT
ajlm-2942	17	1	results	result	NOUN
ajlm-2942	17	2	:	:	PUNCT
ajlm-2942	17	3	in	in	ADP
ajlm-2942	17	4	total	total	NOUN
ajlm-2942	17	5	,	,	PUNCT
ajlm-2942	17	6	172	172	NUM
ajlm-2942	17	7	confirmed	confirm	VERB
ajlm-2942	17	8	ascvd	ascvd	NOUN
ajlm-2942	17	9	patients	patient	NOUN
ajlm-2942	17	10	(	(	PUNCT
ajlm-2942	17	11	mean	mean	INTJ
ajlm-2942	17	12	age	age	NOUN
ajlm-2942	17	13	:	:	PUNCT
ajlm-2942	17	14	54.01	54.01	NUM
ajlm-2942	17	15	±	±	NUM
ajlm-2942	17	16	8.70	8.70	NUM
ajlm-2942	17	17	years	year	NOUN
ajlm-2942	17	18	)	)	PUNCT
ajlm-2942	17	19	and	and	CCONJ
ajlm-2942	17	20	55	55	NUM
ajlm-2942	17	21	healthy	healthy	ADJ
ajlm-2942	17	22	controls	control	NOUN
ajlm-2942	17	23	(	(	PUNCT
ajlm-2942	17	24	mean	mean	INTJ
ajlm-2942	17	25	age	age	NOUN
ajlm-2942	17	26	:	:	PUNCT
ajlm-2942	17	27	44.55	44.55	NUM
ajlm-2942	17	28	±	±	NUM
ajlm-2942	17	29	11.60	11.60	NUM
ajlm-2942	17	30	years	year	NOUN
ajlm-2942	17	31	)	)	PUNCT
ajlm-2942	17	32	were	be	AUX
ajlm-2942	17	33	included	include	VERB
ajlm-2942	17	34	in	in	ADP
ajlm-2942	17	35	the	the	DET
ajlm-2942	17	36	analyses	analysis	NOUN
ajlm-2942	17	37	.	.	PUNCT
ajlm-2942	18	1	compared	compare	VERB
ajlm-2942	18	2	with	with	ADP
ajlm-2942	18	3	the	the	DET
ajlm-2942	18	4	control	control	NOUN
ajlm-2942	18	5	values	value	NOUN
ajlm-2942	18	6	,	,	PUNCT
ajlm-2942	18	7	ascvd	ascvd	NOUN
ajlm-2942	18	8	patients	patient	NOUN
ajlm-2942	18	9	showed	show	VERB
ajlm-2942	18	10	significantly	significantly	ADV
ajlm-2942	18	11	elevated	elevated	ADJ
ajlm-2942	18	12	apolipoprotein	apolipoprotein	ADJ
ajlm-2942	18	13	b	b	PROPN
ajlm-2942	18	14	,	,	PUNCT
ajlm-2942	18	15	apolipoprotein	apolipoprotein	ADJ
ajlm-2942	18	16	b	b	X
ajlm-2942	18	17	/	/	SYM
ajlm-2942	18	18	a1	a1	NOUN
ajlm-2942	18	19	ratio	ratio	NOUN
ajlm-2942	18	20	,	,	PUNCT
ajlm-2942	18	21	atherogenic	atherogenic	ADJ
ajlm-2942	18	22	lipid	lipid	NOUN
ajlm-2942	18	23	indices	index	NOUN
ajlm-2942	18	24	,	,	PUNCT
ajlm-2942	18	25	total	total	ADJ
ajlm-2942	18	26	cholesterol	cholesterol	NOUN
ajlm-2942	18	27	,	,	PUNCT
ajlm-2942	18	28	low	low	ADJ
ajlm-2942	18	29	-	-	PUNCT
ajlm-2942	18	30	density	density	NOUN
ajlm-2942	18	31	lipoprotein	lipoprotein	ADJ
ajlm-2942	18	32	cholesterol	cholesterol	NOUN
ajlm-2942	18	33	,	,	PUNCT
ajlm-2942	18	34	non	non	ADJ
ajlm-2942	18	35	-	-	ADJ
ajlm-2942	18	36	hdl	hdl	ADJ
ajlm-2942	18	37	cholesterol	cholesterol	NOUN
ajlm-2942	18	38	,	,	PUNCT
ajlm-2942	18	39	and	and	CCONJ
ajlm-2942	18	40	triglycerides	triglyceride	NOUN
ajlm-2942	18	41	(	(	PUNCT
ajlm-2942	18	42	p	p	NOUN
ajlm-2942	18	43	≤	≤	NUM
ajlm-2942	18	44	0.001	0.001	NUM
ajlm-2942	18	45	)	)	PUNCT
ajlm-2942	18	46	.	.	PUNCT
ajlm-2942	19	1	in	in	ADP
ajlm-2942	19	2	contrast	contrast	NOUN
ajlm-2942	19	3	,	,	PUNCT
ajlm-2942	19	4	plasma	plasma	NOUN
ajlm-2942	19	5	hdl	hdl	PROPN
ajlm-2942	19	6	phospholipids	phospholipids	PROPN
ajlm-2942	19	7	,	,	PUNCT
ajlm-2942	19	8	apolipoprotein	apolipoprotein	ADJ
ajlm-2942	19	9	a1	a1	PROPN
ajlm-2942	19	10	,	,	PUNCT
ajlm-2942	19	11	and	and	CCONJ
ajlm-2942	19	12	hdl	hdl	PROPN
ajlm-2942	19	13	cholesterol	cholesterol	NOUN
ajlm-2942	19	14	were	be	AUX
ajlm-2942	19	15	markedly	markedly	ADV
ajlm-2942	19	16	lower	low	ADJ
ajlm-2942	19	17	(	(	PUNCT
ajlm-2942	19	18	p	p	NOUN
ajlm-2942	19	19	≤	≤	NUM
ajlm-2942	19	20	0.001	0.001	NUM
ajlm-2942	19	21	)	)	PUNCT
ajlm-2942	19	22	.	.	PUNCT
ajlm-2942	20	1	conclusion	conclusion	NOUN
ajlm-2942	20	2	:	:	PUNCT
ajlm-2942	20	3	these	these	DET
ajlm-2942	20	4	findings	finding	NOUN
ajlm-2942	20	5	indicate	indicate	VERB
ajlm-2942	20	6	that	that	SCONJ
ajlm-2942	20	7	altered	alter	VERB
ajlm-2942	20	8	apolipoproteins	apolipoprotein	NOUN
ajlm-2942	20	9	and	and	CCONJ
ajlm-2942	20	10	hdl	hdl	PROPN
ajlm-2942	20	11	phospholipids	phospholipid	NOUN
ajlm-2942	20	12	are	be	AUX
ajlm-2942	20	13	associated	associate	VERB
ajlm-2942	20	14	with	with	ADP
ajlm-2942	20	15	premature	premature	ADJ
ajlm-2942	20	16	ascvd	ascvd	NOUN
ajlm-2942	20	17	risk	risk	NOUN
ajlm-2942	20	18	,	,	PUNCT
ajlm-2942	20	19	with	with	ADP
ajlm-2942	20	20	the	the	DET
ajlm-2942	20	21	apolipoprotein	apolipoprotein	ADJ
ajlm-2942	20	22	b	b	PROPN
ajlm-2942	20	23	/	/	SYM
ajlm-2942	20	24	a1	a1	NOUN
ajlm-2942	20	25	ratio	ratio	NOUN
ajlm-2942	20	26	emerging	emerge	VERB
ajlm-2942	20	27	as	as	ADP
ajlm-2942	20	28	a	a	DET
ajlm-2942	20	29	superior	superior	ADJ
ajlm-2942	20	30	marker	marker	NOUN
ajlm-2942	20	31	for	for	ADP
ajlm-2942	20	32	disease	disease	NOUN
ajlm-2942	20	33	stratification	stratification	NOUN
ajlm-2942	20	34	.	.	PUNCT
ajlm-2942	21	1	what	what	PRON
ajlm-2942	21	2	this	this	DET
ajlm-2942	21	3	study	study	NOUN
ajlm-2942	21	4	adds	add	VERB
ajlm-2942	21	5	:	:	PUNCT
ajlm-2942	21	6	this	this	DET
ajlm-2942	21	7	study	study	NOUN
ajlm-2942	21	8	identifies	identify	VERB
ajlm-2942	21	9	the	the	DET
ajlm-2942	21	10	apolipoprotein	apolipoprotein	ADJ
ajlm-2942	21	11	b	b	PROPN
ajlm-2942	21	12	/	/	SYM
ajlm-2942	21	13	a1	a1	NOUN
ajlm-2942	21	14	ratio	ratio	NOUN
ajlm-2942	21	15	as	as	ADP
ajlm-2942	21	16	a	a	DET
ajlm-2942	21	17	strong	strong	ADJ
ajlm-2942	21	18	early	early	ADJ
ajlm-2942	21	19	marker	marker	NOUN
ajlm-2942	21	20	of	of	ADP
ajlm-2942	21	21	ascvd	ascvd	NOUN
ajlm-2942	21	22	risk	risk	NOUN
ajlm-2942	21	23	in	in	ADP
ajlm-2942	21	24	nigeria	nigeria	PROPN
ajlm-2942	21	25	.	.	PUNCT
ajlm-2942	22	1	keywords	keyword	NOUN
ajlm-2942	22	2	:	:	PUNCT
ajlm-2942	22	3	atherosclerotic	atherosclerotic	ADJ
ajlm-2942	22	4	cardiovascular	cardiovascular	ADJ
ajlm-2942	22	5	disease	disease	NOUN
ajlm-2942	22	6	;	;	PUNCT
ajlm-2942	22	7	apolipoprotein	apolipoprotein	ADJ
ajlm-2942	22	8	a1	a1	PROPN
ajlm-2942	22	9	;	;	PUNCT
ajlm-2942	22	10	apolipoprotein	apolipoprotein	ADJ
ajlm-2942	22	11	b	b	X
ajlm-2942	22	12	;	;	PUNCT
ajlm-2942	22	13	apolipoprotein	apolipoprotein	ADJ
ajlm-2942	22	14	b	b	X
ajlm-2942	22	15	/	/	SYM
ajlm-2942	22	16	a1	a1	NOUN
ajlm-2942	22	17	ratio	ratio	NOUN
ajlm-2942	22	18	;	;	PUNCT
ajlm-2942	22	19	hdl	hdl	PROPN
ajlm-2942	22	20	phospholipids	phospholipids	PROPN
ajlm-2942	22	21	;	;	PUNCT
ajlm-2942	22	22	lipid	lipid	NOUN
ajlm-2942	22	23	profile	profile	NOUN
ajlm-2942	22	24	.	.	PUNCT
ajlm-2942	23	1	introduction	introduction	NOUN
ajlm-2942	23	2	atherosclerotic	atherosclerotic	ADJ
ajlm-2942	23	3	cardiovascular	cardiovascular	ADJ
ajlm-2942	23	4	disease	disease	NOUN
ajlm-2942	23	5	(	(	PUNCT
ajlm-2942	23	6	ascvd	ascvd	NOUN
ajlm-2942	23	7	)	)	PUNCT
ajlm-2942	23	8	represents	represent	VERB
ajlm-2942	23	9	a	a	DET
ajlm-2942	23	10	significant	significant	ADJ
ajlm-2942	23	11	health	health	NOUN
ajlm-2942	23	12	challenge	challenge	NOUN
ajlm-2942	23	13	globally	globally	ADV
ajlm-2942	23	14	,	,	PUNCT
ajlm-2942	23	15	with	with	ADP
ajlm-2942	23	16	a	a	DET
ajlm-2942	23	17	rising	rise	VERB
ajlm-2942	23	18	incidence	incidence	NOUN
ajlm-2942	23	19	in	in	ADP
ajlm-2942	23	20	nigeria	nigeria	PROPN
ajlm-2942	23	21	and	and	CCONJ
ajlm-2942	23	22	other	other	ADJ
ajlm-2942	23	23	developing	develop	VERB
ajlm-2942	23	24	regions.1,2	regions.1,2	ADJ
ajlm-2942	23	25	high	high	ADJ
ajlm-2942	23	26	-	-	PUNCT
ajlm-2942	23	27	density	density	NOUN
ajlm-2942	23	28	lipoprotein	lipoprotein	ADJ
ajlm-2942	23	29	(	(	PUNCT
ajlm-2942	23	30	hdl	hdl	NOUN
ajlm-2942	23	31	)	)	PUNCT
ajlm-2942	23	32	and	and	CCONJ
ajlm-2942	23	33	its	its	PRON
ajlm-2942	23	34	associated	associated	ADJ
ajlm-2942	23	35	apolipoproteins	apolipoprotein	NOUN
ajlm-2942	23	36	,	,	PUNCT
ajlm-2942	23	37	namely	namely	ADV
ajlm-2942	23	38	apolipoprotein	apolipoprotein	ADJ
ajlm-2942	23	39	a1	a1	NOUN
ajlm-2942	23	40	(	(	PUNCT
ajlm-2942	23	41	apo	apo	NOUN
ajlm-2942	23	42	a1	a1	PROPN
ajlm-2942	23	43	)	)	PUNCT
ajlm-2942	23	44	and	and	CCONJ
ajlm-2942	23	45	apolipoprotein	apolipoprotein	ADJ
ajlm-2942	23	46	b	b	PROPN
ajlm-2942	23	47	(	(	PUNCT
ajlm-2942	23	48	apo	apo	PROPN
ajlm-2942	23	49	b	b	PROPN
ajlm-2942	23	50	)	)	PUNCT
ajlm-2942	23	51	,	,	PUNCT
ajlm-2942	23	52	along	along	ADP
ajlm-2942	23	53	with	with	ADP
ajlm-2942	23	54	hdl	hdl	PROPN
ajlm-2942	23	55	phospholipids	phospholipids	PROPN
ajlm-2942	23	56	,	,	PUNCT
ajlm-2942	23	57	have	have	AUX
ajlm-2942	23	58	garnered	garner	VERB
ajlm-2942	23	59	considerable	considerable	ADJ
ajlm-2942	23	60	attention	attention	NOUN
ajlm-2942	23	61	for	for	ADP
ajlm-2942	23	62	their	their	PRON
ajlm-2942	23	63	intricate	intricate	ADJ
ajlm-2942	23	64	involvement	involvement	NOUN
ajlm-2942	23	65	in	in	ADP
ajlm-2942	23	66	ascvd	ascvd	NOUN
ajlm-2942	23	67	progression	progression	NOUN
ajlm-2942	23	68	.	.	PUNCT
ajlm-2942	24	1	although	although	SCONJ
ajlm-2942	24	2	research	research	NOUN
ajlm-2942	24	3	has	have	AUX
ajlm-2942	24	4	explored	explore	VERB
ajlm-2942	24	5	lipid	lipid	ADJ
ajlm-2942	24	6	dysregulation	dysregulation	NOUN
ajlm-2942	24	7	and	and	CCONJ
ajlm-2942	24	8	atherogenesis	atherogenesis	NOUN
ajlm-2942	24	9	extensively	extensively	ADV
ajlm-2942	24	10	,	,	PUNCT
ajlm-2942	24	11	most	most	ADJ
ajlm-2942	24	12	of	of	ADP
ajlm-2942	24	13	these	these	DET
ajlm-2942	24	14	studies	study	NOUN
ajlm-2942	24	15	have	have	AUX
ajlm-2942	24	16	focused	focus	VERB
ajlm-2942	24	17	predominantly	predominantly	ADV
ajlm-2942	24	18	on	on	ADP
ajlm-2942	24	19	populations	population	NOUN
ajlm-2942	24	20	from	from	ADP
ajlm-2942	24	21	western	western	ADJ
ajlm-2942	24	22	countries,3,4	countries,3,4	ADJ
ajlm-2942	24	23	and	and	CCONJ
ajlm-2942	24	24	asian	asian	ADJ
ajlm-2942	24	25	populations.5,6	populations.5,6	NOUN
ajlm-2942	24	26	however	however	ADV
ajlm-2942	24	27	,	,	PUNCT
ajlm-2942	24	28	it	it	PRON
ajlm-2942	24	29	is	be	AUX
ajlm-2942	24	30	imperative	imperative	ADJ
ajlm-2942	24	31	to	to	PART
ajlm-2942	24	32	recognise	recognise	VERB
ajlm-2942	24	33	the	the	DET
ajlm-2942	24	34	unique	unique	ADJ
ajlm-2942	24	35	genetic	genetic	ADJ
ajlm-2942	24	36	,	,	PUNCT
ajlm-2942	24	37	environmental	environmental	ADJ
ajlm-2942	24	38	,	,	PUNCT
ajlm-2942	24	39	cultural	cultural	ADJ
ajlm-2942	24	40	dietary	dietary	ADJ
ajlm-2942	24	41	habits	habit	NOUN
ajlm-2942	24	42	and	and	CCONJ
ajlm-2942	24	43	lifestyle	lifestyle	NOUN
ajlm-2942	24	44	factors	factor	NOUN
ajlm-2942	24	45	that	that	PRON
ajlm-2942	24	46	contribute	contribute	VERB
ajlm-2942	24	47	to	to	AUX
ajlm-2942	24	48	ascvd	ascvd	NOUN
ajlm-2942	24	49	susceptibility	susceptibility	NOUN
ajlm-2942	24	50	in	in	ADP
ajlm-2942	24	51	diverse	diverse	ADJ
ajlm-2942	24	52	ethnic	ethnic	ADJ
ajlm-2942	24	53	groups	group	NOUN
ajlm-2942	24	54	,	,	PUNCT
ajlm-2942	24	55	particularly	particularly	ADV
ajlm-2942	24	56	african	african	ADJ
ajlm-2942	24	57	populations	population	NOUN
ajlm-2942	24	58	.	.	PUNCT
ajlm-2942	25	1	nigeria	nigeria	PROPN
ajlm-2942	25	2	,	,	PUNCT
ajlm-2942	25	3	as	as	ADP
ajlm-2942	25	4	a	a	DET
ajlm-2942	25	5	key	key	ADJ
ajlm-2942	25	6	part	part	NOUN
ajlm-2942	25	7	of	of	ADP
ajlm-2942	25	8	africa	africa	PROPN
ajlm-2942	25	9	,	,	PUNCT
ajlm-2942	25	10	is	be	AUX
ajlm-2942	25	11	experiencing	experience	VERB
ajlm-2942	25	12	a	a	DET
ajlm-2942	25	13	growing	grow	VERB
ajlm-2942	25	14	ascvd	ascvd	NOUN
ajlm-2942	25	15	epidemic	epidemic	NOUN
ajlm-2942	25	16	as	as	ADP
ajlm-2942	25	17	a	a	DET
ajlm-2942	25	18	result	result	NOUN
ajlm-2942	25	19	of	of	ADP
ajlm-2942	25	20	urbanisation	urbanisation	NOUN
ajlm-2942	25	21	,	,	PUNCT
ajlm-2942	25	22	westernised	westernise	VERB
ajlm-2942	25	23	diets	diet	NOUN
ajlm-2942	25	24	and	and	CCONJ
ajlm-2942	25	25	changing	change	VERB
ajlm-2942	25	26	lifestyles.7,8	lifestyles.7,8	NOUN
ajlm-2942	25	27	despite	despite	SCONJ
ajlm-2942	25	28	the	the	DET
ajlm-2942	25	29	increase	increase	NOUN
ajlm-2942	25	30	in	in	ADP
ajlm-2942	25	31	ascvd	ascvd	NOUN
ajlm-2942	25	32	in	in	ADP
ajlm-2942	25	33	nigeria	nigeria	PROPN
ajlm-2942	25	34	and	and	CCONJ
ajlm-2942	25	35	africa	africa	PROPN
ajlm-2942	25	36	,	,	PUNCT
ajlm-2942	25	37	comprehensive	comprehensive	ADJ
ajlm-2942	25	38	studies	study	NOUN
ajlm-2942	25	39	are	be	AUX
ajlm-2942	25	40	scarce	scarce	ADJ
ajlm-2942	25	41	on	on	ADP
ajlm-2942	25	42	the	the	DET
ajlm-2942	25	43	specific	specific	ADJ
ajlm-2942	25	44	lipid	lipid	NOUN
ajlm-2942	25	45	profiles	profile	NOUN
ajlm-2942	25	46	associated	associate	VERB
ajlm-2942	25	47	with	with	ADP
ajlm-2942	25	48	atherosclerosis	atherosclerosis	NOUN
ajlm-2942	25	49	.	.	PUNCT
ajlm-2942	26	1	apolipoprotein	apolipoprotein	ADJ
ajlm-2942	26	2	a1	a1	PROPN
ajlm-2942	26	3	,	,	PUNCT
ajlm-2942	26	4	the	the	DET
ajlm-2942	26	5	major	major	ADJ
ajlm-2942	26	6	protein	protein	NOUN
ajlm-2942	26	7	component	component	NOUN
ajlm-2942	26	8	of	of	ADP
ajlm-2942	26	9	hdl	hdl	PROPN
ajlm-2942	26	10	,	,	PUNCT
ajlm-2942	26	11	is	be	AUX
ajlm-2942	26	12	integral	integral	ADJ
ajlm-2942	26	13	to	to	ADP
ajlm-2942	26	14	the	the	DET
ajlm-2942	26	15	process	process	NOUN
ajlm-2942	26	16	of	of	ADP
ajlm-2942	26	17	reverse	reverse	ADJ
ajlm-2942	26	18	cholesterol	cholesterol	NOUN
ajlm-2942	26	19	transport,9,10	transport,9,10	NOUN
ajlm-2942	26	20	exerting	exert	VERB
ajlm-2942	26	21	anti	anti	ADJ
ajlm-2942	26	22	-	-	ADJ
ajlm-2942	26	23	inflammatory	inflammatory	ADJ
ajlm-2942	26	24	and	and	CCONJ
ajlm-2942	26	25	antioxidant	antioxidant	ADJ
ajlm-2942	26	26	effects	effect	NOUN
ajlm-2942	26	27	that	that	PRON
ajlm-2942	26	28	confer	confer	VERB
ajlm-2942	26	29	protection	protection	NOUN
ajlm-2942	26	30	against	against	ADP
ajlm-2942	26	31	ascvd.11,12	ascvd.11,12	NOUN
ajlm-2942	26	32	in	in	ADP
ajlm-2942	26	33	contrast	contrast	NOUN
ajlm-2942	26	34	,	,	PUNCT
ajlm-2942	26	35	elevated	elevated	ADJ
ajlm-2942	26	36	levels	level	NOUN
ajlm-2942	26	37	of	of	ADP
ajlm-2942	26	38	apo	apo	PROPN
ajlm-2942	26	39	b	b	PROPN
ajlm-2942	26	40	,	,	PUNCT
ajlm-2942	26	41	which	which	PRON
ajlm-2942	26	42	is	be	AUX
ajlm-2942	26	43	found	find	VERB
ajlm-2942	26	44	predominantly	predominantly	ADV
ajlm-2942	26	45	on	on	ADP
ajlm-2942	26	46	low	low	ADJ
ajlm-2942	26	47	-	-	PUNCT
ajlm-2942	26	48	density	density	NOUN
ajlm-2942	26	49	lipoprotein	lipoprotein	ADJ
ajlm-2942	26	50	particles	particle	NOUN
ajlm-2942	26	51	,	,	PUNCT
ajlm-2942	26	52	are	be	AUX
ajlm-2942	26	53	associated	associate	VERB
ajlm-2942	26	54	strongly	strongly	ADV
ajlm-2942	26	55	with	with	ADP
ajlm-2942	26	56	increased	increase	VERB
ajlm-2942	26	57	ascvd	ascvd	NOUN
ajlm-2942	26	58	risk,13,14	risk,13,14	NOUN
ajlm-2942	26	59	reflecting	reflect	VERB
ajlm-2942	26	60	the	the	DET
ajlm-2942	26	61	proatherogenic	proatherogenic	ADJ
ajlm-2942	26	62	properties	property	NOUN
ajlm-2942	26	63	of	of	ADP
ajlm-2942	26	64	low	low	ADJ
ajlm-2942	26	65	-	-	PUNCT
ajlm-2942	26	66	density	density	NOUN
ajlm-2942	26	67	lipoprotein	lipoprotein	ADJ
ajlm-2942	26	68	cholesterol	cholesterol	NOUN
ajlm-2942	26	69	(	(	PUNCT
ajlm-2942	26	70	ldlc).15	ldlc).15	PROPN
ajlm-2942	26	71	the	the	DET
ajlm-2942	26	72	apo	apo	PROPN
ajlm-2942	26	73	b	b	PROPN
ajlm-2942	26	74	/	/	SYM
ajlm-2942	26	75	a1	a1	NOUN
ajlm-2942	26	76	ratio	ratio	NOUN
ajlm-2942	26	77	is	be	AUX
ajlm-2942	26	78	used	use	VERB
ajlm-2942	26	79	increasingly	increasingly	ADV
ajlm-2942	26	80	to	to	PART
ajlm-2942	26	81	assess	assess	VERB
ajlm-2942	26	82	cardiovascular	cardiovascular	ADJ
ajlm-2942	26	83	risk	risk	NOUN
ajlm-2942	26	84	.	.	PUNCT
ajlm-2942	27	1	a	a	DET
ajlm-2942	27	2	lower	low	ADJ
ajlm-2942	27	3	ratio	ratio	NOUN
ajlm-2942	27	4	indicates	indicate	VERB
ajlm-2942	27	5	a	a	DET
ajlm-2942	27	6	better	well	ADJ
ajlm-2942	27	7	balance	balance	NOUN
ajlm-2942	27	8	between	between	ADP
ajlm-2942	27	9	atherogenic	atherogenic	ADJ
ajlm-2942	27	10	and	and	CCONJ
ajlm-2942	27	11	protective	protective	ADJ
ajlm-2942	27	12	lipoproteins	lipoprotein	NOUN
ajlm-2942	27	13	,	,	PUNCT
ajlm-2942	27	14	which	which	PRON
ajlm-2942	27	15	correlates	correlate	VERB
ajlm-2942	27	16	with	with	ADP
ajlm-2942	27	17	a	a	DET
ajlm-2942	27	18	lower	low	ADJ
ajlm-2942	27	19	risk	risk	NOUN
ajlm-2942	27	20	of	of	ADP
ajlm-2942	27	21	ascvd.16	ascvd.16	PROPN
ajlm-2942	27	22	recent	recent	ADJ
ajlm-2942	27	23	studies	study	NOUN
ajlm-2942	27	24	have	have	AUX
ajlm-2942	27	25	also	also	ADV
ajlm-2942	27	26	emphasised	emphasise	VERB
ajlm-2942	27	27	this	this	DET
ajlm-2942	27	28	ratio	ratio	NOUN
ajlm-2942	27	29	as	as	ADP
ajlm-2942	27	30	a	a	DET
ajlm-2942	27	31	more	more	ADV
ajlm-2942	27	32	accurate	accurate	ADJ
ajlm-2942	27	33	predictor	predictor	NOUN
ajlm-2942	27	34	of	of	ADP
ajlm-2942	27	35	cardiovascular	cardiovascular	ADJ
ajlm-2942	27	36	events	event	NOUN
ajlm-2942	27	37	than	than	ADP
ajlm-2942	27	38	traditional	traditional	ADJ
ajlm-2942	27	39	lipid	lipid	NOUN
ajlm-2942	27	40	measurements.17	measurements.17	PROPN
ajlm-2942	27	41	advances	advance	NOUN
ajlm-2942	27	42	in	in	ADP
ajlm-2942	27	43	genomics	genomic	NOUN
ajlm-2942	27	44	have	have	AUX
ajlm-2942	27	45	revealed	reveal	VERB
ajlm-2942	27	46	that	that	SCONJ
ajlm-2942	27	47	genetic	genetic	ADJ
ajlm-2942	27	48	variations	variation	NOUN
ajlm-2942	27	49	influence	influence	VERB
ajlm-2942	27	50	apo	apo	PROPN
ajlm-2942	27	51	a1	a1	PROPN
ajlm-2942	27	52	and	and	CCONJ
ajlm-2942	27	53	apo	apo	PROPN
ajlm-2942	27	54	b	b	PROPN
ajlm-2942	27	55	levels	level	NOUN
ajlm-2942	27	56	,	,	PUNCT
ajlm-2942	27	57	affecting	affect	VERB
ajlm-2942	27	58	ascvd.18,19,20	ascvd.18,19,20	ADV
ajlm-2942	27	59	furthermore	furthermore	ADV
ajlm-2942	27	60	,	,	PUNCT
ajlm-2942	27	61	the	the	DET
ajlm-2942	27	62	composition	composition	NOUN
ajlm-2942	27	63	and	and	CCONJ
ajlm-2942	27	64	functionality	functionality	NOUN
ajlm-2942	27	65	of	of	ADP
ajlm-2942	27	66	hdl	hdl	PROPN
ajlm-2942	27	67	,	,	PUNCT
ajlm-2942	27	68	particularly	particularly	ADV
ajlm-2942	27	69	its	its	PRON
ajlm-2942	27	70	phospholipid	phospholipid	NOUN
ajlm-2942	27	71	content	content	NOUN
ajlm-2942	27	72	,	,	PUNCT
ajlm-2942	27	73	have	have	AUX
ajlm-2942	27	74	garnered	garner	VERB
ajlm-2942	27	75	attention	attention	NOUN
ajlm-2942	27	76	for	for	ADP
ajlm-2942	27	77	their	their	PRON
ajlm-2942	27	78	potential	potential	ADJ
ajlm-2942	27	79	impact	impact	NOUN
ajlm-2942	27	80	on	on	ADP
ajlm-2942	27	81	ascvd	ascvd	PROPN
ajlm-2942	27	82	risk	risk	NOUN
ajlm-2942	27	83	.	.	PUNCT
ajlm-2942	28	1	hdl	hdl	PROPN
ajlm-2942	28	2	phospholipids	phospholipids	PROPN
ajlm-2942	28	3	,	,	PUNCT
ajlm-2942	28	4	comprising	comprise	VERB
ajlm-2942	28	5	a	a	DET
ajlm-2942	28	6	diverse	diverse	ADJ
ajlm-2942	28	7	array	array	NOUN
ajlm-2942	28	8	of	of	ADP
ajlm-2942	28	9	molecular	molecular	ADJ
ajlm-2942	28	10	species	specie	NOUN
ajlm-2942	28	11	,	,	PUNCT
ajlm-2942	28	12	contribute	contribute	VERB
ajlm-2942	28	13	significantly	significantly	ADV
ajlm-2942	28	14	to	to	ADP
ajlm-2942	28	15	hdl	hdl	PROPN
ajlm-2942	28	16	functionality	functionality	PROPN
ajlm-2942	28	17	,	,	PUNCT
ajlm-2942	28	18	modulating	modulate	VERB
ajlm-2942	28	19	its	its	PRON
ajlm-2942	28	20	anti	anti	ADJ
ajlm-2942	28	21	-	-	ADJ
ajlm-2942	28	22	inflammatory	inflammatory	ADJ
ajlm-2942	28	23	,	,	PUNCT
ajlm-2942	28	24	antioxidative	antioxidative	ADJ
ajlm-2942	28	25	,	,	PUNCT
ajlm-2942	28	26	and	and	CCONJ
ajlm-2942	28	27	vasoprotective	vasoprotective	ADJ
ajlm-2942	28	28	properties.21,22	properties.21,22	NOUN
ajlm-2942	28	29	alterations	alteration	NOUN
ajlm-2942	28	30	in	in	ADP
ajlm-2942	28	31	the	the	DET
ajlm-2942	28	32	composition	composition	NOUN
ajlm-2942	28	33	and	and	CCONJ
ajlm-2942	28	34	functionality	functionality	NOUN
ajlm-2942	28	35	of	of	ADP
ajlm-2942	28	36	hdl	hdl	PROPN
ajlm-2942	28	37	phospholipids	phospholipid	NOUN
ajlm-2942	28	38	have	have	AUX
ajlm-2942	28	39	been	be	AUX
ajlm-2942	28	40	implicated	implicate	VERB
ajlm-2942	28	41	in	in	ADP
ajlm-2942	28	42	ascvd.23,24	ascvd.23,24	NOUN
ajlm-2942	28	43	higher	high	ADJ
ajlm-2942	28	44	levels	level	NOUN
ajlm-2942	28	45	of	of	ADP
ajlm-2942	28	46	specific	specific	ADJ
ajlm-2942	28	47	hdl	hdl	PROPN
ajlm-2942	28	48	phospholipids	phospholipid	NOUN
ajlm-2942	28	49	are	be	AUX
ajlm-2942	28	50	linked	link	VERB
ajlm-2942	28	51	to	to	ADP
ajlm-2942	28	52	a	a	DET
ajlm-2942	28	53	lower	low	ADJ
ajlm-2942	28	54	risk	risk	NOUN
ajlm-2942	28	55	of	of	ADP
ajlm-2942	28	56	major	major	ADJ
ajlm-2942	28	57	adverse	adverse	ADJ
ajlm-2942	28	58	cardiovascular	cardiovascular	ADJ
ajlm-2942	28	59	events	event	NOUN
ajlm-2942	28	60	,	,	PUNCT
ajlm-2942	28	61	suggesting	suggest	VERB
ajlm-2942	28	62	that	that	SCONJ
ajlm-2942	28	63	they	they	PRON
ajlm-2942	28	64	could	could	AUX
ajlm-2942	28	65	enhance	enhance	VERB
ajlm-2942	28	66	traditional	traditional	ADJ
ajlm-2942	28	67	lipid	lipid	NOUN
ajlm-2942	28	68	markers	marker	NOUN
ajlm-2942	28	69	for	for	ADP
ajlm-2942	28	70	better	well	ADJ
ajlm-2942	28	71	risk	risk	NOUN
ajlm-2942	28	72	stratification.23,25	stratification.23,25	NOUN
ajlm-2942	28	73	emerging	emerge	VERB
ajlm-2942	28	74	evidence	evidence	NOUN
ajlm-2942	28	75	suggests	suggest	VERB
ajlm-2942	28	76	that	that	SCONJ
ajlm-2942	28	77	hdl	hdl	PROPN
ajlm-2942	28	78	phospholipid	phospholipid	NOUN
ajlm-2942	28	79	composition	composition	NOUN
ajlm-2942	28	80	may	may	AUX
ajlm-2942	28	81	be	be	AUX
ajlm-2942	28	82	a	a	DET
ajlm-2942	28	83	cardiovascular	cardiovascular	ADJ
ajlm-2942	28	84	risk	risk	NOUN
ajlm-2942	28	85	biomarker.26	biomarker.26	ADJ
ajlm-2942	28	86	this	this	DET
ajlm-2942	28	87	study	study	NOUN
ajlm-2942	28	88	assessed	assess	VERB
ajlm-2942	28	89	atherogenic	atherogenic	ADJ
ajlm-2942	28	90	lipid	lipid	NOUN
ajlm-2942	28	91	profiles	profile	NOUN
ajlm-2942	28	92	in	in	ADP
ajlm-2942	28	93	nigerian	nigerian	ADJ
ajlm-2942	28	94	patients	patient	NOUN
ajlm-2942	28	95	with	with	ADP
ajlm-2942	28	96	ascvd	ascvd	PROPN
ajlm-2942	28	97	,	,	PUNCT
ajlm-2942	28	98	with	with	ADP
ajlm-2942	28	99	a	a	DET
ajlm-2942	28	100	specific	specific	ADJ
ajlm-2942	28	101	focus	focus	NOUN
ajlm-2942	28	102	on	on	ADP
ajlm-2942	28	103	apolipoproteins	apolipoprotein	NOUN
ajlm-2942	28	104	and	and	CCONJ
ajlm-2942	28	105	hdl	hdl	PROPN
ajlm-2942	28	106	phospholipids	phospholipid	NOUN
ajlm-2942	28	107	.	.	PUNCT
ajlm-2942	29	1	this	this	DET
ajlm-2942	29	2	study	study	NOUN
ajlm-2942	29	3	examined	examine	VERB
ajlm-2942	29	4	plasma	plasma	NOUN
ajlm-2942	29	5	apo	apo	PROPN
ajlm-2942	29	6	a1	a1	PROPN
ajlm-2942	29	7	,	,	PUNCT
ajlm-2942	29	8	apo	apo	PROPN
ajlm-2942	29	9	b	b	PROPN
ajlm-2942	29	10	,	,	PUNCT
ajlm-2942	29	11	total	total	ADJ
ajlm-2942	29	12	and	and	CCONJ
ajlm-2942	29	13	hdl	hdl	PROPN
ajlm-2942	29	14	phospholipids	phospholipid	NOUN
ajlm-2942	29	15	,	,	PUNCT
ajlm-2942	29	16	and	and	CCONJ
ajlm-2942	29	17	lipid	lipid	NOUN
ajlm-2942	29	18	profiles	profile	NOUN
ajlm-2942	29	19	in	in	ADP
ajlm-2942	29	20	ascvd	ascvd	NOUN
ajlm-2942	29	21	patients	patient	NOUN
ajlm-2942	29	22	.	.	PUNCT
ajlm-2942	30	1	methods	method	NOUN
ajlm-2942	30	2	ethical	ethical	ADJ
ajlm-2942	30	3	considerations	consideration	NOUN
ajlm-2942	30	4	this	this	DET
ajlm-2942	30	5	study	study	NOUN
ajlm-2942	30	6	was	be	AUX
ajlm-2942	30	7	approved	approve	VERB
ajlm-2942	30	8	by	by	ADP
ajlm-2942	30	9	the	the	DET
ajlm-2942	30	10	health	health	NOUN
ajlm-2942	30	11	research	research	NOUN
ajlm-2942	30	12	and	and	CCONJ
ajlm-2942	30	13	ethics	ethic	NOUN
ajlm-2942	30	14	committee	committee	PROPN
ajlm-2942	30	15	of	of	ADP
ajlm-2942	30	16	lagos	lagos	PROPN
ajlm-2942	30	17	state	state	PROPN
ajlm-2942	30	18	university	university	PROPN
ajlm-2942	30	19	teaching	teaching	NOUN
ajlm-2942	30	20	hospital	hospital	NOUN
ajlm-2942	30	21	in	in	ADP
ajlm-2942	30	22	nigeria	nigeria	PROPN
ajlm-2942	30	23	(	(	PUNCT
ajlm-2942	30	24	reference	reference	NOUN
ajlm-2942	30	25	number	number	NOUN
ajlm-2942	30	26	:	:	PUNCT
ajlm-2942	30	27	lrec/06/10/1706	lrec/06/10/1706	PROPN
ajlm-2942	30	28	)	)	PUNCT
ajlm-2942	30	29	.	.	PUNCT
ajlm-2942	31	1	before	before	ADP
ajlm-2942	31	2	participation	participation	NOUN
ajlm-2942	31	3	,	,	PUNCT
ajlm-2942	31	4	all	all	DET
ajlm-2942	31	5	individuals	individual	NOUN
ajlm-2942	31	6	provided	provide	VERB
ajlm-2942	31	7	written	write	VERB
ajlm-2942	31	8	informed	inform	VERB
ajlm-2942	31	9	consent	consent	NOUN
ajlm-2942	31	10	.	.	PUNCT
ajlm-2942	32	1	all	all	DET
ajlm-2942	32	2	procedures	procedure	NOUN
ajlm-2942	32	3	followed	follow	VERB
ajlm-2942	32	4	the	the	DET
ajlm-2942	32	5	ethical	ethical	ADJ
ajlm-2942	32	6	principles	principle	NOUN
ajlm-2942	32	7	of	of	ADP
ajlm-2942	32	8	the	the	DET
ajlm-2942	32	9	2024	2024	NUM
ajlm-2942	32	10	declaration	declaration	NOUN
ajlm-2942	32	11	of	of	ADP
ajlm-2942	32	12	helsinki	helsinki	PROPN
ajlm-2942	32	13	.	.	PUNCT
ajlm-2942	33	1	to	to	PART
ajlm-2942	33	2	ensure	ensure	VERB
ajlm-2942	33	3	anonymity	anonymity	NOUN
ajlm-2942	33	4	,	,	PUNCT
ajlm-2942	33	5	a	a	DET
ajlm-2942	33	6	barcode	barcode	NOUN
ajlm-2942	33	7	system	system	NOUN
ajlm-2942	33	8	was	be	AUX
ajlm-2942	33	9	employed	employ	VERB
ajlm-2942	33	10	,	,	PUNCT
ajlm-2942	33	11	and	and	CCONJ
ajlm-2942	33	12	all	all	DET
ajlm-2942	33	13	data	datum	NOUN
ajlm-2942	33	14	were	be	AUX
ajlm-2942	33	15	handled	handle	VERB
ajlm-2942	33	16	with	with	ADP
ajlm-2942	33	17	strict	strict	ADJ
ajlm-2942	33	18	confidentiality	confidentiality	NOUN
ajlm-2942	33	19	.	.	PUNCT
ajlm-2942	34	1	the	the	DET
ajlm-2942	34	2	collected	collect	VERB
ajlm-2942	34	3	data	datum	NOUN
ajlm-2942	34	4	were	be	AUX
ajlm-2942	34	5	used	use	VERB
ajlm-2942	34	6	solely	solely	ADV
ajlm-2942	34	7	for	for	ADP
ajlm-2942	34	8	this	this	DET
ajlm-2942	34	9	study	study	NOUN
ajlm-2942	34	10	.	.	PUNCT
ajlm-2942	35	1	study	study	NOUN
ajlm-2942	35	2	design	design	NOUN
ajlm-2942	35	3	this	this	DET
ajlm-2942	35	4	cross	cross	ADJ
ajlm-2942	35	5	-	-	ADJ
ajlm-2942	35	6	sectional	sectional	ADJ
ajlm-2942	35	7	case	case	NOUN
ajlm-2942	35	8	-	-	PUNCT
ajlm-2942	35	9	control	control	NOUN
ajlm-2942	35	10	study	study	NOUN
ajlm-2942	35	11	determined	determine	VERB
ajlm-2942	35	12	a	a	DET
ajlm-2942	35	13	sample	sample	NOUN
ajlm-2942	35	14	size	size	NOUN
ajlm-2942	35	15	of	of	ADP
ajlm-2942	35	16	138	138	NUM
ajlm-2942	35	17	based	base	VERB
ajlm-2942	35	18	on	on	ADP
ajlm-2942	35	19	prevalence	prevalence	NOUN
ajlm-2942	35	20	data	datum	NOUN
ajlm-2942	35	21	from	from	ADP
ajlm-2942	35	22	a	a	DET
ajlm-2942	35	23	previous	previous	ADJ
ajlm-2942	35	24	regional	regional	ADJ
ajlm-2942	35	25	study,27	study,27	NOUN
ajlm-2942	35	26	which	which	PRON
ajlm-2942	35	27	reported	report	VERB
ajlm-2942	35	28	an	an	DET
ajlm-2942	35	29	8	8	NUM
ajlm-2942	35	30	%	%	NOUN
ajlm-2942	35	31	–	–	PUNCT
ajlm-2942	35	32	12	12	NUM
ajlm-2942	35	33	%	%	NOUN
ajlm-2942	35	34	prevalence	prevalence	NOUN
ajlm-2942	35	35	of	of	ADP
ajlm-2942	35	36	cardiovascular	cardiovascular	ADJ
ajlm-2942	35	37	disease	disease	NOUN
ajlm-2942	35	38	in	in	ADP
ajlm-2942	35	39	sub	sub	ADJ
ajlm-2942	35	40	-	-	ADJ
ajlm-2942	35	41	saharan	saharan	ADJ
ajlm-2942	35	42	african	african	ADJ
ajlm-2942	35	43	countries.28	countries.28	NOUN
ajlm-2942	35	44	in	in	ADP
ajlm-2942	35	45	total	total	ADJ
ajlm-2942	35	46	,	,	PUNCT
ajlm-2942	35	47	172	172	NUM
ajlm-2942	35	48	confirmed	confirm	VERB
ajlm-2942	35	49	ascvd	ascvd	NOUN
ajlm-2942	35	50	patients	patient	NOUN
ajlm-2942	35	51	,	,	PUNCT
ajlm-2942	35	52	aged	age	VERB
ajlm-2942	35	53	20	20	NUM
ajlm-2942	35	54	years	year	NOUN
ajlm-2942	35	55	to	to	ADP
ajlm-2942	35	56	64	64	NUM
ajlm-2942	35	57	years	year	NOUN
ajlm-2942	35	58	,	,	PUNCT
ajlm-2942	35	59	were	be	AUX
ajlm-2942	35	60	enrolled	enrol	VERB
ajlm-2942	35	61	.	.	PUNCT
ajlm-2942	36	1	participants	participant	NOUN
ajlm-2942	36	2	were	be	AUX
ajlm-2942	36	3	selected	select	VERB
ajlm-2942	36	4	using	use	VERB
ajlm-2942	36	5	a	a	DET
ajlm-2942	36	6	simple	simple	ADJ
ajlm-2942	36	7	random	random	ADJ
ajlm-2942	36	8	sampling	sampling	NOUN
ajlm-2942	36	9	technique	technique	NOUN
ajlm-2942	36	10	at	at	ADP
ajlm-2942	36	11	the	the	DET
ajlm-2942	36	12	lagos	lagos	PROPN
ajlm-2942	36	13	state	state	PROPN
ajlm-2942	36	14	university	university	PROPN
ajlm-2942	36	15	teaching	teaching	NOUN
ajlm-2942	36	16	hospital	hospital	NOUN
ajlm-2942	36	17	,	,	PUNCT
ajlm-2942	36	18	lagos	lagos	PROPN
ajlm-2942	36	19	,	,	PUNCT
ajlm-2942	36	20	nigeria	nigeria	PROPN
ajlm-2942	36	21	.	.	PUNCT
ajlm-2942	37	1	we	we	PRON
ajlm-2942	37	2	enrolled	enrol	VERB
ajlm-2942	37	3	participants	participant	NOUN
ajlm-2942	37	4	diagnosed	diagnose	VERB
ajlm-2942	37	5	with	with	ADP
ajlm-2942	37	6	hypertensive	hypertensive	ADJ
ajlm-2942	37	7	heart	heart	NOUN
ajlm-2942	37	8	disease	disease	NOUN
ajlm-2942	37	9	with	with	ADP
ajlm-2942	37	10	significant	significant	ADJ
ajlm-2942	37	11	atherosclerosis	atherosclerosis	NOUN
ajlm-2942	37	12	,	,	PUNCT
ajlm-2942	37	13	ischaemic	ischaemic	ADJ
ajlm-2942	37	14	heart	heart	NOUN
ajlm-2942	37	15	disease	disease	NOUN
ajlm-2942	37	16	(	(	PUNCT
ajlm-2942	37	17	ihd	ihd	ADJ
ajlm-2942	37	18	)	)	PUNCT
ajlm-2942	37	19	,	,	PUNCT
ajlm-2942	37	20	myocardial	myocardial	ADJ
ajlm-2942	37	21	infarction	infarction	NOUN
ajlm-2942	37	22	(	(	PUNCT
ajlm-2942	37	23	mi	mi	NOUN
ajlm-2942	37	24	)	)	PUNCT
ajlm-2942	37	25	,	,	PUNCT
ajlm-2942	37	26	ischaemic	ischaemic	ADJ
ajlm-2942	37	27	stroke	stroke	NOUN
ajlm-2942	37	28	,	,	PUNCT
ajlm-2942	37	29	or	or	CCONJ
ajlm-2942	37	30	congestive	congestive	ADJ
ajlm-2942	37	31	heart	heart	NOUN
ajlm-2942	37	32	failure	failure	NOUN
ajlm-2942	37	33	linked	link	VERB
ajlm-2942	37	34	to	to	ADP
ajlm-2942	37	35	prior	prior	ADJ
ajlm-2942	37	36	ihd	ihd	PROPN
ajlm-2942	37	37	or	or	CCONJ
ajlm-2942	37	38	mi	mi	PROPN
ajlm-2942	37	39	.	.	PROPN
ajlm-2942	37	40	recruitment	recruitment	NOUN
ajlm-2942	37	41	took	take	VERB
ajlm-2942	37	42	place	place	NOUN
ajlm-2942	37	43	during	during	ADP
ajlm-2942	37	44	routine	routine	ADJ
ajlm-2942	37	45	outpatient	outpatient	NOUN
ajlm-2942	37	46	visits	visit	NOUN
ajlm-2942	37	47	at	at	ADP
ajlm-2942	37	48	the	the	DET
ajlm-2942	37	49	cardiology	cardiology	NOUN
ajlm-2942	37	50	clinic	clinic	NOUN
ajlm-2942	37	51	,	,	PUNCT
ajlm-2942	37	52	lagos	lagos	PROPN
ajlm-2942	37	53	state	state	NOUN
ajlm-2942	37	54	university	university	PROPN
ajlm-2942	37	55	teaching	teaching	NOUN
ajlm-2942	37	56	hospital	hospital	NOUN
ajlm-2942	37	57	,	,	PUNCT
ajlm-2942	37	58	lagos	lago	NOUN
ajlm-2942	37	59	,	,	PUNCT
ajlm-2942	37	60	nigeria	nigeria	PROPN
ajlm-2942	37	61	,	,	PUNCT
ajlm-2942	37	62	from	from	ADP
ajlm-2942	37	63	november	november	PROPN
ajlm-2942	37	64	2021	2021	NUM
ajlm-2942	37	65	to	to	ADP
ajlm-2942	37	66	november	november	PROPN
ajlm-2942	37	67	2022	2022	NUM
ajlm-2942	37	68	.	.	PUNCT
ajlm-2942	38	1	eligible	eligible	ADJ
ajlm-2942	38	2	participants	participant	NOUN
ajlm-2942	38	3	were	be	AUX
ajlm-2942	38	4	identified	identify	VERB
ajlm-2942	38	5	through	through	ADP
ajlm-2942	38	6	consecutive	consecutive	ADJ
ajlm-2942	38	7	clinic	clinic	NOUN
ajlm-2942	38	8	record	record	NOUN
ajlm-2942	38	9	reviews	review	NOUN
ajlm-2942	38	10	and	and	CCONJ
ajlm-2942	38	11	were	be	AUX
ajlm-2942	38	12	enrolled	enrol	VERB
ajlm-2942	38	13	at	at	ADP
ajlm-2942	38	14	most	most	ADJ
ajlm-2942	38	15	six	six	NUM
ajlm-2942	38	16	months	month	NOUN
ajlm-2942	38	17	post	post	ADJ
ajlm-2942	38	18	-	-	NOUN
ajlm-2942	38	19	diagnosis	diagnosis	NOUN
ajlm-2942	38	20	,	,	PUNCT
ajlm-2942	38	21	with	with	ADP
ajlm-2942	38	22	clinical	clinical	ADJ
ajlm-2942	38	23	stability	stability	NOUN
ajlm-2942	38	24	confirmed	confirm	VERB
ajlm-2942	38	25	by	by	ADP
ajlm-2942	38	26	no	no	DET
ajlm-2942	38	27	acute	acute	ADJ
ajlm-2942	38	28	cardiovascular	cardiovascular	ADJ
ajlm-2942	38	29	events	event	NOUN
ajlm-2942	38	30	(	(	PUNCT
ajlm-2942	38	31	e.g.	e.g.	ADV
ajlm-2942	38	32	mi	mi	PROPN
ajlm-2942	38	33	or	or	CCONJ
ajlm-2942	38	34	stroke	stroke	NOUN
ajlm-2942	38	35	)	)	PUNCT
ajlm-2942	38	36	in	in	ADP
ajlm-2942	38	37	the	the	DET
ajlm-2942	38	38	prior	prior	ADJ
ajlm-2942	38	39	three	three	NUM
ajlm-2942	38	40	months	month	NOUN
ajlm-2942	38	41	,	,	PUNCT
ajlm-2942	38	42	as	as	SCONJ
ajlm-2942	38	43	verified	verify	VERB
ajlm-2942	38	44	by	by	ADP
ajlm-2942	38	45	a	a	DET
ajlm-2942	38	46	cardiologist	cardiologist	ADJ
ajlm-2942	38	47	and	and	CCONJ
ajlm-2942	38	48	medical	medical	ADJ
ajlm-2942	38	49	records	record	NOUN
ajlm-2942	38	50	.	.	PUNCT
ajlm-2942	39	1	the	the	DET
ajlm-2942	39	2	ihd	ihd	ADJ
ajlm-2942	39	3	group	group	NOUN
ajlm-2942	39	4	comprised	comprise	VERB
ajlm-2942	39	5	patients	patient	NOUN
ajlm-2942	39	6	with	with	ADP
ajlm-2942	39	7	stable	stable	ADJ
ajlm-2942	39	8	conditions	condition	NOUN
ajlm-2942	39	9	,	,	PUNCT
ajlm-2942	39	10	such	such	ADJ
ajlm-2942	39	11	as	as	ADP
ajlm-2942	39	12	stable	stable	ADJ
ajlm-2942	39	13	angina	angina	NOUN
ajlm-2942	39	14	,	,	PUNCT
ajlm-2942	39	15	without	without	ADP
ajlm-2942	39	16	a	a	DET
ajlm-2942	39	17	documented	document	VERB
ajlm-2942	39	18	mi	mi	PROPN
ajlm-2942	39	19	.	.	PROPN
ajlm-2942	40	1	the	the	DET
ajlm-2942	40	2	mi	mi	PROPN
ajlm-2942	40	3	group	group	PROPN
ajlm-2942	40	4	included	include	VERB
ajlm-2942	40	5	those	those	PRON
ajlm-2942	40	6	with	with	ADP
ajlm-2942	40	7	a	a	DET
ajlm-2942	40	8	prior	prior	ADJ
ajlm-2942	40	9	mi	mi	NOUN
ajlm-2942	40	10	,	,	PUNCT
ajlm-2942	40	11	defined	define	VERB
ajlm-2942	40	12	per	per	ADP
ajlm-2942	40	13	the	the	DET
ajlm-2942	40	14	2012	2012	NUM
ajlm-2942	40	15	universal	universal	ADJ
ajlm-2942	40	16	definition	definition	NOUN
ajlm-2942	40	17	of	of	ADP
ajlm-2942	40	18	myocardial	myocardial	ADJ
ajlm-2942	40	19	infarction,29	infarction,29	NOUN
ajlm-2942	40	20	based	base	VERB
ajlm-2942	40	21	on	on	ADP
ajlm-2942	40	22	clinical	clinical	ADJ
ajlm-2942	40	23	signs	sign	NOUN
ajlm-2942	40	24	of	of	ADP
ajlm-2942	40	25	ischaemia	ischaemia	PROPN
ajlm-2942	40	26	,	,	PUNCT
ajlm-2942	40	27	elevated	elevated	ADJ
ajlm-2942	40	28	cardiac	cardiac	ADJ
ajlm-2942	40	29	biomarkers	biomarker	NOUN
ajlm-2942	40	30	(	(	PUNCT
ajlm-2942	40	31	e.g.	e.g.	ADV
ajlm-2942	40	32	troponin	troponin	ADJ
ajlm-2942	40	33	)	)	PUNCT
ajlm-2942	40	34	and	and	CCONJ
ajlm-2942	40	35	echocardiographic	echocardiographic	ADJ
ajlm-2942	40	36	findings	finding	NOUN
ajlm-2942	40	37	.	.	PUNCT
ajlm-2942	41	1	to	to	PART
ajlm-2942	41	2	minimise	minimise	VERB
ajlm-2942	41	3	confounding	confound	VERB
ajlm-2942	41	4	effects	effect	NOUN
ajlm-2942	41	5	on	on	ADP
ajlm-2942	41	6	lipid	lipid	NOUN
ajlm-2942	41	7	-	-	PUNCT
ajlm-2942	41	8	related	relate	VERB
ajlm-2942	41	9	biomarkers	biomarker	NOUN
ajlm-2942	41	10	,	,	PUNCT
ajlm-2942	41	11	we	we	PRON
ajlm-2942	41	12	excluded	exclude	VERB
ajlm-2942	41	13	patients	patient	NOUN
ajlm-2942	41	14	on	on	ADP
ajlm-2942	41	15	lipid	lipid	NOUN
ajlm-2942	41	16	-	-	PUNCT
ajlm-2942	41	17	lowering	lower	VERB
ajlm-2942	41	18	therapy	therapy	NOUN
ajlm-2942	41	19	at	at	ADP
ajlm-2942	41	20	recruitment	recruitment	NOUN
ajlm-2942	41	21	or	or	CCONJ
ajlm-2942	41	22	within	within	ADP
ajlm-2942	41	23	the	the	DET
ajlm-2942	41	24	prior	prior	ADJ
ajlm-2942	41	25	six	six	NUM
ajlm-2942	41	26	months	month	NOUN
ajlm-2942	41	27	,	,	PUNCT
ajlm-2942	41	28	as	as	ADV
ajlm-2942	41	29	well	well	ADV
ajlm-2942	41	30	as	as	ADP
ajlm-2942	41	31	those	those	PRON
ajlm-2942	41	32	on	on	ADP
ajlm-2942	41	33	hormonal	hormonal	ADJ
ajlm-2942	41	34	therapy	therapy	NOUN
ajlm-2942	41	35	,	,	PUNCT
ajlm-2942	41	36	pregnant	pregnant	ADJ
ajlm-2942	41	37	women	woman	NOUN
ajlm-2942	41	38	,	,	PUNCT
ajlm-2942	41	39	or	or	CCONJ
ajlm-2942	41	40	individuals	individual	NOUN
ajlm-2942	41	41	who	who	PRON
ajlm-2942	41	42	declined	decline	VERB
ajlm-2942	41	43	participation	participation	NOUN
ajlm-2942	41	44	.	.	PUNCT
ajlm-2942	42	1	in	in	ADP
ajlm-2942	42	2	our	our	PRON
ajlm-2942	42	3	setting	setting	NOUN
ajlm-2942	42	4	,	,	PUNCT
ajlm-2942	42	5	some	some	DET
ajlm-2942	42	6	patients	patient	NOUN
ajlm-2942	42	7	were	be	AUX
ajlm-2942	42	8	not	not	PART
ajlm-2942	42	9	on	on	ADP
ajlm-2942	42	10	lipid	lipid	NOUN
ajlm-2942	42	11	-	-	PUNCT
ajlm-2942	42	12	lowering	lower	VERB
ajlm-2942	42	13	therapy	therapy	NOUN
ajlm-2942	42	14	owing	owe	VERB
ajlm-2942	42	15	to	to	ADP
ajlm-2942	42	16	clinical	clinical	ADJ
ajlm-2942	42	17	contraindications	contraindication	NOUN
ajlm-2942	42	18	(	(	PUNCT
ajlm-2942	42	19	e.g.	e.g.	ADV
ajlm-2942	42	20	statin	statin	ADJ
ajlm-2942	42	21	intolerance	intolerance	NOUN
ajlm-2942	42	22	)	)	PUNCT
ajlm-2942	42	23	or	or	CCONJ
ajlm-2942	42	24	non	non	ADJ
ajlm-2942	42	25	-	-	NOUN
ajlm-2942	42	26	adherence	adherence	NOUN
ajlm-2942	42	27	,	,	PUNCT
ajlm-2942	42	28	verified	verify	VERB
ajlm-2942	42	29	through	through	ADP
ajlm-2942	42	30	medical	medical	ADJ
ajlm-2942	42	31	records	record	NOUN
ajlm-2942	42	32	and	and	CCONJ
ajlm-2942	42	33	patient	patient	NOUN
ajlm-2942	42	34	interviews	interview	NOUN
ajlm-2942	42	35	.	.	PUNCT
ajlm-2942	43	1	we	we	PRON
ajlm-2942	43	2	also	also	ADV
ajlm-2942	43	3	excluded	exclude	VERB
ajlm-2942	43	4	patients	patient	NOUN
ajlm-2942	43	5	with	with	ADP
ajlm-2942	43	6	acute	acute	PROPN
ajlm-2942	43	7	mi	mi	PROPN
ajlm-2942	43	8	,	,	PUNCT
ajlm-2942	43	9	stroke	stroke	NOUN
ajlm-2942	43	10	,	,	PUNCT
ajlm-2942	43	11	or	or	CCONJ
ajlm-2942	43	12	other	other	ADJ
ajlm-2942	43	13	cardiovascular	cardiovascular	ADJ
ajlm-2942	43	14	events	event	NOUN
ajlm-2942	43	15	within	within	ADP
ajlm-2942	43	16	three	three	NUM
ajlm-2942	43	17	months	month	NOUN
ajlm-2942	43	18	before	before	ADP
ajlm-2942	43	19	sampling	sample	VERB
ajlm-2942	43	20	,	,	PUNCT
ajlm-2942	43	21	to	to	PART
ajlm-2942	43	22	focus	focus	VERB
ajlm-2942	43	23	on	on	ADP
ajlm-2942	43	24	early	early	ADJ
ajlm-2942	43	25	-	-	PUNCT
ajlm-2942	43	26	stage	stage	NOUN
ajlm-2942	43	27	ascvd	ascvd	NOUN
ajlm-2942	43	28	and	and	CCONJ
ajlm-2942	43	29	to	to	PART
ajlm-2942	43	30	support	support	VERB
ajlm-2942	43	31	our	our	PRON
ajlm-2942	43	32	aim	aim	NOUN
ajlm-2942	43	33	of	of	ADP
ajlm-2942	43	34	evaluating	evaluate	VERB
ajlm-2942	43	35	plasma	plasma	NOUN
ajlm-2942	43	36	biomarkers	biomarker	NOUN
ajlm-2942	43	37	for	for	ADP
ajlm-2942	43	38	early	early	ADJ
ajlm-2942	43	39	detection	detection	NOUN
ajlm-2942	43	40	.	.	PUNCT
ajlm-2942	44	1	the	the	DET
ajlm-2942	44	2	control	control	PROPN
ajlm-2942	44	3	group	group	NOUN
ajlm-2942	44	4	consisted	consist	VERB
ajlm-2942	44	5	of	of	ADP
ajlm-2942	44	6	55	55	NUM
ajlm-2942	44	7	healthy	healthy	ADJ
ajlm-2942	44	8	volunteers	volunteer	NOUN
ajlm-2942	44	9	with	with	ADP
ajlm-2942	44	10	no	no	DET
ajlm-2942	44	11	history	history	NOUN
ajlm-2942	44	12	of	of	ADP
ajlm-2942	44	13	chronic	chronic	ADJ
ajlm-2942	44	14	or	or	CCONJ
ajlm-2942	44	15	degenerative	degenerative	ADJ
ajlm-2942	44	16	diseases	disease	NOUN
ajlm-2942	44	17	,	,	PUNCT
ajlm-2942	44	18	recruited	recruit	VERB
ajlm-2942	44	19	from	from	ADP
ajlm-2942	44	20	relatives	relative	NOUN
ajlm-2942	44	21	of	of	ADP
ajlm-2942	44	22	patients	patient	NOUN
ajlm-2942	44	23	and	and	CCONJ
ajlm-2942	44	24	staff	staff	NOUN
ajlm-2942	44	25	at	at	ADP
ajlm-2942	44	26	the	the	DET
ajlm-2942	44	27	lagos	lagos	PROPN
ajlm-2942	44	28	state	state	PROPN
ajlm-2942	44	29	university	university	PROPN
ajlm-2942	44	30	teaching	teaching	NOUN
ajlm-2942	44	31	hospital	hospital	NOUN
ajlm-2942	44	32	.	.	PUNCT
ajlm-2942	45	1	all	all	DET
ajlm-2942	45	2	participants	participant	NOUN
ajlm-2942	45	3	completed	complete	VERB
ajlm-2942	45	4	a	a	DET
ajlm-2942	45	5	standardised	standardised	ADJ
ajlm-2942	45	6	,	,	PUNCT
ajlm-2942	45	7	structured	structured	ADJ
ajlm-2942	45	8	paper	paper	NOUN
ajlm-2942	45	9	questionnaire	questionnaire	NOUN
ajlm-2942	45	10	(	(	PUNCT
ajlm-2942	45	11	online	online	ADJ
ajlm-2942	45	12	supplementary	supplementary	ADJ
ajlm-2942	45	13	questionnaire	questionnaire	NOUN
ajlm-2942	45	14	)	)	PUNCT
ajlm-2942	45	15	to	to	PART
ajlm-2942	45	16	capture	capture	VERB
ajlm-2942	45	17	general	general	ADJ
ajlm-2942	45	18	characteristics	characteristic	NOUN
ajlm-2942	45	19	,	,	PUNCT
ajlm-2942	45	20	inclusion	inclusion	NOUN
ajlm-2942	45	21	/	/	SYM
ajlm-2942	45	22	exclusion	exclusion	NOUN
ajlm-2942	45	23	criteria	criterion	NOUN
ajlm-2942	45	24	,	,	PUNCT
ajlm-2942	45	25	and	and	CCONJ
ajlm-2942	45	26	potential	potential	ADJ
ajlm-2942	45	27	confounding	confound	VERB
ajlm-2942	45	28	factors	factor	NOUN
ajlm-2942	45	29	that	that	PRON
ajlm-2942	45	30	could	could	AUX
ajlm-2942	45	31	influence	influence	VERB
ajlm-2942	45	32	study	study	NOUN
ajlm-2942	45	33	outcomes	outcome	NOUN
ajlm-2942	45	34	.	.	PUNCT
ajlm-2942	46	1	control	control	NOUN
ajlm-2942	46	2	participants	participant	NOUN
ajlm-2942	46	3	were	be	AUX
ajlm-2942	46	4	further	far	ADV
ajlm-2942	46	5	evaluated	evaluate	VERB
ajlm-2942	46	6	for	for	ADP
ajlm-2942	46	7	clinical	clinical	ADJ
ajlm-2942	46	8	examination	examination	NOUN
ajlm-2942	46	9	,	,	PUNCT
ajlm-2942	46	10	and	and	CCONJ
ajlm-2942	46	11	basic	basic	ADJ
ajlm-2942	46	12	laboratory	laboratory	NOUN
ajlm-2942	46	13	screening	screening	NOUN
ajlm-2942	46	14	,	,	PUNCT
ajlm-2942	46	15	including	include	VERB
ajlm-2942	46	16	fasting	fast	VERB
ajlm-2942	46	17	plasma	plasma	NOUN
ajlm-2942	46	18	glucose	glucose	NOUN
ajlm-2942	46	19	,	,	PUNCT
ajlm-2942	46	20	lipid	lipid	NOUN
ajlm-2942	46	21	profile	profile	NOUN
ajlm-2942	46	22	,	,	PUNCT
ajlm-2942	46	23	and	and	CCONJ
ajlm-2942	46	24	blood	blood	NOUN
ajlm-2942	46	25	pressure	pressure	NOUN
ajlm-2942	46	26	measurements	measurement	NOUN
ajlm-2942	46	27	,	,	PUNCT
ajlm-2942	46	28	to	to	PART
ajlm-2942	46	29	confirm	confirm	VERB
ajlm-2942	46	30	their	their	PRON
ajlm-2942	46	31	apparently	apparently	ADV
ajlm-2942	46	32	healthy	healthy	ADJ
ajlm-2942	46	33	status	status	NOUN
ajlm-2942	46	34	and	and	CCONJ
ajlm-2942	46	35	exclude	exclude	VERB
ajlm-2942	46	36	subclinical	subclinical	ADJ
ajlm-2942	46	37	chronic	chronic	ADJ
ajlm-2942	46	38	or	or	CCONJ
ajlm-2942	46	39	metabolic	metabolic	NOUN
ajlm-2942	46	40	conditions	condition	NOUN
ajlm-2942	46	41	blood	blood	NOUN
ajlm-2942	46	42	sample	sample	NOUN
ajlm-2942	46	43	collection	collection	NOUN
ajlm-2942	46	44	blood	blood	NOUN
ajlm-2942	46	45	samples	sample	NOUN
ajlm-2942	46	46	from	from	ADP
ajlm-2942	46	47	ascvd	ascvd	NOUN
ajlm-2942	46	48	patients	patient	NOUN
ajlm-2942	46	49	were	be	AUX
ajlm-2942	46	50	collected	collect	VERB
ajlm-2942	46	51	within	within	ADP
ajlm-2942	46	52	0–6	0–6	NOUN
ajlm-2942	46	53	months	month	NOUN
ajlm-2942	46	54	of	of	ADP
ajlm-2942	46	55	diagnosis	diagnosis	NOUN
ajlm-2942	46	56	to	to	PART
ajlm-2942	46	57	capture	capture	VERB
ajlm-2942	46	58	early	early	ADJ
ajlm-2942	46	59	-	-	PUNCT
ajlm-2942	46	60	stage	stage	NOUN
ajlm-2942	46	61	disease	disease	NOUN
ajlm-2942	46	62	,	,	PUNCT
ajlm-2942	46	63	consistent	consistent	ADJ
ajlm-2942	46	64	with	with	ADP
ajlm-2942	46	65	the	the	DET
ajlm-2942	46	66	aim	aim	NOUN
ajlm-2942	46	67	of	of	ADP
ajlm-2942	46	68	the	the	DET
ajlm-2942	46	69	study	study	NOUN
ajlm-2942	46	70	to	to	PART
ajlm-2942	46	71	evaluate	evaluate	VERB
ajlm-2942	46	72	apolipoprotein	apolipoprotein	ADJ
ajlm-2942	46	73	a1	a1	NOUN
ajlm-2942	46	74	,	,	PUNCT
ajlm-2942	46	75	apolipoprotein	apolipoprotein	ADJ
ajlm-2942	46	76	b	b	NUM
ajlm-2942	46	77	,	,	PUNCT
ajlm-2942	46	78	and	and	CCONJ
ajlm-2942	46	79	hdl	hdl	PROPN
ajlm-2942	46	80	phospholipids	phospholipid	NOUN
ajlm-2942	46	81	as	as	ADP
ajlm-2942	46	82	potential	potential	ADJ
ajlm-2942	46	83	early	early	ADJ
ajlm-2942	46	84	diagnostic	diagnostic	ADJ
ajlm-2942	46	85	markers	marker	NOUN
ajlm-2942	46	86	.	.	PUNCT
ajlm-2942	47	1	approximately	approximately	ADV
ajlm-2942	47	2	7	7	NUM
ajlm-2942	47	3	ml	ml	NOUN
ajlm-2942	47	4	of	of	ADP
ajlm-2942	47	5	venous	venous	ADJ
ajlm-2942	47	6	blood	blood	NOUN
ajlm-2942	47	7	was	be	AUX
ajlm-2942	47	8	drawn	draw	VERB
ajlm-2942	47	9	from	from	ADP
ajlm-2942	47	10	each	each	DET
ajlm-2942	47	11	participant	participant	NOUN
ajlm-2942	47	12	after	after	ADP
ajlm-2942	47	13	an	an	DET
ajlm-2942	47	14	overnight	overnight	ADJ
ajlm-2942	47	15	fast	fast	NOUN
ajlm-2942	47	16	(	(	PUNCT
ajlm-2942	47	17	8	8	NUM
ajlm-2942	47	18	h	h	NOUN
ajlm-2942	47	19	–	–	PUNCT
ajlm-2942	47	20	12	12	NUM
ajlm-2942	47	21	h	h	NOUN
ajlm-2942	47	22	)	)	PUNCT
ajlm-2942	47	23	.	.	PUNCT
ajlm-2942	48	1	samples	sample	NOUN
ajlm-2942	48	2	were	be	AUX
ajlm-2942	48	3	collected	collect	VERB
ajlm-2942	48	4	in	in	ADP
ajlm-2942	48	5	potassium	potassium	NOUN
ajlm-2942	48	6	-	-	PUNCT
ajlm-2942	48	7	ethylenediaminetetraacetic	ethylenediaminetetraacetic	ADJ
ajlm-2942	48	8	acid	acid	NOUN
ajlm-2942	48	9	(	(	PUNCT
ajlm-2942	48	10	1	1	NUM
ajlm-2942	48	11	mg	mg	NUM
ajlm-2942	48	12	/	/	SYM
ajlm-2942	48	13	ml	ml	NOUN
ajlm-2942	48	14	)	)	PUNCT
ajlm-2942	48	15	tubes	tube	NOUN
ajlm-2942	48	16	,	,	PUNCT
ajlm-2942	48	17	maintained	maintain	VERB
ajlm-2942	48	18	at	at	ADP
ajlm-2942	48	19	4	4	NUM
ajlm-2942	48	20	°	°	NOUN
ajlm-2942	48	21	c	c	NOUN
ajlm-2942	48	22	,	,	PUNCT
ajlm-2942	48	23	and	and	CCONJ
ajlm-2942	48	24	processed	process	VERB
ajlm-2942	48	25	within	within	ADP
ajlm-2942	48	26	two	two	NUM
ajlm-2942	48	27	hours	hour	NOUN
ajlm-2942	48	28	.	.	PUNCT
ajlm-2942	49	1	plasma	plasma	NOUN
ajlm-2942	49	2	was	be	AUX
ajlm-2942	49	3	separated	separate	VERB
ajlm-2942	49	4	by	by	ADP
ajlm-2942	49	5	centrifugation	centrifugation	NOUN
ajlm-2942	49	6	at	at	ADP
ajlm-2942	49	7	3000	3000	NUM
ajlm-2942	49	8	rpm	rpm	NOUN
ajlm-2942	49	9	for	for	ADP
ajlm-2942	49	10	5	5	NUM
ajlm-2942	49	11	min	min	NOUN
ajlm-2942	49	12	,	,	PUNCT
ajlm-2942	49	13	aliquoted	aliquote	VERB
ajlm-2942	49	14	into	into	ADP
ajlm-2942	49	15	labelled	label	VERB
ajlm-2942	49	16	vials	vial	NOUN
ajlm-2942	49	17	,	,	PUNCT
ajlm-2942	49	18	and	and	CCONJ
ajlm-2942	49	19	stored	store	VERB
ajlm-2942	49	20	at	at	ADP
ajlm-2942	49	21	–	–	PUNCT
ajlm-2942	49	22	20	20	NUM
ajlm-2942	49	23	°	°	NUM
ajlm-2942	49	24	c	c	NOUN
ajlm-2942	49	25	until	until	ADP
ajlm-2942	49	26	analysis	analysis	NOUN
ajlm-2942	49	27	,	,	PUNCT
ajlm-2942	49	28	conducted	conduct	VERB
ajlm-2942	49	29	within	within	ADP
ajlm-2942	49	30	1–12	1–12	PROPN
ajlm-2942	49	31	months	month	NOUN
ajlm-2942	49	32	.	.	PUNCT
ajlm-2942	50	1	the	the	DET
ajlm-2942	50	2	use	use	NOUN
ajlm-2942	50	3	of	of	ADP
ajlm-2942	50	4	potassium	potassium	NOUN
ajlm-2942	50	5	-	-	PUNCT
ajlm-2942	50	6	ethylenediaminetetraacetic	ethylenediaminetetraacetic	ADJ
ajlm-2942	50	7	acid	acid	NOUN
ajlm-2942	50	8	minimised	minimise	VERB
ajlm-2942	50	9	lipid	lipid	NOUN
ajlm-2942	50	10	peroxidation	peroxidation	NOUN
ajlm-2942	50	11	and	and	CCONJ
ajlm-2942	50	12	was	be	AUX
ajlm-2942	50	13	appropriate	appropriate	ADJ
ajlm-2942	50	14	for	for	ADP
ajlm-2942	50	15	apolipoprotein	apolipoprotein	ADJ
ajlm-2942	50	16	and	and	CCONJ
ajlm-2942	50	17	phospholipid	phospholipid	NOUN
ajlm-2942	50	18	assays	assay	NOUN
ajlm-2942	50	19	.	.	PUNCT
ajlm-2942	51	1	although	although	SCONJ
ajlm-2942	51	2	minor	minor	ADJ
ajlm-2942	51	3	effects	effect	NOUN
ajlm-2942	51	4	on	on	ADP
ajlm-2942	51	5	total	total	ADJ
ajlm-2942	51	6	cholesterol	cholesterol	NOUN
ajlm-2942	51	7	and	and	CCONJ
ajlm-2942	51	8	ldlc	ldlc	NOUN
ajlm-2942	51	9	might	might	AUX
ajlm-2942	51	10	occur	occur	VERB
ajlm-2942	51	11	,	,	PUNCT
ajlm-2942	51	12	consistent	consistent	ADJ
ajlm-2942	51	13	use	use	NOUN
ajlm-2942	51	14	across	across	ADP
ajlm-2942	51	15	all	all	DET
ajlm-2942	51	16	samples	sample	NOUN
ajlm-2942	51	17	ensured	ensure	VERB
ajlm-2942	51	18	data	datum	NOUN
ajlm-2942	51	19	comparability	comparability	NOUN
ajlm-2942	51	20	and	and	CCONJ
ajlm-2942	51	21	analyte	analyte	NOUN
ajlm-2942	51	22	stability	stability	NOUN
ajlm-2942	51	23	.	.	PUNCT
ajlm-2942	52	1	biochemical	biochemical	ADJ
ajlm-2942	52	2	analysis	analysis	NOUN
ajlm-2942	52	3	lipid	lipid	NOUN
ajlm-2942	52	4	profile	profile	NOUN
ajlm-2942	52	5	parameters	parameter	NOUN
ajlm-2942	52	6	(	(	PUNCT
ajlm-2942	52	7	total	total	ADJ
ajlm-2942	52	8	cholesterol	cholesterol	NOUN
ajlm-2942	52	9	,	,	PUNCT
ajlm-2942	52	10	high	high	ADJ
ajlm-2942	52	11	-	-	PUNCT
ajlm-2942	52	12	density	density	NOUN
ajlm-2942	52	13	lipoprotein	lipoprotein	ADJ
ajlm-2942	52	14	cholesterol	cholesterol	NOUN
ajlm-2942	52	15	[	[	X
ajlm-2942	52	16	hdlc	hdlc	X
ajlm-2942	52	17	]	]	PUNCT
ajlm-2942	52	18	and	and	CCONJ
ajlm-2942	52	19	triglycerides	triglyceride	NOUN
ajlm-2942	52	20	)	)	PUNCT
ajlm-2942	52	21	,	,	PUNCT
ajlm-2942	52	22	were	be	AUX
ajlm-2942	52	23	measured	measure	VERB
ajlm-2942	52	24	via	via	ADP
ajlm-2942	52	25	commercial	commercial	ADJ
ajlm-2942	52	26	kits	kit	NOUN
ajlm-2942	52	27	(	(	PUNCT
ajlm-2942	52	28	randox	randox	PROPN
ajlm-2942	52	29	laboratories	laboratories	PROPN
ajlm-2942	52	30	ltd	ltd	PROPN
ajlm-2942	52	31	.	.	PROPN
ajlm-2942	52	32	,	,	PUNCT
ajlm-2942	52	33	crumlin	crumlin	PROPN
ajlm-2942	52	34	,	,	PUNCT
ajlm-2942	52	35	northern	northern	PROPN
ajlm-2942	52	36	ireland	ireland	PROPN
ajlm-2942	52	37	,	,	PUNCT
ajlm-2942	52	38	united	united	ADJ
ajlm-2942	52	39	kingdom	kingdom	PROPN
ajlm-2942	52	40	)	)	PUNCT
ajlm-2942	52	41	.	.	PUNCT
ajlm-2942	53	1	total	total	ADJ
ajlm-2942	53	2	cholesterol	cholesterol	NOUN
ajlm-2942	53	3	and	and	CCONJ
ajlm-2942	53	4	hdlc	hdlc	PROPN
ajlm-2942	53	5	(	(	PUNCT
ajlm-2942	53	6	following	follow	VERB
ajlm-2942	53	7	the	the	DET
ajlm-2942	53	8	removal	removal	NOUN
ajlm-2942	53	9	of	of	ADP
ajlm-2942	53	10	all	all	DET
ajlm-2942	53	11	non	non	ADJ
ajlm-2942	53	12	-	-	ADJ
ajlm-2942	53	13	hdl	hdl	ADJ
ajlm-2942	53	14	lipid	lipid	NOUN
ajlm-2942	53	15	fractions	fraction	NOUN
ajlm-2942	53	16	with	with	ADP
ajlm-2942	53	17	phosphotungstic	phosphotungstic	ADJ
ajlm-2942	53	18	acid	acid	NOUN
ajlm-2942	53	19	and	and	CCONJ
ajlm-2942	53	20	magnesium	magnesium	NOUN
ajlm-2942	53	21	ions	ion	NOUN
ajlm-2942	53	22	)	)	PUNCT
ajlm-2942	53	23	were	be	AUX
ajlm-2942	53	24	estimated	estimate	VERB
ajlm-2942	53	25	using	use	VERB
ajlm-2942	53	26	the	the	DET
ajlm-2942	53	27	methods	method	NOUN
ajlm-2942	53	28	of	of	ADP
ajlm-2942	53	29	allain	allain	PROPN
ajlm-2942	53	30	et	et	PROPN
ajlm-2942	53	31	al.30	al.30	NOUN
ajlm-2942	53	32	triglycerides	triglyceride	NOUN
ajlm-2942	53	33	were	be	AUX
ajlm-2942	53	34	measured	measure	VERB
ajlm-2942	53	35	via	via	ADP
ajlm-2942	53	36	the	the	DET
ajlm-2942	53	37	method	method	NOUN
ajlm-2942	53	38	developed	develop	VERB
ajlm-2942	53	39	by	by	ADP
ajlm-2942	53	40	bucolo	bucolo	NOUN
ajlm-2942	53	41	and	and	CCONJ
ajlm-2942	53	42	david.31	david.31	VERB
ajlm-2942	53	43	the	the	DET
ajlm-2942	53	44	calculation	calculation	NOUN
ajlm-2942	53	45	of	of	ADP
ajlm-2942	53	46	ldlc	ldlc	NOUN
ajlm-2942	53	47	was	be	AUX
ajlm-2942	53	48	performed	perform	VERB
ajlm-2942	53	49	using	use	VERB
ajlm-2942	53	50	the	the	DET
ajlm-2942	53	51	formula	formula	NOUN
ajlm-2942	53	52	provided	provide	VERB
ajlm-2942	53	53	by	by	ADP
ajlm-2942	53	54	friedewald	friedewald	ADJ
ajlm-2942	53	55	,	,	PUNCT
ajlm-2942	53	56	levy	levy	NOUN
ajlm-2942	53	57	and	and	CCONJ
ajlm-2942	53	58	fredrickson,32	fredrickson,32	NOUN
ajlm-2942	53	59	selected	select	VERB
ajlm-2942	53	60	for	for	ADP
ajlm-2942	53	61	its	its	PRON
ajlm-2942	53	62	validation	validation	NOUN
ajlm-2942	53	63	,	,	PUNCT
ajlm-2942	53	64	cost	cost	NOUN
ajlm-2942	53	65	-	-	PUNCT
ajlm-2942	53	66	effectiveness	effectiveness	NOUN
ajlm-2942	53	67	,	,	PUNCT
ajlm-2942	53	68	and	and	CCONJ
ajlm-2942	53	69	suitability	suitability	NOUN
ajlm-2942	53	70	in	in	ADP
ajlm-2942	53	71	resource	resource	NOUN
ajlm-2942	53	72	-	-	PUNCT
ajlm-2942	53	73	limited	limit	VERB
ajlm-2942	53	74	settings	setting	NOUN
ajlm-2942	53	75	such	such	ADJ
ajlm-2942	53	76	as	as	ADP
ajlm-2942	53	77	sub	sub	ADJ
ajlm-2942	53	78	-	-	ADJ
ajlm-2942	53	79	saharan	saharan	ADJ
ajlm-2942	53	80	africa	africa	PROPN
ajlm-2942	53	81	,	,	PUNCT
ajlm-2942	53	82	where	where	SCONJ
ajlm-2942	53	83	direct	direct	ADJ
ajlm-2942	53	84	methods	method	NOUN
ajlm-2942	53	85	(	(	PUNCT
ajlm-2942	53	86	e.g.	e.g.	ADV
ajlm-2942	53	87	ultracentrifugation	ultracentrifugation	NOUN
ajlm-2942	53	88	or	or	CCONJ
ajlm-2942	53	89	the	the	DET
ajlm-2942	53	90	martin	martin	PROPN
ajlm-2942	53	91	-	-	PUNCT
ajlm-2942	53	92	hopkins	hopkins	PROPN
ajlm-2942	53	93	equation	equation	NOUN
ajlm-2942	53	94	)	)	PUNCT
ajlm-2942	53	95	are	be	AUX
ajlm-2942	53	96	often	often	ADV
ajlm-2942	53	97	impractical	impractical	ADJ
ajlm-2942	53	98	.	.	PUNCT
ajlm-2942	54	1	all	all	DET
ajlm-2942	54	2	samples	sample	NOUN
ajlm-2942	54	3	had	have	VERB
ajlm-2942	54	4	triglyceride	triglyceride	ADJ
ajlm-2942	54	5	levels	level	NOUN
ajlm-2942	54	6	below	below	ADP
ajlm-2942	54	7	4.52	4.52	NUM
ajlm-2942	54	8	mmol	mmol	NOUN
ajlm-2942	54	9	/	/	SYM
ajlm-2942	54	10	l	l	NOUN
ajlm-2942	54	11	,	,	PUNCT
ajlm-2942	54	12	confirming	confirm	VERB
ajlm-2942	54	13	the	the	DET
ajlm-2942	54	14	validity	validity	NOUN
ajlm-2942	54	15	of	of	ADP
ajlm-2942	54	16	the	the	DET
ajlm-2942	54	17	equation	equation	NOUN
ajlm-2942	54	18	.	.	PUNCT
ajlm-2942	55	1	based	base	VERB
ajlm-2942	55	2	on	on	ADP
ajlm-2942	55	3	these	these	DET
ajlm-2942	55	4	measurements	measurement	NOUN
ajlm-2942	55	5	,	,	PUNCT
ajlm-2942	55	6	we	we	PRON
ajlm-2942	55	7	further	far	ADV
ajlm-2942	55	8	evaluated	evaluate	VERB
ajlm-2942	55	9	derived	derived	ADJ
ajlm-2942	55	10	lipid	lipid	NOUN
ajlm-2942	55	11	indices	index	NOUN
ajlm-2942	55	12	,	,	PUNCT
ajlm-2942	55	13	including	include	VERB
ajlm-2942	55	14	ldlc	ldlc	NOUN
ajlm-2942	55	15	,	,	PUNCT
ajlm-2942	55	16	non	non	ADJ
ajlm-2942	55	17	-	-	NOUN
ajlm-2942	55	18	hdlc	hdlc	NOUN
ajlm-2942	55	19	,	,	PUNCT
ajlm-2942	55	20	castelli	castelli	PROPN
ajlm-2942	55	21	’s	’s	PART
ajlm-2942	55	22	risk	risk	NOUN
ajlm-2942	55	23	indices	index	NOUN
ajlm-2942	55	24	(	(	PUNCT
ajlm-2942	55	25	cri	cri	PROPN
ajlm-2942	55	26	-	-	PROPN
ajlm-2942	55	27	i	i	PROPN
ajlm-2942	55	28	,	,	PUNCT
ajlm-2942	55	29	cri	cri	PROPN
ajlm-2942	55	30	-	-	NOUN
ajlm-2942	55	31	ii	ii	NOUN
ajlm-2942	55	32	)	)	PUNCT
ajlm-2942	55	33	,	,	PUNCT
ajlm-2942	55	34	atherogenic	atherogenic	ADJ
ajlm-2942	55	35	coefficient	coefficient	NOUN
ajlm-2942	55	36	(	(	PUNCT
ajlm-2942	55	37	ac	ac	PROPN
ajlm-2942	55	38	)	)	PUNCT
ajlm-2942	55	39	,	,	PUNCT
ajlm-2942	55	40	and	and	CCONJ
ajlm-2942	55	41	atherogenic	atherogenic	ADJ
ajlm-2942	55	42	index	index	NOUN
ajlm-2942	55	43	of	of	ADP
ajlm-2942	55	44	plasma	plasma	NOUN
ajlm-2942	55	45	(	(	PUNCT
ajlm-2942	55	46	aip	aip	PROPN
ajlm-2942	55	47	)	)	PUNCT
ajlm-2942	55	48	,	,	PUNCT
ajlm-2942	55	49	using	use	VERB
ajlm-2942	55	50	standard	standard	ADJ
ajlm-2942	55	51	lipid	lipid	NOUN
ajlm-2942	55	52	panel	panel	NOUN
ajlm-2942	55	53	measurements	measurement	NOUN
ajlm-2942	55	54	(	(	PUNCT
ajlm-2942	55	55	total	total	ADJ
ajlm-2942	55	56	cholesterol	cholesterol	NOUN
ajlm-2942	56	1	[	[	X
ajlm-2942	56	2	tc	tc	X
ajlm-2942	56	3	]	]	X
ajlm-2942	56	4	,	,	PUNCT
ajlm-2942	56	5	triglycerides	triglyceride	NOUN
ajlm-2942	56	6	,	,	PUNCT
ajlm-2942	56	7	hdlc	hdlc	PROPN
ajlm-2942	56	8	)	)	PUNCT
ajlm-2942	56	9	.	.	PUNCT
ajlm-2942	57	1	formulas	formula	NOUN
ajlm-2942	57	2	and	and	CCONJ
ajlm-2942	57	3	clinical	clinical	ADJ
ajlm-2942	57	4	relevance	relevance	NOUN
ajlm-2942	57	5	are	be	AUX
ajlm-2942	57	6	provided	provide	VERB
ajlm-2942	57	7	in	in	ADP
ajlm-2942	57	8	online	online	ADJ
ajlm-2942	57	9	supplementary	supplementary	ADJ
ajlm-2942	57	10	table	table	NOUN
ajlm-2942	57	11	1.32,33,34	1.32,33,34	NUM
ajlm-2942	57	12	table	table	NOUN
ajlm-2942	57	13	1	1	NUM
ajlm-2942	57	14	:	:	PUNCT
ajlm-2942	57	15	 	 	SPACE
ajlm-2942	57	16	general	general	ADJ
ajlm-2942	57	17	characteristics	characteristic	NOUN
ajlm-2942	57	18	and	and	CCONJ
ajlm-2942	57	19	biochemical	biochemical	ADJ
ajlm-2942	57	20	parameters	parameter	NOUN
ajlm-2942	57	21	of	of	ADP
ajlm-2942	57	22	study	study	NOUN
ajlm-2942	57	23	population	population	NOUN
ajlm-2942	57	24	at	at	ADP
ajlm-2942	57	25	lagos	lagos	PROPN
ajlm-2942	57	26	state	state	NOUN
ajlm-2942	57	27	university	university	PROPN
ajlm-2942	57	28	teaching	teaching	NOUN
ajlm-2942	57	29	hospital	hospital	NOUN
ajlm-2942	57	30	,	,	PUNCT
ajlm-2942	57	31	lagos	lago	NOUN
ajlm-2942	57	32	,	,	PUNCT
ajlm-2942	57	33	nigeria	nigeria	PROPN
ajlm-2942	57	34	,	,	PUNCT
ajlm-2942	57	35	between	between	ADP
ajlm-2942	57	36	november	november	PROPN
ajlm-2942	57	37	2021	2021	NUM
ajlm-2942	57	38	and	and	CCONJ
ajlm-2942	57	39	november	november	PROPN
ajlm-2942	57	40	2022	2022	NUM
ajlm-2942	57	41	.	.	PUNCT
ajlm-2942	58	1	plasma	plasma	NOUN
ajlm-2942	58	2	total	total	ADJ
ajlm-2942	58	3	phospholipids	phospholipid	NOUN
ajlm-2942	58	4	were	be	AUX
ajlm-2942	58	5	analysed	analyse	VERB
ajlm-2942	58	6	via	via	ADP
ajlm-2942	58	7	the	the	DET
ajlm-2942	58	8	wako	wako	PROPN
ajlm-2942	58	9	phospholipid	phospholipid	PROPN
ajlm-2942	58	10	c	c	PROPN
ajlm-2942	58	11	assay	assay	PROPN
ajlm-2942	58	12	kit	kit	NOUN
ajlm-2942	58	13	(	(	PUNCT
ajlm-2942	58	14	fujifilm	fujifilm	PROPN
ajlm-2942	58	15	wako	wako	PROPN
ajlm-2942	58	16	pure	pure	ADJ
ajlm-2942	58	17	chemical	chemical	NOUN
ajlm-2942	58	18	industries	industry	NOUN
ajlm-2942	58	19	,	,	PUNCT
ajlm-2942	58	20	ltd	ltd	PROPN
ajlm-2942	58	21	.	.	PROPN
ajlm-2942	58	22	,	,	PUNCT
ajlm-2942	58	23	osaka	osaka	PROPN
ajlm-2942	58	24	,	,	PUNCT
ajlm-2942	58	25	japan	japan	PROPN
ajlm-2942	58	26	)	)	PUNCT
ajlm-2942	58	27	,	,	PUNCT
ajlm-2942	58	28	which	which	PRON
ajlm-2942	58	29	employs	employ	VERB
ajlm-2942	58	30	the	the	DET
ajlm-2942	58	31	n	n	CCONJ
ajlm-2942	58	32	-	-	PUNCT
ajlm-2942	58	33	ethyl	ethyl	NOUN
ajlm-2942	58	34	-	-	PUNCT
ajlm-2942	58	35	n-(2	n-(2	PROPN
ajlm-2942	58	36	-	-	PUNCT
ajlm-2942	58	37	hydroxy-3	hydroxy-3	NOUN
ajlm-2942	58	38	-	-	PUNCT
ajlm-2942	58	39	sulfopropyl	sulfopropyl	NOUN
ajlm-2942	58	40	)	)	PUNCT
ajlm-2942	58	41	3,5	3,5	NUM
ajlm-2942	58	42	-	-	PUNCT
ajlm-2942	58	43	dimethoxy	dimethoxy	ADJ
ajlm-2942	58	44	aniline	aniline	NOUN
ajlm-2942	58	45	sodium	sodium	NOUN
ajlm-2942	58	46	salt	salt	NOUN
ajlm-2942	58	47	method.35	method.35	ADJ
ajlm-2942	58	48	high	high	ADJ
ajlm-2942	58	49	-	-	PUNCT
ajlm-2942	58	50	density	density	NOUN
ajlm-2942	58	51	lipoprotein	lipoprotein	ADJ
ajlm-2942	58	52	phospholipids	phospholipid	NOUN
ajlm-2942	58	53	were	be	AUX
ajlm-2942	58	54	assayed	assayed	ADJ
ajlm-2942	58	55	via	via	ADP
ajlm-2942	58	56	this	this	DET
ajlm-2942	58	57	method	method	NOUN
ajlm-2942	58	58	after	after	ADP
ajlm-2942	58	59	treatment	treatment	NOUN
ajlm-2942	58	60	of	of	ADP
ajlm-2942	58	61	participants	participant	NOUN
ajlm-2942	58	62	’	'	PUNCT
ajlm-2942	58	63	plasma	plasma	NOUN
ajlm-2942	58	64	with	with	ADP
ajlm-2942	58	65	phosphotungstic	phosphotungstic	ADJ
ajlm-2942	58	66	acid	acid	NOUN
ajlm-2942	58	67	and	and	CCONJ
ajlm-2942	58	68	magnesium	magnesium	NOUN
ajlm-2942	58	69	ions	ion	NOUN
ajlm-2942	58	70	(	(	PUNCT
ajlm-2942	58	71	to	to	PART
ajlm-2942	58	72	remove	remove	VERB
ajlm-2942	58	73	all	all	DET
ajlm-2942	58	74	non	non	ADJ
ajlm-2942	58	75	-	-	ADJ
ajlm-2942	58	76	hdl	hdl	ADJ
ajlm-2942	58	77	phospholipids	phospholipid	NOUN
ajlm-2942	58	78	fractions).36	fractions).36	VERB
ajlm-2942	58	79	the	the	DET
ajlm-2942	58	80	plasma	plasma	NOUN
ajlm-2942	58	81	levels	level	NOUN
ajlm-2942	58	82	of	of	ADP
ajlm-2942	58	83	human	human	ADJ
ajlm-2942	58	84	apo	apo	PROPN
ajlm-2942	58	85	a1	a1	NOUN
ajlm-2942	58	86	and	and	CCONJ
ajlm-2942	58	87	apo	apo	PROPN
ajlm-2942	58	88	b	b	PROPN
ajlm-2942	58	89	in	in	ADP
ajlm-2942	58	90	the	the	DET
ajlm-2942	58	91	participants	participant	NOUN
ajlm-2942	58	92	were	be	AUX
ajlm-2942	58	93	determined	determine	VERB
ajlm-2942	58	94	using	use	VERB
ajlm-2942	58	95	the	the	DET
ajlm-2942	58	96	sandwich	sandwich	NOUN
ajlm-2942	58	97	enzyme	enzyme	NOUN
ajlm-2942	58	98	-	-	PUNCT
ajlm-2942	58	99	linked	link	VERB
ajlm-2942	58	100	immunosorbent	immunosorbent	NOUN
ajlm-2942	58	101	assay	assay	NOUN
ajlm-2942	58	102	technique,37	technique,37	VERB
ajlm-2942	58	103	with	with	ADP
ajlm-2942	58	104	assay	assay	PROPN
ajlm-2942	58	105	kits	kit	NOUN
ajlm-2942	58	106	sourced	source	VERB
ajlm-2942	58	107	from	from	ADP
ajlm-2942	58	108	elabscience	elabscience	NOUN
ajlm-2942	58	109	biotechnology	biotechnology	NOUN
ajlm-2942	58	110	limited	limit	VERB
ajlm-2942	58	111	,	,	PUNCT
ajlm-2942	58	112	wuhan	wuhan	PROPN
ajlm-2942	58	113	,	,	PUNCT
ajlm-2942	58	114	china	china	PROPN
ajlm-2942	58	115	.	.	PUNCT
ajlm-2942	59	1	analyses	analysis	NOUN
ajlm-2942	59	2	were	be	AUX
ajlm-2942	59	3	performed	perform	VERB
ajlm-2942	59	4	on	on	ADP
ajlm-2942	59	5	a	a	DET
ajlm-2942	59	6	bio	bio	ADJ
ajlm-2942	59	7	-	-	ADJ
ajlm-2942	59	8	rad	rad	ADJ
ajlm-2942	59	9	imark	imark	PROPN
ajlm-2942	59	10	™	™	PROPN
ajlm-2942	59	11	microplate	microplate	NOUN
ajlm-2942	59	12	reader	reader	NOUN
ajlm-2942	59	13	(	(	PUNCT
ajlm-2942	59	14	bio	bio	NOUN
ajlm-2942	59	15	-	-	ADJ
ajlm-2942	59	16	rad	rad	PROPN
ajlm-2942	59	17	laboratories	laboratory	NOUN
ajlm-2942	59	18	,	,	PUNCT
ajlm-2942	59	19	hercules	hercules	PROPN
ajlm-2942	59	20	,	,	PUNCT
ajlm-2942	59	21	california	california	PROPN
ajlm-2942	59	22	,	,	PUNCT
ajlm-2942	59	23	united	united	PROPN
ajlm-2942	59	24	states	states	PROPN
ajlm-2942	59	25	)	)	PUNCT
ajlm-2942	59	26	at	at	ADP
ajlm-2942	59	27	450	450	NUM
ajlm-2942	59	28	nm	nm	NOUN
ajlm-2942	59	29	.	.	PUNCT
ajlm-2942	60	1	the	the	DET
ajlm-2942	60	2	system	system	NOUN
ajlm-2942	60	3	performs	perform	VERB
ajlm-2942	60	4	optical	optical	ADJ
ajlm-2942	60	5	calibration	calibration	NOUN
ajlm-2942	60	6	and	and	CCONJ
ajlm-2942	60	7	data	datum	NOUN
ajlm-2942	60	8	processing	processing	NOUN
ajlm-2942	60	9	automatically	automatically	ADV
ajlm-2942	60	10	,	,	PUNCT
ajlm-2942	60	11	following	follow	VERB
ajlm-2942	60	12	the	the	DET
ajlm-2942	60	13	manufacturer	manufacturer	NOUN
ajlm-2942	60	14	’s	’s	PART
ajlm-2942	60	15	instructions	instruction	NOUN
ajlm-2942	60	16	.	.	PUNCT
ajlm-2942	61	1	quality	quality	NOUN
ajlm-2942	61	2	control	control	PROPN
ajlm-2942	61	3	sera	sera	NOUN
ajlm-2942	61	4	were	be	AUX
ajlm-2942	61	5	included	include	VERB
ajlm-2942	61	6	in	in	ADP
ajlm-2942	61	7	each	each	DET
ajlm-2942	61	8	batch	batch	NOUN
ajlm-2942	61	9	to	to	PART
ajlm-2942	61	10	ensure	ensure	VERB
ajlm-2942	61	11	analytical	analytical	ADJ
ajlm-2942	61	12	precision	precision	NOUN
ajlm-2942	61	13	and	and	CCONJ
ajlm-2942	61	14	reliability	reliability	NOUN
ajlm-2942	61	15	.	.	PUNCT
ajlm-2942	62	1	sandwich	sandwich	NOUN
ajlm-2942	62	2	enzyme	enzyme	NOUN
ajlm-2942	62	3	-	-	PUNCT
ajlm-2942	62	4	linked	link	VERB
ajlm-2942	62	5	immunosorbent	immunosorbent	NOUN
ajlm-2942	62	6	assay	assay	NOUN
ajlm-2942	62	7	was	be	AUX
ajlm-2942	62	8	selected	select	VERB
ajlm-2942	62	9	for	for	ADP
ajlm-2942	62	10	apolipoprotein	apolipoprotein	ADJ
ajlm-2942	62	11	analysis	analysis	NOUN
ajlm-2942	62	12	because	because	SCONJ
ajlm-2942	62	13	of	of	ADP
ajlm-2942	62	14	its	its	PRON
ajlm-2942	62	15	high	high	ADJ
ajlm-2942	62	16	specificity	specificity	NOUN
ajlm-2942	62	17	,	,	PUNCT
ajlm-2942	62	18	sensitivity	sensitivity	NOUN
ajlm-2942	62	19	and	and	CCONJ
ajlm-2942	62	20	practical	practical	ADJ
ajlm-2942	62	21	advantages	advantage	NOUN
ajlm-2942	62	22	over	over	ADP
ajlm-2942	62	23	western	western	ADJ
ajlm-2942	62	24	blotting	blotting	NOUN
ajlm-2942	62	25	and	and	CCONJ
ajlm-2942	62	26	radioactive	radioactive	ADJ
ajlm-2942	62	27	immunoassays	immunoassay	NOUN
ajlm-2942	62	28	.	.	PUNCT
ajlm-2942	63	1	spectrophotometry	spectrophotometry	NOUN
ajlm-2942	63	2	was	be	AUX
ajlm-2942	63	3	chosen	choose	VERB
ajlm-2942	63	4	for	for	ADP
ajlm-2942	63	5	lipid	lipid	NOUN
ajlm-2942	63	6	profiling	profiling	NOUN
ajlm-2942	63	7	because	because	SCONJ
ajlm-2942	63	8	of	of	ADP
ajlm-2942	63	9	its	its	PRON
ajlm-2942	63	10	efficiency	efficiency	NOUN
ajlm-2942	63	11	and	and	CCONJ
ajlm-2942	63	12	cost	cost	NOUN
ajlm-2942	63	13	-	-	PUNCT
ajlm-2942	63	14	effectiveness	effectiveness	NOUN
ajlm-2942	63	15	,	,	PUNCT
ajlm-2942	63	16	providing	provide	VERB
ajlm-2942	63	17	direct	direct	ADJ
ajlm-2942	63	18	measurement	measurement	NOUN
ajlm-2942	63	19	of	of	ADP
ajlm-2942	63	20	lipid	lipid	ADJ
ajlm-2942	63	21	fractions	fraction	NOUN
ajlm-2942	63	22	.	.	PUNCT
ajlm-2942	64	1	chromatographic	chromatographic	ADJ
ajlm-2942	64	2	methods	method	NOUN
ajlm-2942	64	3	,	,	PUNCT
ajlm-2942	64	4	although	although	SCONJ
ajlm-2942	64	5	precise	precise	ADJ
ajlm-2942	64	6	,	,	PUNCT
ajlm-2942	64	7	require	require	VERB
ajlm-2942	64	8	more	more	ADJ
ajlm-2942	64	9	resources	resource	NOUN
ajlm-2942	64	10	and	and	CCONJ
ajlm-2942	64	11	technical	technical	ADJ
ajlm-2942	64	12	skill	skill	NOUN
ajlm-2942	64	13	,	,	PUNCT
ajlm-2942	64	14	making	make	VERB
ajlm-2942	64	15	spectrophotometry	spectrophotometry	NOUN
ajlm-2942	64	16	a	a	DET
ajlm-2942	64	17	more	more	ADV
ajlm-2942	64	18	accessible	accessible	ADJ
ajlm-2942	64	19	option	option	NOUN
ajlm-2942	64	20	for	for	ADP
ajlm-2942	64	21	routine	routine	ADJ
ajlm-2942	64	22	analysis	analysis	NOUN
ajlm-2942	64	23	in	in	ADP
ajlm-2942	64	24	sub	sub	ADJ
ajlm-2942	64	25	-	-	ADJ
ajlm-2942	64	26	saharan	saharan	ADJ
ajlm-2942	64	27	africa	africa	PROPN
ajlm-2942	64	28	.	.	PUNCT
ajlm-2942	65	1	data	datum	NOUN
ajlm-2942	65	2	analysis	analysis	NOUN
ajlm-2942	65	3	statistical	statistical	ADJ
ajlm-2942	65	4	analyses	analysis	NOUN
ajlm-2942	65	5	were	be	AUX
ajlm-2942	65	6	conducted	conduct	VERB
ajlm-2942	65	7	using	use	VERB
ajlm-2942	65	8	ibm	ibm	PROPN
ajlm-2942	65	9	spss	spss	PROPN
ajlm-2942	65	10	statistics	statistic	NOUN
ajlm-2942	65	11	(	(	PUNCT
ajlm-2942	65	12	version	version	NOUN
ajlm-2942	65	13	21	21	NUM
ajlm-2942	65	14	,	,	PUNCT
ajlm-2942	65	15	ibm	ibm	PROPN
ajlm-2942	65	16	corp	corp	PROPN
ajlm-2942	65	17	.	.	PROPN
ajlm-2942	65	18	,	,	PUNCT
ajlm-2942	65	19	armonk	armonk	PROPN
ajlm-2942	65	20	,	,	PUNCT
ajlm-2942	65	21	new	new	PROPN
ajlm-2942	65	22	york	york	PROPN
ajlm-2942	65	23	,	,	PUNCT
ajlm-2942	65	24	united	united	PROPN
ajlm-2942	65	25	states	states	PROPN
ajlm-2942	65	26	)	)	PUNCT
ajlm-2942	65	27	.	.	PUNCT
ajlm-2942	66	1	data	datum	NOUN
ajlm-2942	66	2	completeness	completeness	NOUN
ajlm-2942	66	3	and	and	CCONJ
ajlm-2942	66	4	normality	normality	NOUN
ajlm-2942	66	5	were	be	AUX
ajlm-2942	66	6	verified	verify	VERB
ajlm-2942	66	7	,	,	PUNCT
ajlm-2942	66	8	with	with	ADP
ajlm-2942	66	9	continuous	continuous	ADJ
ajlm-2942	66	10	variables	variable	NOUN
ajlm-2942	66	11	reported	report	VERB
ajlm-2942	66	12	as	as	SCONJ
ajlm-2942	66	13	means	mean	VERB
ajlm-2942	66	14	±	±	NUM
ajlm-2942	66	15	standard	standard	ADJ
ajlm-2942	66	16	deviation	deviation	NOUN
ajlm-2942	66	17	,	,	PUNCT
ajlm-2942	66	18	and	and	CCONJ
ajlm-2942	66	19	categorical	categorical	ADJ
ajlm-2942	66	20	variables	variable	NOUN
ajlm-2942	66	21	as	as	ADP
ajlm-2942	66	22	frequencies	frequency	NOUN
ajlm-2942	66	23	(	(	PUNCT
ajlm-2942	66	24	percentages	percentage	NOUN
ajlm-2942	66	25	)	)	PUNCT
ajlm-2942	66	26	.	.	PUNCT
ajlm-2942	67	1	normality	normality	NOUN
ajlm-2942	67	2	of	of	ADP
ajlm-2942	67	3	lipid	lipid	NOUN
ajlm-2942	67	4	and	and	CCONJ
ajlm-2942	67	5	apolipoprotein	apolipoprotein	ADJ
ajlm-2942	67	6	outcomes	outcome	NOUN
ajlm-2942	67	7	(	(	PUNCT
ajlm-2942	67	8	apo	apo	NOUN
ajlm-2942	67	9	a1	a1	PROPN
ajlm-2942	67	10	,	,	PUNCT
ajlm-2942	67	11	apo	apo	PROPN
ajlm-2942	67	12	b	b	PROPN
ajlm-2942	67	13	,	,	PUNCT
ajlm-2942	67	14	hdl	hdl	PROPN
ajlm-2942	67	15	phospholipids	phospholipids	PROPN
ajlm-2942	67	16	,	,	PUNCT
ajlm-2942	67	17	tc	tc	NOUN
ajlm-2942	67	18	,	,	PUNCT
ajlm-2942	67	19	ldlc	ldlc	NOUN
ajlm-2942	67	20	,	,	PUNCT
ajlm-2942	67	21	hdlc	hdlc	PROPN
ajlm-2942	67	22	,	,	PUNCT
ajlm-2942	67	23	triglycerides	triglyceride	NOUN
ajlm-2942	67	24	,	,	PUNCT
ajlm-2942	67	25	non	non	ADJ
ajlm-2942	67	26	-	-	ADJ
ajlm-2942	67	27	hdlc	hdlc	NOUN
ajlm-2942	67	28	,	,	PUNCT
ajlm-2942	67	29	cri	cri	PROPN
ajlm-2942	67	30	-	-	PROPN
ajlm-2942	67	31	i	i	PROPN
ajlm-2942	67	32	,	,	PUNCT
ajlm-2942	67	33	cri	cri	PROPN
ajlm-2942	67	34	-	-	PUNCT
ajlm-2942	67	35	ii	ii	PROPN
ajlm-2942	67	36	,	,	PUNCT
ajlm-2942	67	37	ac	ac	PROPN
ajlm-2942	67	38	,	,	PUNCT
ajlm-2942	67	39	aip	aip	PROPN
ajlm-2942	67	40	)	)	PUNCT
ajlm-2942	67	41	was	be	AUX
ajlm-2942	67	42	assessed	assess	VERB
ajlm-2942	67	43	using	use	VERB
ajlm-2942	67	44	shapiro	shapiro	PROPN
ajlm-2942	67	45	–	–	PUNCT
ajlm-2942	67	46	wilk	wilk	NOUN
ajlm-2942	67	47	tests	test	NOUN
ajlm-2942	67	48	and	and	CCONJ
ajlm-2942	67	49	q	q	X
ajlm-2942	67	50	–	–	PUNCT
ajlm-2942	67	51	q	q	NOUN
ajlm-2942	67	52	plots	plot	NOUN
ajlm-2942	67	53	(	(	PUNCT
ajlm-2942	67	54	n	n	NOUN
ajlm-2942	67	55	=	=	NUM
ajlm-2942	67	56	227	227	NUM
ajlm-2942	67	57	)	)	PUNCT
ajlm-2942	67	58	.	.	PUNCT
ajlm-2942	68	1	non	non	ADJ
ajlm-2942	68	2	-	-	ADJ
ajlm-2942	68	3	normal	normal	ADJ
ajlm-2942	68	4	variables	variable	NOUN
ajlm-2942	68	5	were	be	AUX
ajlm-2942	68	6	log	log	NOUN
ajlm-2942	68	7	-	-	PUNCT
ajlm-2942	68	8	transformed	transform	VERB
ajlm-2942	68	9	.	.	PUNCT
ajlm-2942	69	1	levene	levene	PROPN
ajlm-2942	69	2	’s	’s	PART
ajlm-2942	69	3	test	test	NOUN
ajlm-2942	69	4	confirmed	confirm	VERB
ajlm-2942	69	5	homogeneity	homogeneity	NOUN
ajlm-2942	69	6	of	of	ADP
ajlm-2942	69	7	variances	variance	NOUN
ajlm-2942	69	8	(	(	PUNCT
ajlm-2942	69	9	p	p	X
ajlm-2942	69	10	>	>	X
ajlm-2942	69	11	0.05	0.05	NUM
ajlm-2942	69	12	)	)	PUNCT
ajlm-2942	69	13	.	.	PUNCT
ajlm-2942	70	1	group	group	NOUN
ajlm-2942	70	2	differences	difference	NOUN
ajlm-2942	70	3	(	(	PUNCT
ajlm-2942	70	4	ascvd	ascvd	NOUN
ajlm-2942	70	5	vs	vs	ADP
ajlm-2942	70	6	control	control	NOUN
ajlm-2942	70	7	)	)	PUNCT
ajlm-2942	70	8	were	be	AUX
ajlm-2942	70	9	analysed	analyse	VERB
ajlm-2942	70	10	using	use	VERB
ajlm-2942	70	11	independent	independent	ADJ
ajlm-2942	70	12	samples	sample	NOUN
ajlm-2942	70	13	t	t	NOUN
ajlm-2942	70	14	-	-	PUNCT
ajlm-2942	70	15	tests	test	NOUN
ajlm-2942	70	16	and	and	CCONJ
ajlm-2942	70	17	one	one	NUM
ajlm-2942	70	18	-	-	PUNCT
ajlm-2942	70	19	way	way	NOUN
ajlm-2942	70	20	analysis	analysis	NOUN
ajlm-2942	70	21	of	of	ADP
ajlm-2942	70	22	variance	variance	NOUN
ajlm-2942	70	23	with	with	ADP
ajlm-2942	70	24	bonferroni	bonferroni	NOUN
ajlm-2942	70	25	correction	correction	NOUN
ajlm-2942	70	26	(	(	PUNCT
ajlm-2942	70	27	p	p	X
ajlm-2942	70	28	<	<	X
ajlm-2942	70	29	0.001	0.001	NUM
ajlm-2942	70	30	)	)	PUNCT
ajlm-2942	70	31	.	.	PUNCT
ajlm-2942	71	1	effect	effect	NOUN
ajlm-2942	71	2	sizes	size	NOUN
ajlm-2942	71	3	were	be	AUX
ajlm-2942	71	4	reported	report	VERB
ajlm-2942	71	5	as	as	ADP
ajlm-2942	71	6	cohen	cohen	PROPN
ajlm-2942	71	7	’s	’s	PROPN
ajlm-2942	71	8	d	d	PROPN
ajlm-2942	71	9	,	,	PUNCT
ajlm-2942	71	10	r2	r2	NOUN
ajlm-2942	71	11	,	,	PUNCT
ajlm-2942	71	12	and	and	CCONJ
ajlm-2942	71	13	partial	partial	ADJ
ajlm-2942	71	14	η2	η2	NOUN
ajlm-2942	71	15	.	.	PUNCT
ajlm-2942	72	1	separate	separate	ADJ
ajlm-2942	72	2	analysis	analysis	NOUN
ajlm-2942	72	3	of	of	ADP
ajlm-2942	72	4	covariance	covariance	NOUN
ajlm-2942	72	5	models	model	NOUN
ajlm-2942	72	6	,	,	PUNCT
ajlm-2942	72	7	with	with	ADP
ajlm-2942	72	8	age	age	NOUN
ajlm-2942	72	9	as	as	ADP
ajlm-2942	72	10	the	the	DET
ajlm-2942	72	11	covariate	covariate	NOUN
ajlm-2942	72	12	,	,	PUNCT
ajlm-2942	72	13	were	be	AUX
ajlm-2942	72	14	used	use	VERB
ajlm-2942	72	15	for	for	ADP
ajlm-2942	72	16	each	each	DET
ajlm-2942	72	17	lipid	lipid	NOUN
ajlm-2942	72	18	and	and	CCONJ
ajlm-2942	72	19	apolipoprotein	apolipoprotein	ADJ
ajlm-2942	72	20	outcome	outcome	NOUN
ajlm-2942	72	21	owing	owe	VERB
ajlm-2942	72	22	to	to	ADP
ajlm-2942	72	23	its	its	PRON
ajlm-2942	72	24	significant	significant	ADJ
ajlm-2942	72	25	correlation	correlation	NOUN
ajlm-2942	72	26	with	with	ADP
ajlm-2942	72	27	outcomes	outcome	NOUN
ajlm-2942	72	28	(	(	PUNCT
ajlm-2942	72	29	p	p	X
ajlm-2942	72	30	<	<	X
ajlm-2942	72	31	0.05	0.05	NUM
ajlm-2942	72	32	,	,	PUNCT
ajlm-2942	72	33	pearson	pearson	PROPN
ajlm-2942	72	34	’s	’s	PART
ajlm-2942	72	35	correlation	correlation	NOUN
ajlm-2942	72	36	;	;	PUNCT
ajlm-2942	72	37	online	online	ADJ
ajlm-2942	72	38	supplementary	supplementary	ADJ
ajlm-2942	72	39	table	table	NOUN
ajlm-2942	72	40	2	2	NUM
ajlm-2942	72	41	)	)	PUNCT
ajlm-2942	72	42	other	other	ADJ
ajlm-2942	72	43	potential	potential	ADJ
ajlm-2942	72	44	confounders	confounder	NOUN
ajlm-2942	72	45	(	(	PUNCT
ajlm-2942	72	46	sex	sex	NOUN
ajlm-2942	72	47	,	,	PUNCT
ajlm-2942	72	48	bmi	bmi	NOUN
ajlm-2942	72	49	,	,	PUNCT
ajlm-2942	72	50	smoking	smoking	NOUN
ajlm-2942	72	51	,	,	PUNCT
ajlm-2942	72	52	hypertension	hypertension	NOUN
ajlm-2942	72	53	)	)	PUNCT
ajlm-2942	72	54	were	be	AUX
ajlm-2942	72	55	non	non	ADJ
ajlm-2942	72	56	-	-	ADJ
ajlm-2942	72	57	significant	significant	ADJ
ajlm-2942	72	58	(	(	PUNCT
ajlm-2942	72	59	p	p	X
ajlm-2942	72	60	>	>	X
ajlm-2942	72	61	0.05	0.05	NUM
ajlm-2942	72	62	)	)	PUNCT
ajlm-2942	72	63	and	and	CCONJ
ajlm-2942	72	64	excluded	exclude	VERB
ajlm-2942	72	65	,	,	PUNCT
ajlm-2942	72	66	along	along	ADP
ajlm-2942	72	67	with	with	ADP
ajlm-2942	72	68	diabetes	diabetes	NOUN
ajlm-2942	72	69	and	and	CCONJ
ajlm-2942	72	70	lipid	lipid	NOUN
ajlm-2942	72	71	-	-	PUNCT
ajlm-2942	72	72	lowering	lower	VERB
ajlm-2942	72	73	medication	medication	NOUN
ajlm-2942	72	74	use	use	NOUN
ajlm-2942	72	75	.	.	PUNCT
ajlm-2942	73	1	analysis	analysis	NOUN
ajlm-2942	73	2	of	of	ADP
ajlm-2942	73	3	covariance	covariance	NOUN
ajlm-2942	73	4	assumptions	assumption	NOUN
ajlm-2942	73	5	were	be	AUX
ajlm-2942	73	6	met	meet	VERB
ajlm-2942	73	7	:	:	PUNCT
ajlm-2942	73	8	linearity	linearity	NOUN
ajlm-2942	73	9	(	(	PUNCT
ajlm-2942	73	10	via	via	ADP
ajlm-2942	73	11	scatterplots	scatterplot	NOUN
ajlm-2942	73	12	and	and	CCONJ
ajlm-2942	73	13	pearson	pearson	PROPN
ajlm-2942	73	14	’s	’s	PART
ajlm-2942	73	15	correlation	correlation	NOUN
ajlm-2942	73	16	)	)	PUNCT
ajlm-2942	73	17	,	,	PUNCT
ajlm-2942	73	18	homogeneity	homogeneity	NOUN
ajlm-2942	73	19	of	of	ADP
ajlm-2942	73	20	regression	regression	NOUN
ajlm-2942	73	21	slopes	slope	NOUN
ajlm-2942	73	22	(	(	PUNCT
ajlm-2942	73	23	group	group	NOUN
ajlm-2942	73	24	×	×	NOUN
ajlm-2942	73	25	covariate	covariate	NOUN
ajlm-2942	73	26	interaction	interaction	NOUN
ajlm-2942	73	27	,	,	PUNCT
ajlm-2942	73	28	p	p	X
ajlm-2942	73	29	>	>	X
ajlm-2942	73	30	0.05	0.05	NUM
ajlm-2942	73	31	)	)	PUNCT
ajlm-2942	73	32	,	,	PUNCT
ajlm-2942	73	33	normality	normality	NOUN
ajlm-2942	73	34	of	of	ADP
ajlm-2942	73	35	residuals	residual	NOUN
ajlm-2942	73	36	(	(	PUNCT
ajlm-2942	73	37	shapiro	shapiro	NOUN
ajlm-2942	73	38	–	–	PUNCT
ajlm-2942	73	39	wilk	wilk	NOUN
ajlm-2942	73	40	and	and	CCONJ
ajlm-2942	73	41	q	q	NOUN
ajlm-2942	73	42	–	–	PUNCT
ajlm-2942	73	43	q	q	NOUN
ajlm-2942	73	44	plots	plot	NOUN
ajlm-2942	73	45	)	)	PUNCT
ajlm-2942	73	46	,	,	PUNCT
ajlm-2942	73	47	homoscedasticity	homoscedasticity	NOUN
ajlm-2942	73	48	(	(	PUNCT
ajlm-2942	73	49	breusch	breusch	ADJ
ajlm-2942	73	50	-	-	PUNCT
ajlm-2942	73	51	pagan	pagan	ADJ
ajlm-2942	73	52	test	test	NOUN
ajlm-2942	73	53	,	,	PUNCT
ajlm-2942	73	54	p	p	X
ajlm-2942	73	55	>	>	X
ajlm-2942	73	56	0.05	0.05	NUM
ajlm-2942	73	57	)	)	PUNCT
ajlm-2942	73	58	,	,	PUNCT
ajlm-2942	73	59	and	and	CCONJ
ajlm-2942	73	60	independence	independence	NOUN
ajlm-2942	73	61	of	of	ADP
ajlm-2942	73	62	residuals	residual	NOUN
ajlm-2942	73	63	(	(	PUNCT
ajlm-2942	73	64	durbin	durbin	ADJ
ajlm-2942	73	65	–	–	PUNCT
ajlm-2942	73	66	watson	watson	NOUN
ajlm-2942	73	67	≈	≈	PROPN
ajlm-2942	73	68	2.0	2.0	NUM
ajlm-2942	73	69	)	)	PUNCT
ajlm-2942	73	70	.	.	PUNCT
ajlm-2942	74	1	age	age	NOUN
ajlm-2942	74	2	-	-	PUNCT
ajlm-2942	74	3	adjusted	adjust	VERB
ajlm-2942	74	4	means	mean	NOUN
ajlm-2942	74	5	and	and	CCONJ
ajlm-2942	74	6	partial	partial	ADJ
ajlm-2942	74	7	eta	eta	NOUN
ajlm-2942	74	8	-	-	PUNCT
ajlm-2942	74	9	squared	square	VERB
ajlm-2942	74	10	(	(	PUNCT
ajlm-2942	74	11	η2	η2	ADJ
ajlm-2942	74	12	)	)	PUNCT
ajlm-2942	74	13	values	value	NOUN
ajlm-2942	74	14	for	for	ADP
ajlm-2942	74	15	lipid	lipid	NOUN
ajlm-2942	74	16	parameters	parameter	NOUN
ajlm-2942	74	17	are	be	AUX
ajlm-2942	74	18	presented	present	VERB
ajlm-2942	74	19	in	in	ADP
ajlm-2942	74	20	online	online	ADJ
ajlm-2942	74	21	supplementary	supplementary	ADJ
ajlm-2942	74	22	table	table	NOUN
ajlm-2942	74	23	3	3	NUM
ajlm-2942	74	24	to	to	ADP
ajlm-2942	74	25	online	online	ADJ
ajlm-2942	74	26	supplementary	supplementary	ADJ
ajlm-2942	74	27	table	table	NOUN
ajlm-2942	74	28	9	9	NUM
ajlm-2942	74	29	.	.	PUNCT
ajlm-2942	75	1	results	result	VERB
ajlm-2942	75	2	general	general	ADJ
ajlm-2942	75	3	characteristics	characteristic	NOUN
ajlm-2942	75	4	of	of	ADP
ajlm-2942	75	5	the	the	DET
ajlm-2942	75	6	study	study	NOUN
ajlm-2942	75	7	population	population	NOUN
ajlm-2942	75	8	a	a	DET
ajlm-2942	75	9	total	total	NOUN
ajlm-2942	75	10	of	of	ADP
ajlm-2942	75	11	172	172	NUM
ajlm-2942	75	12	confirmed	confirm	VERB
ajlm-2942	75	13	ascvd	ascvd	NOUN
ajlm-2942	75	14	patients	patient	NOUN
ajlm-2942	75	15	(	(	PUNCT
ajlm-2942	75	16	73	73	NUM
ajlm-2942	75	17	men	man	NOUN
ajlm-2942	75	18	,	,	PUNCT
ajlm-2942	75	19	99	99	NUM
ajlm-2942	75	20	women	woman	NOUN
ajlm-2942	75	21	)	)	PUNCT
ajlm-2942	75	22	aged	aged	ADJ
ajlm-2942	75	23	20–64	20–64	NUM
ajlm-2942	75	24	years	year	NOUN
ajlm-2942	75	25	were	be	AUX
ajlm-2942	75	26	enrolled	enrol	VERB
ajlm-2942	75	27	,	,	PUNCT
ajlm-2942	75	28	including	include	VERB
ajlm-2942	75	29	those	those	PRON
ajlm-2942	75	30	with	with	ADP
ajlm-2942	75	31	ihd	ihd	ADJ
ajlm-2942	75	32	(	(	PUNCT
ajlm-2942	75	33	n	n	NOUN
ajlm-2942	75	34	=	=	NUM
ajlm-2942	75	35	40	40	NUM
ajlm-2942	75	36	)	)	PUNCT
ajlm-2942	75	37	,	,	PUNCT
ajlm-2942	75	38	ischaemic	ischaemic	ADJ
ajlm-2942	75	39	stroke	stroke	NOUN
ajlm-2942	75	40	(	(	PUNCT
ajlm-2942	75	41	n	n	NOUN
ajlm-2942	75	42	=	=	NUM
ajlm-2942	75	43	25	25	NUM
ajlm-2942	75	44	)	)	PUNCT
ajlm-2942	75	45	,	,	PUNCT
ajlm-2942	75	46	hypertensive	hypertensive	ADJ
ajlm-2942	75	47	heart	heart	NOUN
ajlm-2942	75	48	disease	disease	NOUN
ajlm-2942	75	49	with	with	ADP
ajlm-2942	75	50	significant	significant	ADJ
ajlm-2942	75	51	atherosclerosis	atherosclerosis	NOUN
ajlm-2942	75	52	(	(	PUNCT
ajlm-2942	75	53	n	n	NOUN
ajlm-2942	75	54	=	=	SYM
ajlm-2942	75	55	45	45	NUM
ajlm-2942	75	56	)	)	PUNCT
ajlm-2942	75	57	,	,	PUNCT
ajlm-2942	75	58	mi	mi	PROPN
ajlm-2942	75	59	(	(	PUNCT
ajlm-2942	75	60	n	n	NOUN
ajlm-2942	75	61	=	=	NUM
ajlm-2942	75	62	20	20	NUM
ajlm-2942	75	63	)	)	PUNCT
ajlm-2942	75	64	,	,	PUNCT
ajlm-2942	75	65	and	and	CCONJ
ajlm-2942	75	66	congestive	congestive	ADJ
ajlm-2942	75	67	heart	heart	NOUN
ajlm-2942	75	68	failure	failure	NOUN
ajlm-2942	75	69	with	with	ADP
ajlm-2942	75	70	a	a	DET
ajlm-2942	75	71	history	history	NOUN
ajlm-2942	75	72	of	of	ADP
ajlm-2942	75	73	ihd	ihd	NOUN
ajlm-2942	75	74	or	or	CCONJ
ajlm-2942	75	75	mi	mi	PROPN
ajlm-2942	75	76	(	(	PUNCT
ajlm-2942	75	77	n	n	NOUN
ajlm-2942	75	78	=	=	NUM
ajlm-2942	75	79	42	42	NUM
ajlm-2942	75	80	)	)	PUNCT
ajlm-2942	75	81	.	.	PUNCT
ajlm-2942	76	1	the	the	DET
ajlm-2942	76	2	control	control	PROPN
ajlm-2942	76	3	group	group	NOUN
ajlm-2942	76	4	comprised	comprise	VERB
ajlm-2942	76	5	55	55	NUM
ajlm-2942	76	6	healthy	healthy	ADJ
ajlm-2942	76	7	volunteers	volunteer	NOUN
ajlm-2942	76	8	(	(	PUNCT
ajlm-2942	76	9	24	24	NUM
ajlm-2942	76	10	men	man	NOUN
ajlm-2942	76	11	,	,	PUNCT
ajlm-2942	76	12	31	31	NUM
ajlm-2942	76	13	women	woman	NOUN
ajlm-2942	76	14	)	)	PUNCT
ajlm-2942	76	15	aged	age	VERB
ajlm-2942	76	16	20–64	20–64	NUM
ajlm-2942	76	17	years	year	NOUN
ajlm-2942	76	18	.	.	PUNCT
ajlm-2942	77	1	atherosclerotic	atherosclerotic	ADJ
ajlm-2942	77	2	cardiovascular	cardiovascular	ADJ
ajlm-2942	77	3	disease	disease	NOUN
ajlm-2942	77	4	patients	patient	NOUN
ajlm-2942	77	5	showed	show	VERB
ajlm-2942	77	6	significantly	significantly	ADV
ajlm-2942	77	7	higher	high	ADJ
ajlm-2942	77	8	mean	mean	NOUN
ajlm-2942	77	9	plasma	plasma	NOUN
ajlm-2942	77	10	tc	tc	NOUN
ajlm-2942	77	11	,	,	PUNCT
ajlm-2942	77	12	ldlc	ldlc	NOUN
ajlm-2942	77	13	,	,	PUNCT
ajlm-2942	77	14	non	non	ADJ
ajlm-2942	77	15	-	-	NOUN
ajlm-2942	77	16	hdlc	hdlc	ADJ
ajlm-2942	77	17	,	,	PUNCT
ajlm-2942	77	18	and	and	CCONJ
ajlm-2942	77	19	triglycerides	triglyceride	NOUN
ajlm-2942	77	20	levels	level	NOUN
ajlm-2942	77	21	than	than	ADP
ajlm-2942	77	22	controls	control	NOUN
ajlm-2942	77	23	(	(	PUNCT
ajlm-2942	77	24	all	all	PRON
ajlm-2942	77	25	p	p	X
ajlm-2942	77	26	<	<	X
ajlm-2942	77	27	0.001	0.001	NUM
ajlm-2942	77	28	,	,	PUNCT
ajlm-2942	77	29	table	table	NOUN
ajlm-2942	77	30	1	1	NUM
ajlm-2942	77	31	)	)	PUNCT
ajlm-2942	77	32	.	.	PUNCT
ajlm-2942	78	1	similarly	similarly	ADV
ajlm-2942	78	2	,	,	PUNCT
ajlm-2942	78	3	all	all	DET
ajlm-2942	78	4	conventional	conventional	ADJ
ajlm-2942	78	5	lipid	lipid	NOUN
ajlm-2942	78	6	indices	index	NOUN
ajlm-2942	78	7	(	(	PUNCT
ajlm-2942	78	8	cri	cri	PROPN
ajlm-2942	78	9	-	-	PROPN
ajlm-2942	78	10	i	i	PROPN
ajlm-2942	78	11	,	,	PUNCT
ajlm-2942	78	12	cri	cri	PROPN
ajlm-2942	78	13	-	-	PUNCT
ajlm-2942	78	14	ii	ii	PROPN
ajlm-2942	78	15	,	,	PUNCT
ajlm-2942	78	16	ac	ac	PROPN
ajlm-2942	78	17	,	,	PUNCT
ajlm-2942	78	18	and	and	CCONJ
ajlm-2942	78	19	aip	aip	PROPN
ajlm-2942	78	20	)	)	PUNCT
ajlm-2942	78	21	(	(	PUNCT
ajlm-2942	78	22	p	p	X
ajlm-2942	78	23	<	<	X
ajlm-2942	78	24	0.001	0.001	NUM
ajlm-2942	78	25	)	)	PUNCT
ajlm-2942	78	26	,	,	PUNCT
ajlm-2942	78	27	apo	apo	PROPN
ajlm-2942	78	28	b	b	X
ajlm-2942	78	29	(	(	PUNCT
ajlm-2942	78	30	p	p	X
ajlm-2942	78	31	=	=	NOUN
ajlm-2942	78	32	0.002	0.002	NUM
ajlm-2942	78	33	)	)	PUNCT
ajlm-2942	78	34	,	,	PUNCT
ajlm-2942	78	35	and	and	CCONJ
ajlm-2942	78	36	the	the	DET
ajlm-2942	78	37	apo	apo	PROPN
ajlm-2942	78	38	b	b	PROPN
ajlm-2942	78	39	/	/	SYM
ajlm-2942	78	40	a1	a1	NOUN
ajlm-2942	78	41	ratio	ratio	NOUN
ajlm-2942	78	42	(	(	PUNCT
ajlm-2942	78	43	p	p	X
ajlm-2942	78	44	<	<	X
ajlm-2942	78	45	0.001	0.001	NUM
ajlm-2942	78	46	)	)	PUNCT
ajlm-2942	78	47	were	be	AUX
ajlm-2942	78	48	elevated	elevate	VERB
ajlm-2942	78	49	significantly	significantly	ADV
ajlm-2942	78	50	.	.	PUNCT
ajlm-2942	79	1	conversely	conversely	ADV
ajlm-2942	79	2	,	,	PUNCT
ajlm-2942	79	3	mean	mean	VERB
ajlm-2942	79	4	plasma	plasma	NOUN
ajlm-2942	79	5	hdlc	hdlc	NOUN
ajlm-2942	79	6	,	,	PUNCT
ajlm-2942	79	7	apo	apo	PROPN
ajlm-2942	79	8	a1	a1	PROPN
ajlm-2942	79	9	,	,	PUNCT
ajlm-2942	79	10	and	and	CCONJ
ajlm-2942	79	11	hdl	hdl	PROPN
ajlm-2942	79	12	phospholipid	phospholipid	NOUN
ajlm-2942	79	13	levels	level	NOUN
ajlm-2942	79	14	were	be	AUX
ajlm-2942	79	15	significantly	significantly	ADV
ajlm-2942	79	16	lower	low	ADJ
ajlm-2942	79	17	in	in	ADP
ajlm-2942	79	18	ascvd	ascvd	NOUN
ajlm-2942	79	19	patients	patient	NOUN
ajlm-2942	79	20	(	(	PUNCT
ajlm-2942	79	21	all	all	DET
ajlm-2942	79	22	p	p	X
ajlm-2942	79	23	<	<	X
ajlm-2942	79	24	0.001	0.001	NUM
ajlm-2942	79	25	)	)	PUNCT
ajlm-2942	79	26	.	.	PUNCT
ajlm-2942	80	1	after	after	ADP
ajlm-2942	80	2	adjusting	adjust	VERB
ajlm-2942	80	3	for	for	ADP
ajlm-2942	80	4	age	age	NOUN
ajlm-2942	80	5	using	use	VERB
ajlm-2942	80	6	analysis	analysis	NOUN
ajlm-2942	80	7	of	of	ADP
ajlm-2942	80	8	covariance	covariance	NOUN
ajlm-2942	80	9	,	,	PUNCT
ajlm-2942	80	10	significant	significant	ADJ
ajlm-2942	80	11	differences	difference	NOUN
ajlm-2942	80	12	remained	remain	VERB
ajlm-2942	80	13	in	in	ADP
ajlm-2942	80	14	all	all	DET
ajlm-2942	80	15	lipid	lipid	NOUN
ajlm-2942	80	16	and	and	CCONJ
ajlm-2942	80	17	apolipoprotein	apolipoprotein	ADJ
ajlm-2942	80	18	parameters	parameter	NOUN
ajlm-2942	80	19	between	between	ADP
ajlm-2942	80	20	ascvd	ascvd	NOUN
ajlm-2942	80	21	patients	patient	NOUN
ajlm-2942	80	22	and	and	CCONJ
ajlm-2942	80	23	controls	control	NOUN
ajlm-2942	80	24	.	.	PUNCT
ajlm-2942	81	1	full	full	ADJ
ajlm-2942	81	2	statistical	statistical	ADJ
ajlm-2942	81	3	details	detail	NOUN
ajlm-2942	81	4	are	be	AUX
ajlm-2942	81	5	provided	provide	VERB
ajlm-2942	81	6	in	in	ADP
ajlm-2942	81	7	online	online	ADJ
ajlm-2942	81	8	supplementary	supplementary	ADJ
ajlm-2942	81	9	table	table	NOUN
ajlm-2942	81	10	3	3	NUM
ajlm-2942	81	11	to	to	ADP
ajlm-2942	81	12	online	online	ADJ
ajlm-2942	81	13	supplementary	supplementary	ADJ
ajlm-2942	81	14	table	table	NOUN
ajlm-2942	81	15	10	10	NUM
ajlm-2942	81	16	.	.	PUNCT
ajlm-2942	81	17	conventional	conventional	ADJ
ajlm-2942	81	18	lipid	lipid	NOUN
ajlm-2942	81	19	profiles	profile	NOUN
ajlm-2942	81	20	of	of	ADP
ajlm-2942	81	21	atherosclerotic	atherosclerotic	ADJ
ajlm-2942	81	22	cardiovascular	cardiovascular	ADJ
ajlm-2942	81	23	disease	disease	NOUN
ajlm-2942	81	24	subclasses	subclasse	VERB
ajlm-2942	81	25	significant	significant	ADJ
ajlm-2942	81	26	increases	increase	NOUN
ajlm-2942	81	27	were	be	AUX
ajlm-2942	81	28	observed	observe	VERB
ajlm-2942	81	29	in	in	ADP
ajlm-2942	81	30	the	the	DET
ajlm-2942	81	31	mean	mean	ADJ
ajlm-2942	81	32	plasma	plasma	NOUN
ajlm-2942	81	33	levels	level	NOUN
ajlm-2942	81	34	of	of	ADP
ajlm-2942	81	35	tc	tc	NOUN
ajlm-2942	81	36	,	,	PUNCT
ajlm-2942	81	37	ldlc	ldlc	NOUN
ajlm-2942	81	38	,	,	PUNCT
ajlm-2942	81	39	non	non	ADJ
ajlm-2942	81	40	-	-	NOUN
ajlm-2942	81	41	hdlc	hdlc	ADJ
ajlm-2942	81	42	,	,	PUNCT
ajlm-2942	81	43	and	and	CCONJ
ajlm-2942	81	44	triglycerides	triglyceride	NOUN
ajlm-2942	81	45	(	(	PUNCT
ajlm-2942	81	46	p	p	X
ajlm-2942	81	47	<	<	X
ajlm-2942	81	48	0.001	0.001	NUM
ajlm-2942	81	49	)	)	PUNCT
ajlm-2942	81	50	across	across	ADP
ajlm-2942	81	51	ascvd	ascvd	NOUN
ajlm-2942	81	52	subclasses	subclass	NOUN
ajlm-2942	81	53	and	and	CCONJ
ajlm-2942	81	54	controls	control	NOUN
ajlm-2942	81	55	(	(	PUNCT
ajlm-2942	81	56	table	table	NOUN
ajlm-2942	81	57	2	2	NUM
ajlm-2942	81	58	)	)	PUNCT
ajlm-2942	81	59	.	.	PUNCT
ajlm-2942	82	1	similarly	similarly	ADV
ajlm-2942	82	2	,	,	PUNCT
ajlm-2942	82	3	all	all	DET
ajlm-2942	82	4	conventional	conventional	ADJ
ajlm-2942	82	5	lipid	lipid	NOUN
ajlm-2942	82	6	indices	index	NOUN
ajlm-2942	82	7	(	(	PUNCT
ajlm-2942	82	8	cri	cri	PROPN
ajlm-2942	82	9	-	-	PROPN
ajlm-2942	82	10	i	i	PROPN
ajlm-2942	82	11	,	,	PUNCT
ajlm-2942	82	12	cri	cri	PROPN
ajlm-2942	82	13	-	-	PUNCT
ajlm-2942	82	14	ii	ii	PROPN
ajlm-2942	82	15	,	,	PUNCT
ajlm-2942	82	16	ac	ac	PROPN
ajlm-2942	82	17	,	,	PUNCT
ajlm-2942	82	18	and	and	CCONJ
ajlm-2942	82	19	aip	aip	PROPN
ajlm-2942	82	20	)	)	PUNCT
ajlm-2942	82	21	showed	show	VERB
ajlm-2942	82	22	marked	mark	VERB
ajlm-2942	82	23	elevations	elevation	NOUN
ajlm-2942	82	24	(	(	PUNCT
ajlm-2942	82	25	p	p	X
ajlm-2942	82	26	<	<	X
ajlm-2942	82	27	0.001	0.001	NUM
ajlm-2942	82	28	)	)	PUNCT
ajlm-2942	82	29	.	.	PUNCT
ajlm-2942	83	1	in	in	ADP
ajlm-2942	83	2	contrast	contrast	NOUN
ajlm-2942	83	3	,	,	PUNCT
ajlm-2942	83	4	plasma	plasma	NOUN
ajlm-2942	83	5	hdlc	hdlc	NOUN
ajlm-2942	83	6	levels	level	NOUN
ajlm-2942	83	7	were	be	AUX
ajlm-2942	83	8	significantly	significantly	ADV
ajlm-2942	83	9	reduced	reduce	VERB
ajlm-2942	83	10	(	(	PUNCT
ajlm-2942	83	11	p	p	X
ajlm-2942	83	12	<	<	X
ajlm-2942	83	13	0.001	0.001	NUM
ajlm-2942	83	14	)	)	PUNCT
ajlm-2942	83	15	across	across	ADP
ajlm-2942	83	16	the	the	DET
ajlm-2942	83	17	ascvd	ascvd	NOUN
ajlm-2942	83	18	subclasses	subclass	NOUN
ajlm-2942	83	19	and	and	CCONJ
ajlm-2942	83	20	controls	control	NOUN
ajlm-2942	83	21	.	.	PUNCT
ajlm-2942	84	1	patients	patient	NOUN
ajlm-2942	84	2	with	with	ADP
ajlm-2942	84	3	ihd	ihd	PROPN
ajlm-2942	84	4	and	and	CCONJ
ajlm-2942	84	5	mi	mi	PROPN
ajlm-2942	84	6	had	have	VERB
ajlm-2942	84	7	the	the	DET
ajlm-2942	84	8	highest	high	ADJ
ajlm-2942	84	9	levels	level	NOUN
ajlm-2942	84	10	of	of	ADP
ajlm-2942	84	11	atherogenic	atherogenic	ADJ
ajlm-2942	84	12	lipids	lipid	NOUN
ajlm-2942	84	13	(	(	PUNCT
ajlm-2942	84	14	triglycerides	triglyceride	NOUN
ajlm-2942	84	15	and	and	CCONJ
ajlm-2942	84	16	tc	tc	NUM
ajlm-2942	84	17	)	)	PUNCT
ajlm-2942	84	18	and	and	CCONJ
ajlm-2942	84	19	lipoproteins	lipoprotein	NOUN
ajlm-2942	84	20	(	(	PUNCT
ajlm-2942	84	21	ldlc	ldlc	NOUN
ajlm-2942	84	22	and	and	CCONJ
ajlm-2942	84	23	non	non	ADJ
ajlm-2942	84	24	-	-	NOUN
ajlm-2942	84	25	hdlc	hdlc	NOUN
ajlm-2942	84	26	)	)	PUNCT
ajlm-2942	84	27	,	,	PUNCT
ajlm-2942	84	28	with	with	ADP
ajlm-2942	84	29	mean	mean	ADJ
ajlm-2942	84	30	values	value	NOUN
ajlm-2942	84	31	significantly	significantly	ADV
ajlm-2942	84	32	elevated	elevate	VERB
ajlm-2942	84	33	compared	compare	VERB
ajlm-2942	84	34	to	to	ADP
ajlm-2942	84	35	controls	control	NOUN
ajlm-2942	84	36	and	and	CCONJ
ajlm-2942	84	37	other	other	ADJ
ajlm-2942	84	38	ascvd	ascvd	NOUN
ajlm-2942	84	39	subgroups	subgroup	NOUN
ajlm-2942	84	40	(	(	PUNCT
ajlm-2942	84	41	p	p	X
ajlm-2942	84	42	<	<	X
ajlm-2942	84	43	0.001	0.001	NUM
ajlm-2942	84	44	)	)	PUNCT
ajlm-2942	84	45	.	.	PUNCT
ajlm-2942	85	1	these	these	DET
ajlm-2942	85	2	groups	group	NOUN
ajlm-2942	85	3	also	also	ADV
ajlm-2942	85	4	presented	present	VERB
ajlm-2942	85	5	the	the	DET
ajlm-2942	85	6	lowest	low	ADJ
ajlm-2942	85	7	hdlc	hdlc	PROPN
ajlm-2942	85	8	levels	level	NOUN
ajlm-2942	85	9	(	(	PUNCT
ajlm-2942	85	10	p	p	X
ajlm-2942	85	11	<	<	X
ajlm-2942	85	12	0.001	0.001	NUM
ajlm-2942	85	13	)	)	PUNCT
ajlm-2942	85	14	,	,	PUNCT
ajlm-2942	85	15	indicating	indicate	VERB
ajlm-2942	85	16	a	a	DET
ajlm-2942	85	17	more	more	ADV
ajlm-2942	85	18	atherogenic	atherogenic	ADJ
ajlm-2942	85	19	lipid	lipid	NOUN
ajlm-2942	85	20	profile	profile	NOUN
ajlm-2942	85	21	.	.	PUNCT
ajlm-2942	86	1	table	table	NOUN
ajlm-2942	86	2	2	2	NUM
ajlm-2942	86	3	:	:	PUNCT
ajlm-2942	86	4	 	 	SPACE
ajlm-2942	86	5	conventional	conventional	ADJ
ajlm-2942	86	6	lipid	lipid	NOUN
ajlm-2942	86	7	profile	profile	NOUN
ajlm-2942	86	8	and	and	CCONJ
ajlm-2942	86	9	indices	indice	VERB
ajlm-2942	86	10	in	in	ADP
ajlm-2942	86	11	atherosclerotic	atherosclerotic	ADJ
ajlm-2942	86	12	cardiovascular	cardiovascular	ADJ
ajlm-2942	86	13	disease	disease	NOUN
ajlm-2942	86	14	subclasses	subclass	NOUN
ajlm-2942	86	15	and	and	CCONJ
ajlm-2942	86	16	controls	control	NOUN
ajlm-2942	86	17	at	at	ADP
ajlm-2942	86	18	lagos	lagos	PROPN
ajlm-2942	86	19	state	state	NOUN
ajlm-2942	86	20	university	university	PROPN
ajlm-2942	86	21	teaching	teaching	NOUN
ajlm-2942	86	22	hospital	hospital	NOUN
ajlm-2942	86	23	,	,	PUNCT
ajlm-2942	86	24	lagos	lago	NOUN
ajlm-2942	86	25	,	,	PUNCT
ajlm-2942	86	26	nigeria	nigeria	PROPN
ajlm-2942	86	27	,	,	PUNCT
ajlm-2942	86	28	between	between	ADP
ajlm-2942	86	29	november	november	PROPN
ajlm-2942	86	30	2021	2021	NUM
ajlm-2942	86	31	and	and	CCONJ
ajlm-2942	86	32	november	november	PROPN
ajlm-2942	86	33	2022	2022	NUM
ajlm-2942	86	34	.	.	PUNCT
ajlm-2942	87	1	apolipoproteins	apolipoprotein	NOUN
ajlm-2942	87	2	and	and	CCONJ
ajlm-2942	87	3	high	high	ADJ
ajlm-2942	87	4	-	-	PUNCT
ajlm-2942	87	5	density	density	NOUN
ajlm-2942	87	6	lipoprotein	lipoprotein	ADJ
ajlm-2942	87	7	phospholipid	phospholipid	NOUN
ajlm-2942	87	8	levels	level	NOUN
ajlm-2942	87	9	in	in	ADP
ajlm-2942	87	10	atherosclerotic	atherosclerotic	ADJ
ajlm-2942	87	11	cardiovascular	cardiovascular	ADJ
ajlm-2942	87	12	disease	disease	NOUN
ajlm-2942	87	13	subclasses	subclasse	VERB
ajlm-2942	87	14	significant	significant	ADJ
ajlm-2942	87	15	increases	increase	NOUN
ajlm-2942	87	16	in	in	ADP
ajlm-2942	87	17	mean	mean	ADJ
ajlm-2942	87	18	plasma	plasma	NOUN
ajlm-2942	87	19	apo	apo	PROPN
ajlm-2942	87	20	b	b	PROPN
ajlm-2942	87	21	,	,	PUNCT
ajlm-2942	87	22	and	and	CCONJ
ajlm-2942	87	23	the	the	DET
ajlm-2942	87	24	apo	apo	PROPN
ajlm-2942	87	25	b	b	PROPN
ajlm-2942	87	26	/	/	SYM
ajlm-2942	87	27	a1	a1	NOUN
ajlm-2942	87	28	ratio	ratio	NOUN
ajlm-2942	87	29	(	(	PUNCT
ajlm-2942	87	30	p	p	X
ajlm-2942	87	31	<	<	X
ajlm-2942	87	32	0.001	0.001	NUM
ajlm-2942	87	33	)	)	PUNCT
ajlm-2942	87	34	were	be	AUX
ajlm-2942	87	35	observed	observe	VERB
ajlm-2942	87	36	across	across	ADP
ajlm-2942	87	37	ascvd	ascvd	NOUN
ajlm-2942	87	38	subclasses	subclass	NOUN
ajlm-2942	87	39	and	and	CCONJ
ajlm-2942	87	40	controls	control	NOUN
ajlm-2942	87	41	(	(	PUNCT
ajlm-2942	87	42	table	table	NOUN
ajlm-2942	87	43	3	3	NUM
ajlm-2942	87	44	)	)	PUNCT
ajlm-2942	87	45	.	.	PUNCT
ajlm-2942	88	1	conversely	conversely	ADV
ajlm-2942	88	2	,	,	PUNCT
ajlm-2942	88	3	mean	mean	VERB
ajlm-2942	88	4	plasma	plasma	NOUN
ajlm-2942	88	5	apo	apo	PROPN
ajlm-2942	88	6	a1	a1	PROPN
ajlm-2942	88	7	and	and	CCONJ
ajlm-2942	88	8	hdl	hdl	PROPN
ajlm-2942	88	9	phospholipid	phospholipid	NOUN
ajlm-2942	88	10	levels	level	NOUN
ajlm-2942	88	11	were	be	AUX
ajlm-2942	88	12	significantly	significantly	ADV
ajlm-2942	88	13	reduced	reduce	VERB
ajlm-2942	88	14	(	(	PUNCT
ajlm-2942	88	15	p	p	X
ajlm-2942	88	16	<	<	X
ajlm-2942	88	17	0.001	0.001	NUM
ajlm-2942	88	18	)	)	PUNCT
ajlm-2942	88	19	.	.	PUNCT
ajlm-2942	89	1	the	the	DET
ajlm-2942	89	2	highest	high	ADJ
ajlm-2942	89	3	apo	apo	PROPN
ajlm-2942	89	4	b	b	PROPN
ajlm-2942	89	5	and	and	CCONJ
ajlm-2942	89	6	apo	apo	PROPN
ajlm-2942	89	7	b	b	PROPN
ajlm-2942	89	8	/	/	SYM
ajlm-2942	89	9	a1	a1	NOUN
ajlm-2942	89	10	ratios	ratio	NOUN
ajlm-2942	89	11	were	be	AUX
ajlm-2942	89	12	found	find	VERB
ajlm-2942	89	13	in	in	ADP
ajlm-2942	89	14	patients	patient	NOUN
ajlm-2942	89	15	with	with	ADP
ajlm-2942	89	16	mi	mi	PROPN
ajlm-2942	89	17	and	and	CCONJ
ajlm-2942	89	18	ihd	ihd	PROPN
ajlm-2942	89	19	,	,	PUNCT
ajlm-2942	89	20	who	who	PRON
ajlm-2942	89	21	also	also	ADV
ajlm-2942	89	22	had	have	VERB
ajlm-2942	89	23	the	the	DET
ajlm-2942	89	24	lowest	low	ADJ
ajlm-2942	89	25	levels	level	NOUN
ajlm-2942	89	26	of	of	ADP
ajlm-2942	89	27	apo	apo	PROPN
ajlm-2942	89	28	a1	a1	PROPN
ajlm-2942	89	29	and	and	CCONJ
ajlm-2942	89	30	hdl	hdl	PROPN
ajlm-2942	89	31	phospholipids	phospholipid	NOUN
ajlm-2942	89	32	.	.	PUNCT
ajlm-2942	90	1	the	the	DET
ajlm-2942	90	2	apo	apo	PROPN
ajlm-2942	90	3	b	b	PROPN
ajlm-2942	90	4	/	/	SYM
ajlm-2942	90	5	a1	a1	NOUN
ajlm-2942	90	6	ratio	ratio	NOUN
ajlm-2942	90	7	proved	prove	VERB
ajlm-2942	90	8	to	to	PART
ajlm-2942	90	9	be	be	AUX
ajlm-2942	90	10	a	a	DET
ajlm-2942	90	11	superior	superior	ADJ
ajlm-2942	90	12	marker	marker	NOUN
ajlm-2942	90	13	for	for	ADP
ajlm-2942	90	14	ascvd	ascvd	NOUN
ajlm-2942	90	15	stratification	stratification	NOUN
ajlm-2942	90	16	compared	compare	VERB
ajlm-2942	90	17	to	to	ADP
ajlm-2942	90	18	apo	apo	PROPN
ajlm-2942	90	19	a1	a1	PROPN
ajlm-2942	90	20	or	or	CCONJ
ajlm-2942	90	21	apo	apo	PROPN
ajlm-2942	90	22	b	b	PROPN
ajlm-2942	90	23	alone.38	alone.38	PROPN
ajlm-2942	90	24	for	for	ADP
ajlm-2942	90	25	instance	instance	NOUN
ajlm-2942	90	26	,	,	PUNCT
ajlm-2942	90	27	apo	apo	PROPN
ajlm-2942	90	28	b	b	PROPN
ajlm-2942	90	29	levels	level	NOUN
ajlm-2942	90	30	did	do	AUX
ajlm-2942	90	31	not	not	PART
ajlm-2942	90	32	differ	differ	VERB
ajlm-2942	90	33	significantly	significantly	ADV
ajlm-2942	90	34	when	when	SCONJ
ajlm-2942	90	35	patients	patient	NOUN
ajlm-2942	90	36	suffering	suffer	VERB
ajlm-2942	90	37	from	from	ADP
ajlm-2942	90	38	stroke	stroke	NOUN
ajlm-2942	90	39	and	and	CCONJ
ajlm-2942	90	40	heart	heart	NOUN
ajlm-2942	90	41	failure	failure	NOUN
ajlm-2942	90	42	were	be	AUX
ajlm-2942	90	43	compared	compare	VERB
ajlm-2942	90	44	with	with	ADP
ajlm-2942	90	45	the	the	DET
ajlm-2942	90	46	control	control	NOUN
ajlm-2942	90	47	group	group	NOUN
ajlm-2942	90	48	(	(	PUNCT
ajlm-2942	90	49	online	online	PROPN
ajlm-2942	90	50	supplementary	supplementary	ADJ
ajlm-2942	90	51	table	table	NOUN
ajlm-2942	90	52	10	10	NUM
ajlm-2942	90	53	)	)	PUNCT
ajlm-2942	90	54	,	,	PUNCT
ajlm-2942	90	55	whereas	whereas	SCONJ
ajlm-2942	90	56	the	the	DET
ajlm-2942	90	57	apo	apo	PROPN
ajlm-2942	90	58	b	b	PROPN
ajlm-2942	90	59	/	/	SYM
ajlm-2942	90	60	a1	a1	NOUN
ajlm-2942	90	61	ratio	ratio	NOUN
ajlm-2942	90	62	showed	show	VERB
ajlm-2942	90	63	statistically	statistically	ADV
ajlm-2942	90	64	significant	significant	ADJ
ajlm-2942	90	65	differences	difference	NOUN
ajlm-2942	90	66	across	across	ADP
ajlm-2942	90	67	all	all	DET
ajlm-2942	90	68	ascvd	ascvd	NOUN
ajlm-2942	90	69	subclasses	subclass	NOUN
ajlm-2942	90	70	when	when	SCONJ
ajlm-2942	90	71	each	each	DET
ajlm-2942	90	72	subclass	subclass	NOUN
ajlm-2942	90	73	is	be	AUX
ajlm-2942	90	74	compared	compare	VERB
ajlm-2942	90	75	with	with	ADP
ajlm-2942	90	76	the	the	DET
ajlm-2942	90	77	control	control	NOUN
ajlm-2942	90	78	group	group	NOUN
ajlm-2942	90	79	(	(	PUNCT
ajlm-2942	90	80	online	online	PROPN
ajlm-2942	90	81	supplementary	supplementary	ADJ
ajlm-2942	90	82	table	table	NOUN
ajlm-2942	90	83	11	11	NUM
ajlm-2942	90	84	)	)	PUNCT
ajlm-2942	90	85	.	.	PUNCT
ajlm-2942	91	1	table	table	NOUN
ajlm-2942	91	2	3	3	NUM
ajlm-2942	91	3	:	:	PUNCT
ajlm-2942	91	4	 	 	SPACE
ajlm-2942	91	5	apolipoproteins	apolipoprotein	NOUN
ajlm-2942	91	6	and	and	CCONJ
ajlm-2942	91	7	high	high	ADJ
ajlm-2942	91	8	-	-	PUNCT
ajlm-2942	91	9	density	density	NOUN
ajlm-2942	91	10	lipoprotein	lipoprotein	ADJ
ajlm-2942	91	11	phospholipids	phospholipid	NOUN
ajlm-2942	91	12	in	in	ADP
ajlm-2942	91	13	atherosclerotic	atherosclerotic	ADJ
ajlm-2942	91	14	cardiovascular	cardiovascular	ADJ
ajlm-2942	91	15	disease	disease	NOUN
ajlm-2942	91	16	subclasses	subclass	NOUN
ajlm-2942	91	17	and	and	CCONJ
ajlm-2942	91	18	controls	control	NOUN
ajlm-2942	91	19	at	at	ADP
ajlm-2942	91	20	lagos	lagos	PROPN
ajlm-2942	91	21	state	state	NOUN
ajlm-2942	91	22	university	university	PROPN
ajlm-2942	91	23	teaching	teaching	NOUN
ajlm-2942	91	24	hospital	hospital	NOUN
ajlm-2942	91	25	,	,	PUNCT
ajlm-2942	91	26	lagos	lago	NOUN
ajlm-2942	91	27	,	,	PUNCT
ajlm-2942	91	28	nigeria	nigeria	PROPN
ajlm-2942	91	29	,	,	PUNCT
ajlm-2942	91	30	between	between	ADP
ajlm-2942	91	31	november	november	PROPN
ajlm-2942	91	32	2021	2021	NUM
ajlm-2942	91	33	and	and	CCONJ
ajlm-2942	91	34	november	november	PROPN
ajlm-2942	91	35	2022	2022	NUM
ajlm-2942	91	36	.	.	PUNCT
ajlm-2942	92	1	associations	association	NOUN
ajlm-2942	92	2	between	between	ADP
ajlm-2942	92	3	apolipoproteins	apolipoprotein	NOUN
ajlm-2942	92	4	,	,	PUNCT
ajlm-2942	92	5	high	high	ADJ
ajlm-2942	92	6	-	-	PUNCT
ajlm-2942	92	7	density	density	NOUN
ajlm-2942	92	8	lipoprotein	lipoprotein	ADJ
ajlm-2942	92	9	phospholipids	phospholipid	NOUN
ajlm-2942	92	10	and	and	CCONJ
ajlm-2942	92	11	conventional	conventional	ADJ
ajlm-2942	92	12	lipid	lipid	NOUN
ajlm-2942	92	13	profiles	profile	NOUN
ajlm-2942	92	14	a	a	DET
ajlm-2942	92	15	significant	significant	ADJ
ajlm-2942	92	16	negative	negative	ADJ
ajlm-2942	92	17	correlation	correlation	NOUN
ajlm-2942	92	18	was	be	AUX
ajlm-2942	92	19	observed	observe	VERB
ajlm-2942	92	20	between	between	ADP
ajlm-2942	92	21	mean	mean	ADJ
ajlm-2942	92	22	plasma	plasma	NOUN
ajlm-2942	92	23	apo	apo	PROPN
ajlm-2942	92	24	a1	a1	NOUN
ajlm-2942	92	25	levels	level	NOUN
ajlm-2942	92	26	and	and	CCONJ
ajlm-2942	92	27	atherogenic	atherogenic	ADJ
ajlm-2942	92	28	lipids	lipid	NOUN
ajlm-2942	92	29	,	,	PUNCT
ajlm-2942	92	30	including	include	VERB
ajlm-2942	92	31	triglycerides	triglyceride	NOUN
ajlm-2942	92	32	(	(	PUNCT
ajlm-2942	92	33	r	r	NOUN
ajlm-2942	92	34	=	=	PUNCT
ajlm-2942	92	35	–	–	PUNCT
ajlm-2942	92	36	0.386	0.386	NUM
ajlm-2942	92	37	,	,	PUNCT
ajlm-2942	92	38	p	p	X
ajlm-2942	92	39	<	<	X
ajlm-2942	92	40	0.001	0.001	NUM
ajlm-2942	92	41	)	)	PUNCT
ajlm-2942	92	42	,	,	PUNCT
ajlm-2942	92	43	tc	tc	PRON
ajlm-2942	92	44	(	(	PUNCT
ajlm-2942	92	45	r	r	NOUN
ajlm-2942	92	46	=	=	PUNCT
ajlm-2942	92	47	–	–	PUNCT
ajlm-2942	92	48	0.471	0.471	NUM
ajlm-2942	92	49	,	,	PUNCT
ajlm-2942	92	50	p	p	X
ajlm-2942	92	51	<	<	X
ajlm-2942	92	52	0.001	0.001	NUM
ajlm-2942	92	53	)	)	PUNCT
ajlm-2942	92	54	,	,	PUNCT
ajlm-2942	92	55	ldlc	ldlc	NOUN
ajlm-2942	92	56	(	(	PUNCT
ajlm-2942	92	57	r	r	NOUN
ajlm-2942	92	58	=	=	PUNCT
ajlm-2942	92	59	–	–	PUNCT
ajlm-2942	92	60	0.483	0.483	NUM
ajlm-2942	92	61	,	,	PUNCT
ajlm-2942	92	62	p	p	X
ajlm-2942	92	63	<	<	X
ajlm-2942	92	64	0.001	0.001	NUM
ajlm-2942	92	65	)	)	PUNCT
ajlm-2942	92	66	,	,	PUNCT
ajlm-2942	92	67	and	and	CCONJ
ajlm-2942	92	68	non	non	ADJ
ajlm-2942	92	69	-	-	ADJ
ajlm-2942	92	70	hdlc	hdlc	NOUN
ajlm-2942	92	71	(	(	PUNCT
ajlm-2942	92	72	r	r	NOUN
ajlm-2942	92	73	=	=	PUNCT
ajlm-2942	92	74	–	–	PUNCT
ajlm-2942	92	75	0.500	0.500	NUM
ajlm-2942	92	76	,	,	PUNCT
ajlm-2942	92	77	p	p	X
ajlm-2942	92	78	<	<	X
ajlm-2942	92	79	0.001	0.001	NUM
ajlm-2942	92	80	)	)	PUNCT
ajlm-2942	92	81	(	(	PUNCT
ajlm-2942	92	82	table	table	NOUN
ajlm-2942	92	83	4	4	NUM
ajlm-2942	92	84	)	)	PUNCT
ajlm-2942	92	85	.	.	PUNCT
ajlm-2942	93	1	in	in	ADP
ajlm-2942	93	2	contrast	contrast	NOUN
ajlm-2942	93	3	,	,	PUNCT
ajlm-2942	93	4	apo	apo	PROPN
ajlm-2942	93	5	a1	a1	NOUN
ajlm-2942	93	6	showed	show	VERB
ajlm-2942	93	7	a	a	DET
ajlm-2942	93	8	strong	strong	ADJ
ajlm-2942	93	9	positive	positive	ADJ
ajlm-2942	93	10	correlation	correlation	NOUN
ajlm-2942	93	11	with	with	ADP
ajlm-2942	93	12	antiatherogenic	antiatherogenic	ADJ
ajlm-2942	93	13	hdlc	hdlc	PROPN
ajlm-2942	93	14	(	(	PUNCT
ajlm-2942	93	15	r	r	NOUN
ajlm-2942	93	16	=	=	SYM
ajlm-2942	93	17	0.386	0.386	NUM
ajlm-2942	93	18	,	,	PUNCT
ajlm-2942	93	19	p	p	X
ajlm-2942	93	20	<	<	X
ajlm-2942	93	21	0.001	0.001	NUM
ajlm-2942	93	22	)	)	PUNCT
ajlm-2942	93	23	.	.	PUNCT
ajlm-2942	94	1	table	table	NOUN
ajlm-2942	94	2	4	4	NUM
ajlm-2942	94	3	:	:	PUNCT
ajlm-2942	94	4	 	 	SPACE
ajlm-2942	94	5	association	association	NOUN
ajlm-2942	94	6	between	between	ADP
ajlm-2942	94	7	apolipoproteins	apolipoprotein	NOUN
ajlm-2942	94	8	,	,	PUNCT
ajlm-2942	94	9	high	high	ADJ
ajlm-2942	94	10	-	-	PUNCT
ajlm-2942	94	11	density	density	NOUN
ajlm-2942	94	12	lipoprotein	lipoprotein	ADJ
ajlm-2942	94	13	phospholipids	phospholipid	NOUN
ajlm-2942	94	14	and	and	CCONJ
ajlm-2942	94	15	conventional	conventional	ADJ
ajlm-2942	94	16	lipid	lipid	NOUN
ajlm-2942	94	17	profiles	profile	NOUN
ajlm-2942	94	18	at	at	ADP
ajlm-2942	94	19	lagos	lagos	PROPN
ajlm-2942	94	20	state	state	NOUN
ajlm-2942	94	21	university	university	PROPN
ajlm-2942	94	22	teaching	teaching	NOUN
ajlm-2942	94	23	hospital	hospital	NOUN
ajlm-2942	94	24	,	,	PUNCT
ajlm-2942	94	25	lagos	lago	NOUN
ajlm-2942	94	26	,	,	PUNCT
ajlm-2942	94	27	nigeria	nigeria	PROPN
ajlm-2942	94	28	,	,	PUNCT
ajlm-2942	94	29	between	between	ADP
ajlm-2942	94	30	november	november	PROPN
ajlm-2942	94	31	2021	2021	NUM
ajlm-2942	94	32	and	and	CCONJ
ajlm-2942	94	33	november	november	PROPN
ajlm-2942	94	34	2022	2022	NUM
ajlm-2942	94	35	.	.	PUNCT
ajlm-2942	95	1	apo	apo	PROPN
ajlm-2942	95	2	b	b	PROPN
ajlm-2942	95	3	was	be	AUX
ajlm-2942	95	4	positively	positively	ADV
ajlm-2942	95	5	correlated	correlate	VERB
ajlm-2942	95	6	with	with	ADP
ajlm-2942	95	7	atherogenic	atherogenic	ADJ
ajlm-2942	95	8	lipids	lipid	NOUN
ajlm-2942	95	9	and	and	CCONJ
ajlm-2942	95	10	lipoproteins	lipoprotein	NOUN
ajlm-2942	95	11	(	(	PUNCT
ajlm-2942	95	12	triglycerides	triglyceride	NOUN
ajlm-2942	95	13	,	,	PUNCT
ajlm-2942	95	14	tc	tc	NOUN
ajlm-2942	95	15	,	,	PUNCT
ajlm-2942	95	16	ldlc	ldlc	NOUN
ajlm-2942	95	17	,	,	PUNCT
ajlm-2942	95	18	and	and	CCONJ
ajlm-2942	95	19	non	non	ADJ
ajlm-2942	95	20	-	-	NOUN
ajlm-2942	95	21	hdlc	hdlc	NOUN
ajlm-2942	95	22	)	)	PUNCT
ajlm-2942	95	23	.	.	PUNCT
ajlm-2942	96	1	in	in	ADP
ajlm-2942	96	2	addition	addition	NOUN
ajlm-2942	96	3	,	,	PUNCT
ajlm-2942	96	4	the	the	DET
ajlm-2942	96	5	apo	apo	PROPN
ajlm-2942	96	6	b	b	PROPN
ajlm-2942	96	7	/	/	SYM
ajlm-2942	96	8	a1	a1	NOUN
ajlm-2942	96	9	ratio	ratio	NOUN
ajlm-2942	96	10	exhibited	exhibit	VERB
ajlm-2942	96	11	strong	strong	ADJ
ajlm-2942	96	12	positive	positive	ADJ
ajlm-2942	96	13	correlations	correlation	NOUN
ajlm-2942	96	14	with	with	ADP
ajlm-2942	96	15	conventional	conventional	ADJ
ajlm-2942	96	16	lipid	lipid	NOUN
ajlm-2942	96	17	indices	index	NOUN
ajlm-2942	96	18	,	,	PUNCT
ajlm-2942	96	19	including	include	VERB
ajlm-2942	96	20	cri	cri	PROPN
ajlm-2942	96	21	-	-	PROPN
ajlm-2942	96	22	i	i	PRON
ajlm-2942	96	23	(	(	PUNCT
ajlm-2942	96	24	r	r	NOUN
ajlm-2942	96	25	=	=	NOUN
ajlm-2942	96	26	0.626	0.626	NUM
ajlm-2942	96	27	,	,	PUNCT
ajlm-2942	96	28	p	p	X
ajlm-2942	96	29	<	<	X
ajlm-2942	96	30	0.001	0.001	NUM
ajlm-2942	96	31	)	)	PUNCT
ajlm-2942	96	32	,	,	PUNCT
ajlm-2942	96	33	cri	cri	PROPN
ajlm-2942	96	34	-	-	NOUN
ajlm-2942	96	35	ii	ii	PROPN
ajlm-2942	96	36	(	(	PUNCT
ajlm-2942	96	37	r	r	NOUN
ajlm-2942	96	38	=	=	SYM
ajlm-2942	96	39	0.601	0.601	NUM
ajlm-2942	96	40	,	,	PUNCT
ajlm-2942	96	41	p	p	X
ajlm-2942	96	42	<	<	X
ajlm-2942	96	43	0.001	0.001	NUM
ajlm-2942	96	44	)	)	PUNCT
ajlm-2942	96	45	,	,	PUNCT
ajlm-2942	96	46	ac	ac	PROPN
ajlm-2942	96	47	(	(	PUNCT
ajlm-2942	96	48	r	r	NOUN
ajlm-2942	96	49	=	=	SYM
ajlm-2942	96	50	0.613	0.613	NUM
ajlm-2942	96	51	,	,	PUNCT
ajlm-2942	96	52	p	p	X
ajlm-2942	96	53	<	<	X
ajlm-2942	96	54	0.001	0.001	NUM
ajlm-2942	96	55	)	)	PUNCT
ajlm-2942	96	56	,	,	PUNCT
ajlm-2942	96	57	and	and	CCONJ
ajlm-2942	96	58	aip	aip	PROPN
ajlm-2942	96	59	(	(	PUNCT
ajlm-2942	96	60	r	r	NOUN
ajlm-2942	96	61	=	=	SYM
ajlm-2942	96	62	0.604	0.604	NUM
ajlm-2942	96	63	,	,	PUNCT
ajlm-2942	96	64	p	p	X
ajlm-2942	96	65	<	<	X
ajlm-2942	96	66	0.001	0.001	NUM
ajlm-2942	96	67	)	)	PUNCT
ajlm-2942	96	68	.	.	PUNCT
ajlm-2942	97	1	high	high	ADJ
ajlm-2942	97	2	-	-	PUNCT
ajlm-2942	97	3	density	density	NOUN
ajlm-2942	97	4	lipoprotein	lipoprotein	ADJ
ajlm-2942	97	5	phospholipid	phospholipid	NOUN
ajlm-2942	97	6	levels	level	NOUN
ajlm-2942	97	7	correlated	correlate	VERB
ajlm-2942	97	8	positively	positively	ADV
ajlm-2942	97	9	with	with	ADP
ajlm-2942	97	10	apo	apo	PROPN
ajlm-2942	97	11	a1	a1	NOUN
ajlm-2942	97	12	(	(	PUNCT
ajlm-2942	97	13	r	r	NOUN
ajlm-2942	97	14	=	=	SYM
ajlm-2942	97	15	0.524	0.524	NUM
ajlm-2942	97	16	,	,	PUNCT
ajlm-2942	97	17	p	p	X
ajlm-2942	97	18	<	<	X
ajlm-2942	97	19	0.001	0.001	NUM
ajlm-2942	97	20	)	)	PUNCT
ajlm-2942	97	21	but	but	CCONJ
ajlm-2942	97	22	negatively	negatively	ADV
ajlm-2942	97	23	with	with	ADP
ajlm-2942	97	24	apo	apo	PROPN
ajlm-2942	97	25	b	b	PROPN
ajlm-2942	97	26	(	(	PUNCT
ajlm-2942	97	27	r	r	NOUN
ajlm-2942	97	28	=	=	PUNCT
ajlm-2942	97	29	–	–	PUNCT
ajlm-2942	97	30	0.174	0.174	NUM
ajlm-2942	97	31	,	,	PUNCT
ajlm-2942	97	32	p	p	X
ajlm-2942	97	33	=	=	NOUN
ajlm-2942	97	34	0.009	0.009	NUM
ajlm-2942	97	35	)	)	PUNCT
ajlm-2942	97	36	and	and	CCONJ
ajlm-2942	97	37	the	the	DET
ajlm-2942	97	38	apo	apo	PROPN
ajlm-2942	97	39	b	b	PROPN
ajlm-2942	97	40	/	/	SYM
ajlm-2942	97	41	a1	a1	NOUN
ajlm-2942	97	42	ratio	ratio	NOUN
ajlm-2942	97	43	(	(	PUNCT
ajlm-2942	97	44	r	r	NOUN
ajlm-2942	97	45	=	=	PUNCT
ajlm-2942	97	46	–	–	PUNCT
ajlm-2942	97	47	0.586	0.586	NUM
ajlm-2942	97	48	,	,	PUNCT
ajlm-2942	97	49	p	p	X
ajlm-2942	97	50	<	<	X
ajlm-2942	97	51	0.001	0.001	NUM
ajlm-2942	97	52	)	)	PUNCT
ajlm-2942	97	53	.	.	PUNCT
ajlm-2942	98	1	variations	variation	NOUN
ajlm-2942	98	2	in	in	ADP
ajlm-2942	98	3	the	the	DET
ajlm-2942	98	4	concentrations	concentration	NOUN
ajlm-2942	98	5	of	of	ADP
ajlm-2942	98	6	apo	apo	PROPN
ajlm-2942	98	7	a1	a1	PROPN
ajlm-2942	98	8	,	,	PUNCT
ajlm-2942	98	9	apo	apo	PROPN
ajlm-2942	98	10	b	b	NOUN
ajlm-2942	98	11	,	,	PUNCT
ajlm-2942	98	12	and	and	CCONJ
ajlm-2942	98	13	the	the	DET
ajlm-2942	98	14	apo	apo	PROPN
ajlm-2942	98	15	b	b	PROPN
ajlm-2942	98	16	/	/	SYM
ajlm-2942	98	17	a1	a1	NOUN
ajlm-2942	98	18	ratio	ratio	NOUN
ajlm-2942	98	19	across	across	ADP
ajlm-2942	98	20	atherosclerotic	atherosclerotic	ADJ
ajlm-2942	98	21	cardiovascular	cardiovascular	ADJ
ajlm-2942	98	22	disease	disease	NOUN
ajlm-2942	98	23	subclasses	subclass	NOUN
ajlm-2942	98	24	graded	grade	VERB
ajlm-2942	98	25	variations	variation	NOUN
ajlm-2942	98	26	were	be	AUX
ajlm-2942	98	27	observed	observe	VERB
ajlm-2942	98	28	in	in	ADP
ajlm-2942	98	29	mean	mean	ADJ
ajlm-2942	98	30	plasma	plasma	PROPN
ajlm-2942	98	31	apo	apo	PROPN
ajlm-2942	98	32	b	b	PROPN
ajlm-2942	98	33	concentrations	concentration	NOUN
ajlm-2942	98	34	across	across	ADP
ajlm-2942	98	35	ascvd	ascvd	NOUN
ajlm-2942	98	36	subclasses	subclass	NOUN
ajlm-2942	98	37	(	(	PUNCT
ajlm-2942	98	38	figure	figure	NOUN
ajlm-2942	98	39	1	1	NUM
ajlm-2942	98	40	)	)	PUNCT
ajlm-2942	98	41	,	,	PUNCT
ajlm-2942	98	42	with	with	ADP
ajlm-2942	98	43	the	the	DET
ajlm-2942	98	44	highest	high	ADJ
ajlm-2942	98	45	levels	level	NOUN
ajlm-2942	98	46	found	find	VERB
ajlm-2942	98	47	in	in	ADP
ajlm-2942	98	48	mi	mi	NOUN
ajlm-2942	98	49	patients	patient	NOUN
ajlm-2942	98	50	.	.	PUNCT
ajlm-2942	99	1	similarly	similarly	ADV
ajlm-2942	99	2	,	,	PUNCT
ajlm-2942	99	3	the	the	DET
ajlm-2942	99	4	mean	mean	ADJ
ajlm-2942	99	5	plasma	plasma	NOUN
ajlm-2942	99	6	apo	apo	PROPN
ajlm-2942	99	7	b	b	X
ajlm-2942	99	8	/	/	SYM
ajlm-2942	99	9	a1	a1	NOUN
ajlm-2942	99	10	ratio	ratio	NOUN
ajlm-2942	99	11	showed	show	VERB
ajlm-2942	99	12	a	a	DET
ajlm-2942	99	13	graded	grade	VERB
ajlm-2942	99	14	increase	increase	NOUN
ajlm-2942	99	15	(	(	PUNCT
ajlm-2942	99	16	figure	figure	NOUN
ajlm-2942	99	17	2	2	NUM
ajlm-2942	99	18	)	)	PUNCT
ajlm-2942	99	19	,	,	PUNCT
ajlm-2942	99	20	peaking	peak	VERB
ajlm-2942	99	21	in	in	ADP
ajlm-2942	99	22	ihd	ihd	ADJ
ajlm-2942	99	23	patients	patient	NOUN
ajlm-2942	99	24	.	.	PUNCT
ajlm-2942	100	1	in	in	ADP
ajlm-2942	100	2	contrast	contrast	NOUN
ajlm-2942	100	3	,	,	PUNCT
ajlm-2942	100	4	mean	mean	VERB
ajlm-2942	100	5	plasma	plasma	NOUN
ajlm-2942	100	6	apo	apo	PROPN
ajlm-2942	100	7	a1	a1	NOUN
ajlm-2942	100	8	levels	level	NOUN
ajlm-2942	100	9	exhibited	exhibit	VERB
ajlm-2942	100	10	a	a	DET
ajlm-2942	100	11	graded	grade	VERB
ajlm-2942	100	12	decline	decline	NOUN
ajlm-2942	100	13	(	(	PUNCT
ajlm-2942	100	14	figure	figure	NOUN
ajlm-2942	100	15	3	3	NUM
ajlm-2942	100	16	)	)	PUNCT
ajlm-2942	100	17	,	,	PUNCT
ajlm-2942	100	18	with	with	ADP
ajlm-2942	100	19	the	the	DET
ajlm-2942	100	20	lowest	low	ADJ
ajlm-2942	100	21	levels	level	NOUN
ajlm-2942	100	22	recorded	record	VERB
ajlm-2942	100	23	in	in	ADP
ajlm-2942	100	24	mi	mi	PROPN
ajlm-2942	100	25	patients	patient	NOUN
ajlm-2942	100	26	.	.	PUNCT
ajlm-2942	101	1	figure	figure	VERB
ajlm-2942	101	2	1	1	NUM
ajlm-2942	101	3	:	:	PUNCT
ajlm-2942	101	4	graded	grade	VERB
ajlm-2942	101	5	variations	variation	NOUN
ajlm-2942	101	6	in	in	ADP
ajlm-2942	101	7	the	the	DET
ajlm-2942	101	8	mean	mean	ADJ
ajlm-2942	101	9	plasma	plasma	NOUN
ajlm-2942	101	10	apolipoprotein	apolipoprotein	VERB
ajlm-2942	101	11	b	b	PROPN
ajlm-2942	101	12	concentrations	concentration	NOUN
ajlm-2942	101	13	in	in	ADP
ajlm-2942	101	14	atherosclerotic	atherosclerotic	ADJ
ajlm-2942	101	15	cardiovascular	cardiovascular	ADJ
ajlm-2942	101	16	disease	disease	NOUN
ajlm-2942	101	17	subclasses	subclass	NOUN
ajlm-2942	101	18	and	and	CCONJ
ajlm-2942	101	19	controls	control	NOUN
ajlm-2942	101	20	at	at	ADP
ajlm-2942	101	21	lagos	lagos	PROPN
ajlm-2942	101	22	state	state	NOUN
ajlm-2942	101	23	university	university	PROPN
ajlm-2942	101	24	teaching	teaching	NOUN
ajlm-2942	101	25	hospital	hospital	NOUN
ajlm-2942	101	26	,	,	PUNCT
ajlm-2942	101	27	lagos	lago	NOUN
ajlm-2942	101	28	,	,	PUNCT
ajlm-2942	101	29	nigeria	nigeria	PROPN
ajlm-2942	101	30	,	,	PUNCT
ajlm-2942	101	31	between	between	ADP
ajlm-2942	101	32	november	november	PROPN
ajlm-2942	101	33	2021	2021	NUM
ajlm-2942	101	34	and	and	CCONJ
ajlm-2942	101	35	november	november	PROPN
ajlm-2942	101	36	2022	2022	NUM
ajlm-2942	101	37	.	.	PUNCT
ajlm-2942	102	1	figure	figure	NOUN
ajlm-2942	102	2	2	2	NUM
ajlm-2942	102	3	:	:	PUNCT
ajlm-2942	102	4	graded	grade	VERB
ajlm-2942	102	5	variations	variation	NOUN
ajlm-2942	102	6	in	in	ADP
ajlm-2942	102	7	apolipoprotein	apolipoprotein	ADJ
ajlm-2942	102	8	b	b	X
ajlm-2942	102	9	/	/	SYM
ajlm-2942	102	10	a1	a1	NOUN
ajlm-2942	102	11	ratio	ratio	NOUN
ajlm-2942	102	12	in	in	ADP
ajlm-2942	102	13	atherosclerotic	atherosclerotic	ADJ
ajlm-2942	102	14	cardiovascular	cardiovascular	ADJ
ajlm-2942	102	15	disease	disease	NOUN
ajlm-2942	102	16	subclasses	subclass	NOUN
ajlm-2942	102	17	and	and	CCONJ
ajlm-2942	102	18	controls	control	NOUN
ajlm-2942	102	19	at	at	ADP
ajlm-2942	102	20	lagos	lagos	PROPN
ajlm-2942	102	21	state	state	NOUN
ajlm-2942	102	22	university	university	PROPN
ajlm-2942	102	23	teaching	teaching	NOUN
ajlm-2942	102	24	hospital	hospital	NOUN
ajlm-2942	102	25	,	,	PUNCT
ajlm-2942	102	26	lagos	lago	NOUN
ajlm-2942	102	27	,	,	PUNCT
ajlm-2942	102	28	nigeria	nigeria	PROPN
ajlm-2942	102	29	,	,	PUNCT
ajlm-2942	102	30	between	between	ADP
ajlm-2942	102	31	november	november	PROPN
ajlm-2942	102	32	2021	2021	NUM
ajlm-2942	102	33	and	and	CCONJ
ajlm-2942	102	34	november	november	PROPN
ajlm-2942	102	35	2022	2022	NUM
ajlm-2942	102	36	.	.	PUNCT
ajlm-2942	103	1	figure	figure	VERB
ajlm-2942	103	2	3	3	NUM
ajlm-2942	103	3	:	:	PUNCT
ajlm-2942	103	4	graded	grade	VERB
ajlm-2942	103	5	variations	variation	NOUN
ajlm-2942	103	6	in	in	ADP
ajlm-2942	103	7	the	the	DET
ajlm-2942	103	8	mean	mean	ADJ
ajlm-2942	103	9	plasma	plasma	NOUN
ajlm-2942	103	10	apolipoprotein	apolipoprotein	VERB
ajlm-2942	103	11	a1	a1	NOUN
ajlm-2942	103	12	levels	level	NOUN
ajlm-2942	103	13	in	in	ADP
ajlm-2942	103	14	atherosclerotic	atherosclerotic	ADJ
ajlm-2942	103	15	cardiovascular	cardiovascular	ADJ
ajlm-2942	103	16	disease	disease	NOUN
ajlm-2942	103	17	subclasses	subclass	NOUN
ajlm-2942	103	18	and	and	CCONJ
ajlm-2942	103	19	controls	control	NOUN
ajlm-2942	103	20	at	at	ADP
ajlm-2942	103	21	lagos	lagos	PROPN
ajlm-2942	103	22	state	state	NOUN
ajlm-2942	103	23	university	university	PROPN
ajlm-2942	103	24	teaching	teaching	NOUN
ajlm-2942	103	25	hospital	hospital	NOUN
ajlm-2942	103	26	,	,	PUNCT
ajlm-2942	103	27	lagos	lago	NOUN
ajlm-2942	103	28	,	,	PUNCT
ajlm-2942	103	29	nigeria	nigeria	PROPN
ajlm-2942	103	30	,	,	PUNCT
ajlm-2942	103	31	between	between	ADP
ajlm-2942	103	32	november	november	PROPN
ajlm-2942	103	33	2021	2021	NUM
ajlm-2942	103	34	and	and	CCONJ
ajlm-2942	103	35	november	november	PROPN
ajlm-2942	103	36	2022	2022	NUM
ajlm-2942	103	37	.	.	PUNCT
ajlm-2942	104	1	comparison	comparison	NOUN
ajlm-2942	104	2	of	of	ADP
ajlm-2942	104	3	the	the	DET
ajlm-2942	104	4	total	total	ADJ
ajlm-2942	104	5	and	and	CCONJ
ajlm-2942	104	6	high	high	ADJ
ajlm-2942	104	7	-	-	PUNCT
ajlm-2942	104	8	density	density	NOUN
ajlm-2942	104	9	lipoprotein	lipoprotein	ADJ
ajlm-2942	104	10	phospholipids	phospholipid	NOUN
ajlm-2942	104	11	levels	level	NOUN
ajlm-2942	104	12	across	across	ADP
ajlm-2942	104	13	different	different	ADJ
ajlm-2942	104	14	classes	class	NOUN
ajlm-2942	104	15	of	of	ADP
ajlm-2942	104	16	atherosclerotic	atherosclerotic	ADJ
ajlm-2942	104	17	cardiovascular	cardiovascular	ADJ
ajlm-2942	104	18	disease	disease	NOUN
ajlm-2942	104	19	the	the	DET
ajlm-2942	104	20	mean	mean	ADJ
ajlm-2942	104	21	total	total	ADJ
ajlm-2942	104	22	plasma	plasma	NOUN
ajlm-2942	104	23	phospholipid	phospholipid	NOUN
ajlm-2942	104	24	levels	level	NOUN
ajlm-2942	104	25	remained	remain	VERB
ajlm-2942	104	26	within	within	ADP
ajlm-2942	104	27	a	a	DET
ajlm-2942	104	28	narrow	narrow	ADJ
ajlm-2942	104	29	range	range	NOUN
ajlm-2942	104	30	across	across	ADP
ajlm-2942	104	31	ascvd	ascvd	NOUN
ajlm-2942	104	32	patients	patient	NOUN
ajlm-2942	104	33	and	and	CCONJ
ajlm-2942	104	34	controls	control	NOUN
ajlm-2942	104	35	(	(	PUNCT
ajlm-2942	104	36	figure	figure	NOUN
ajlm-2942	104	37	4	4	NUM
ajlm-2942	104	38	)	)	PUNCT
ajlm-2942	104	39	,	,	PUNCT
ajlm-2942	104	40	with	with	ADP
ajlm-2942	104	41	no	no	DET
ajlm-2942	104	42	significant	significant	ADJ
ajlm-2942	104	43	difference	difference	NOUN
ajlm-2942	104	44	between	between	ADP
ajlm-2942	104	45	the	the	DET
ajlm-2942	104	46	groups	group	NOUN
ajlm-2942	104	47	(	(	PUNCT
ajlm-2942	104	48	table	table	NOUN
ajlm-2942	104	49	1	1	NUM
ajlm-2942	104	50	)	)	PUNCT
ajlm-2942	104	51	.	.	PUNCT
ajlm-2942	105	1	however	however	ADV
ajlm-2942	105	2	,	,	PUNCT
ajlm-2942	105	3	the	the	DET
ajlm-2942	105	4	mean	mean	ADJ
ajlm-2942	105	5	plasma	plasma	NOUN
ajlm-2942	105	6	hdl	hdl	PROPN
ajlm-2942	105	7	phospholipid	phospholipid	PROPN
ajlm-2942	105	8	fraction	fraction	NOUN
ajlm-2942	105	9	was	be	AUX
ajlm-2942	105	10	significantly	significantly	ADV
ajlm-2942	105	11	higher	high	ADJ
ajlm-2942	105	12	in	in	ADP
ajlm-2942	105	13	controls	control	NOUN
ajlm-2942	105	14	than	than	ADP
ajlm-2942	105	15	in	in	ADP
ajlm-2942	105	16	ascvd	ascvd	NOUN
ajlm-2942	105	17	patients	patient	NOUN
ajlm-2942	105	18	,	,	PUNCT
ajlm-2942	105	19	with	with	ADP
ajlm-2942	105	20	the	the	DET
ajlm-2942	105	21	lowest	low	ADJ
ajlm-2942	105	22	levels	level	NOUN
ajlm-2942	105	23	observed	observe	VERB
ajlm-2942	105	24	in	in	ADP
ajlm-2942	105	25	those	those	PRON
ajlm-2942	105	26	with	with	ADP
ajlm-2942	105	27	mi	mi	PROPN
ajlm-2942	105	28	and	and	CCONJ
ajlm-2942	105	29	ihd	ihd	PROPN
ajlm-2942	105	30	.	.	PUNCT
ajlm-2942	106	1	figure	figure	NOUN
ajlm-2942	106	2	4	4	NUM
ajlm-2942	106	3	:	:	PUNCT
ajlm-2942	106	4	plasma	plasma	NOUN
ajlm-2942	106	5	total	total	NOUN
ajlm-2942	106	6	and	and	CCONJ
ajlm-2942	106	7	high	high	ADJ
ajlm-2942	106	8	-	-	PUNCT
ajlm-2942	106	9	density	density	NOUN
ajlm-2942	106	10	lipoprotein	lipoprotein	ADJ
ajlm-2942	106	11	phospholipids	phospholipid	NOUN
ajlm-2942	106	12	levels	level	NOUN
ajlm-2942	106	13	in	in	ADP
ajlm-2942	106	14	atherosclerotic	atherosclerotic	ADJ
ajlm-2942	106	15	cardiovascular	cardiovascular	ADJ
ajlm-2942	106	16	disease	disease	NOUN
ajlm-2942	106	17	subclasses	subclass	NOUN
ajlm-2942	106	18	and	and	CCONJ
ajlm-2942	106	19	controls	control	NOUN
ajlm-2942	106	20	at	at	ADP
ajlm-2942	106	21	lagos	lagos	PROPN
ajlm-2942	106	22	state	state	NOUN
ajlm-2942	106	23	university	university	PROPN
ajlm-2942	106	24	teaching	teaching	NOUN
ajlm-2942	106	25	hospital	hospital	NOUN
ajlm-2942	106	26	,	,	PUNCT
ajlm-2942	106	27	lagos	lago	NOUN
ajlm-2942	106	28	,	,	PUNCT
ajlm-2942	106	29	nigeria	nigeria	PROPN
ajlm-2942	106	30	,	,	PUNCT
ajlm-2942	106	31	between	between	ADP
ajlm-2942	106	32	november	november	PROPN
ajlm-2942	106	33	2021	2021	NUM
ajlm-2942	106	34	and	and	CCONJ
ajlm-2942	106	35	november	november	PROPN
ajlm-2942	106	36	2022	2022	NUM
ajlm-2942	106	37	.	.	PUNCT
ajlm-2942	107	1	discussion	discussion	NOUN
ajlm-2942	107	2	the	the	DET
ajlm-2942	107	3	present	present	ADJ
ajlm-2942	107	4	study	study	NOUN
ajlm-2942	107	5	demonstrated	demonstrate	VERB
ajlm-2942	107	6	significant	significant	ADJ
ajlm-2942	107	7	disruptions	disruption	NOUN
ajlm-2942	107	8	in	in	ADP
ajlm-2942	107	9	atherogenic	atherogenic	ADJ
ajlm-2942	107	10	lipids	lipid	NOUN
ajlm-2942	107	11	and	and	CCONJ
ajlm-2942	107	12	lipoproteins	lipoprotein	NOUN
ajlm-2942	107	13	among	among	ADP
ajlm-2942	107	14	ascvd	ascvd	NOUN
ajlm-2942	107	15	patients	patient	NOUN
ajlm-2942	107	16	.	.	PUNCT
ajlm-2942	108	1	notably	notably	ADV
ajlm-2942	108	2	,	,	PUNCT
ajlm-2942	108	3	there	there	PRON
ajlm-2942	108	4	were	be	VERB
ajlm-2942	108	5	substantial	substantial	ADJ
ajlm-2942	108	6	increases	increase	NOUN
ajlm-2942	108	7	in	in	ADP
ajlm-2942	108	8	plasma	plasma	NOUN
ajlm-2942	108	9	triglycerides	triglyceride	NOUN
ajlm-2942	108	10	,	,	PUNCT
ajlm-2942	108	11	tc	tc	NOUN
ajlm-2942	108	12	,	,	PUNCT
ajlm-2942	108	13	ldlc	ldlc	NOUN
ajlm-2942	108	14	,	,	PUNCT
ajlm-2942	108	15	and	and	CCONJ
ajlm-2942	108	16	non	non	ADJ
ajlm-2942	108	17	-	-	ADJ
ajlm-2942	108	18	hdlc	hdlc	ADJ
ajlm-2942	108	19	levels	level	NOUN
ajlm-2942	108	20	,	,	PUNCT
ajlm-2942	108	21	whereas	whereas	SCONJ
ajlm-2942	108	22	hdlc	hdlc	PROPN
ajlm-2942	108	23	(	(	PUNCT
ajlm-2942	108	24	an	an	DET
ajlm-2942	108	25	antiatherogenic	antiatherogenic	ADJ
ajlm-2942	108	26	lipid	lipid	NOUN
ajlm-2942	108	27	)	)	PUNCT
ajlm-2942	108	28	was	be	AUX
ajlm-2942	108	29	markedly	markedly	ADV
ajlm-2942	108	30	reduced	reduce	VERB
ajlm-2942	108	31	compared	compare	VERB
ajlm-2942	108	32	with	with	ADP
ajlm-2942	108	33	the	the	DET
ajlm-2942	108	34	control	control	NOUN
ajlm-2942	108	35	values	value	NOUN
ajlm-2942	108	36	.	.	PUNCT
ajlm-2942	109	1	similarly	similarly	ADV
ajlm-2942	109	2	,	,	PUNCT
ajlm-2942	109	3	conventional	conventional	ADJ
ajlm-2942	109	4	lipid	lipid	NOUN
ajlm-2942	109	5	parameters	parameter	NOUN
ajlm-2942	109	6	(	(	PUNCT
ajlm-2942	109	7	cri	cri	PROPN
ajlm-2942	109	8	-	-	PROPN
ajlm-2942	109	9	i	i	PROPN
ajlm-2942	109	10	,	,	PUNCT
ajlm-2942	109	11	cri	cri	PROPN
ajlm-2942	109	12	-	-	PUNCT
ajlm-2942	109	13	ii	ii	PROPN
ajlm-2942	109	14	,	,	PUNCT
ajlm-2942	109	15	ac	ac	PROPN
ajlm-2942	109	16	,	,	PUNCT
ajlm-2942	109	17	and	and	CCONJ
ajlm-2942	109	18	aip	aip	PROPN
ajlm-2942	109	19	)	)	PUNCT
ajlm-2942	109	20	were	be	AUX
ajlm-2942	109	21	markedly	markedly	ADV
ajlm-2942	109	22	elevated	elevate	VERB
ajlm-2942	109	23	in	in	ADP
ajlm-2942	109	24	ascvd	ascvd	NOUN
ajlm-2942	109	25	patients	patient	NOUN
ajlm-2942	109	26	compared	compare	VERB
ajlm-2942	109	27	with	with	ADP
ajlm-2942	109	28	controls	control	NOUN
ajlm-2942	109	29	.	.	PUNCT
ajlm-2942	110	1	these	these	DET
ajlm-2942	110	2	findings	finding	NOUN
ajlm-2942	110	3	are	be	AUX
ajlm-2942	110	4	consistent	consistent	ADJ
ajlm-2942	110	5	with	with	ADP
ajlm-2942	110	6	earlier	early	ADJ
ajlm-2942	110	7	studies,20,39	studies,20,39	NOUN
ajlm-2942	110	8	reporting	report	VERB
ajlm-2942	110	9	elevated	elevated	ADJ
ajlm-2942	110	10	levels	level	NOUN
ajlm-2942	110	11	of	of	ADP
ajlm-2942	110	12	atherogenic	atherogenic	ADJ
ajlm-2942	110	13	lipids	lipid	NOUN
ajlm-2942	110	14	and	and	CCONJ
ajlm-2942	110	15	lipid	lipid	NOUN
ajlm-2942	110	16	indices	index	NOUN
ajlm-2942	110	17	in	in	ADP
ajlm-2942	110	18	cardiovascular	cardiovascular	ADJ
ajlm-2942	110	19	disease	disease	NOUN
ajlm-2942	110	20	patients	patient	NOUN
ajlm-2942	110	21	.	.	PUNCT
ajlm-2942	111	1	in	in	ADP
ajlm-2942	111	2	addition	addition	NOUN
ajlm-2942	111	3	,	,	PUNCT
ajlm-2942	111	4	this	this	DET
ajlm-2942	111	5	study	study	NOUN
ajlm-2942	111	6	revealed	reveal	VERB
ajlm-2942	111	7	significant	significant	ADJ
ajlm-2942	111	8	variations	variation	NOUN
ajlm-2942	111	9	in	in	ADP
ajlm-2942	111	10	lipid	lipid	ADJ
ajlm-2942	111	11	profiles	profile	NOUN
ajlm-2942	111	12	and	and	CCONJ
ajlm-2942	111	13	indices	index	NOUN
ajlm-2942	111	14	across	across	ADP
ajlm-2942	111	15	different	different	ADJ
ajlm-2942	111	16	subclasses	subclass	NOUN
ajlm-2942	111	17	of	of	ADP
ajlm-2942	111	18	ascvd	ascvd	NOUN
ajlm-2942	111	19	.	.	PUNCT
ajlm-2942	112	1	notably	notably	ADV
ajlm-2942	112	2	,	,	PUNCT
ajlm-2942	112	3	the	the	DET
ajlm-2942	112	4	greatest	great	ADJ
ajlm-2942	112	5	elevations	elevation	NOUN
ajlm-2942	112	6	in	in	ADP
ajlm-2942	112	7	atherogenic	atherogenic	ADJ
ajlm-2942	112	8	lipid	lipid	NOUN
ajlm-2942	112	9	and	and	CCONJ
ajlm-2942	112	10	lipid	lipid	NOUN
ajlm-2942	112	11	indices	index	NOUN
ajlm-2942	112	12	were	be	AUX
ajlm-2942	112	13	observed	observe	VERB
ajlm-2942	112	14	in	in	ADP
ajlm-2942	112	15	patients	patient	NOUN
ajlm-2942	112	16	with	with	ADP
ajlm-2942	112	17	myocardial	myocardial	ADJ
ajlm-2942	112	18	infarction	infarction	NOUN
ajlm-2942	112	19	and	and	CCONJ
ajlm-2942	112	20	ihd	ihd	ADJ
ajlm-2942	112	21	.	.	PUNCT
ajlm-2942	113	1	conversely	conversely	ADV
ajlm-2942	113	2	,	,	PUNCT
ajlm-2942	113	3	these	these	DET
ajlm-2942	113	4	groups	group	NOUN
ajlm-2942	113	5	also	also	ADV
ajlm-2942	113	6	presented	present	VERB
ajlm-2942	113	7	the	the	DET
ajlm-2942	113	8	lowest	low	ADJ
ajlm-2942	113	9	reduction	reduction	NOUN
ajlm-2942	113	10	in	in	ADP
ajlm-2942	113	11	antiatherogenic	antiatherogenic	PROPN
ajlm-2942	113	12	hdl	hdl	PROPN
ajlm-2942	113	13	cholesterol	cholesterol	PROPN
ajlm-2942	113	14	levels	level	NOUN
ajlm-2942	113	15	compared	compare	VERB
ajlm-2942	113	16	with	with	ADP
ajlm-2942	113	17	the	the	DET
ajlm-2942	113	18	other	other	ADJ
ajlm-2942	113	19	ascvd	ascvd	NOUN
ajlm-2942	113	20	subclasses	subclass	NOUN
ajlm-2942	113	21	.	.	PUNCT
ajlm-2942	114	1	these	these	DET
ajlm-2942	114	2	findings	finding	NOUN
ajlm-2942	114	3	align	align	VERB
ajlm-2942	114	4	with	with	ADP
ajlm-2942	114	5	previous	previous	ADJ
ajlm-2942	114	6	reports	report	NOUN
ajlm-2942	114	7	demonstrating	demonstrate	VERB
ajlm-2942	114	8	severe	severe	ADJ
ajlm-2942	114	9	dyslipidaemia	dyslipidaemia	NOUN
ajlm-2942	114	10	in	in	ADP
ajlm-2942	114	11	patients	patient	NOUN
ajlm-2942	114	12	with	with	ADP
ajlm-2942	114	13	mi	mi	PROPN
ajlm-2942	114	14	and	and	CCONJ
ajlm-2942	114	15	ihd	ihd	ADJ
ajlm-2942	114	16	compared	compare	VERB
ajlm-2942	114	17	with	with	ADP
ajlm-2942	114	18	other	other	ADJ
ajlm-2942	114	19	ascvd	ascvd	NOUN
ajlm-2942	114	20	subtypes.8,40	subtypes.8,40	VERB
ajlm-2942	114	21	the	the	DET
ajlm-2942	114	22	results	result	NOUN
ajlm-2942	114	23	of	of	ADP
ajlm-2942	114	24	this	this	DET
ajlm-2942	114	25	study	study	NOUN
ajlm-2942	114	26	further	far	ADV
ajlm-2942	114	27	underscore	underscore	VERB
ajlm-2942	114	28	the	the	DET
ajlm-2942	114	29	pronounced	pronounced	ADJ
ajlm-2942	114	30	severity	severity	NOUN
ajlm-2942	114	31	of	of	ADP
ajlm-2942	114	32	dyslipidaemia	dyslipidaemia	NOUN
ajlm-2942	114	33	in	in	ADP
ajlm-2942	114	34	these	these	DET
ajlm-2942	114	35	patient	patient	ADJ
ajlm-2942	114	36	groups	group	NOUN
ajlm-2942	114	37	.	.	PUNCT
ajlm-2942	115	1	furthermore	furthermore	ADV
ajlm-2942	115	2	,	,	PUNCT
ajlm-2942	115	3	this	this	DET
ajlm-2942	115	4	study	study	NOUN
ajlm-2942	115	5	revealed	reveal	VERB
ajlm-2942	115	6	a	a	DET
ajlm-2942	115	7	substantial	substantial	ADJ
ajlm-2942	115	8	decrease	decrease	NOUN
ajlm-2942	115	9	in	in	ADP
ajlm-2942	115	10	the	the	DET
ajlm-2942	115	11	mean	mean	ADJ
ajlm-2942	115	12	plasma	plasma	NOUN
ajlm-2942	115	13	apo	apo	PROPN
ajlm-2942	115	14	a1	a1	NOUN
ajlm-2942	115	15	concentration	concentration	NOUN
ajlm-2942	115	16	,	,	PUNCT
ajlm-2942	115	17	and	and	CCONJ
ajlm-2942	115	18	notable	notable	ADJ
ajlm-2942	115	19	increases	increase	NOUN
ajlm-2942	115	20	in	in	ADP
ajlm-2942	115	21	apo	apo	PROPN
ajlm-2942	115	22	b	b	PROPN
ajlm-2942	115	23	levels	level	NOUN
ajlm-2942	115	24	and	and	CCONJ
ajlm-2942	115	25	the	the	DET
ajlm-2942	115	26	apo	apo	PROPN
ajlm-2942	115	27	b	b	PROPN
ajlm-2942	115	28	/	/	SYM
ajlm-2942	115	29	a1	a1	NOUN
ajlm-2942	115	30	ratio	ratio	NOUN
ajlm-2942	115	31	in	in	ADP
ajlm-2942	115	32	ascvd	ascvd	NOUN
ajlm-2942	115	33	patients	patient	NOUN
ajlm-2942	115	34	,	,	PUNCT
ajlm-2942	115	35	compared	compare	VERB
ajlm-2942	115	36	with	with	ADP
ajlm-2942	115	37	those	those	PRON
ajlm-2942	115	38	in	in	ADP
ajlm-2942	115	39	the	the	DET
ajlm-2942	115	40	control	control	NOUN
ajlm-2942	115	41	group	group	NOUN
ajlm-2942	115	42	.	.	PUNCT
ajlm-2942	116	1	these	these	DET
ajlm-2942	116	2	findings	finding	NOUN
ajlm-2942	116	3	are	be	AUX
ajlm-2942	116	4	consistent	consistent	ADJ
ajlm-2942	116	5	with	with	ADP
ajlm-2942	116	6	prior	prior	ADJ
ajlm-2942	116	7	research	research	NOUN
ajlm-2942	116	8	across	across	ADP
ajlm-2942	116	9	diverse	diverse	ADJ
ajlm-2942	116	10	populations	population	NOUN
ajlm-2942	116	11	worldwide,13,14,16,17	worldwide,13,14,16,17	NOUN
ajlm-2942	116	12	which	which	PRON
ajlm-2942	116	13	revealed	reveal	VERB
ajlm-2942	116	14	that	that	SCONJ
ajlm-2942	116	15	low	low	ADJ
ajlm-2942	116	16	apo	apo	PROPN
ajlm-2942	116	17	a1	a1	NOUN
ajlm-2942	116	18	levels	level	NOUN
ajlm-2942	116	19	,	,	PUNCT
ajlm-2942	116	20	elevated	elevate	VERB
ajlm-2942	116	21	apo	apo	PROPN
ajlm-2942	116	22	b	b	PROPN
ajlm-2942	116	23	levels	level	NOUN
ajlm-2942	116	24	,	,	PUNCT
ajlm-2942	116	25	and	and	CCONJ
ajlm-2942	116	26	a	a	DET
ajlm-2942	116	27	higher	high	ADJ
ajlm-2942	116	28	apo	apo	NOUN
ajlm-2942	116	29	b	b	PROPN
ajlm-2942	116	30	/	/	SYM
ajlm-2942	116	31	a1	a1	NOUN
ajlm-2942	116	32	ratio	ratio	NOUN
ajlm-2942	116	33	are	be	AUX
ajlm-2942	116	34	associated	associate	VERB
ajlm-2942	116	35	with	with	ADP
ajlm-2942	116	36	a	a	DET
ajlm-2942	116	37	heightened	heightened	ADJ
ajlm-2942	116	38	risk	risk	NOUN
ajlm-2942	116	39	of	of	ADP
ajlm-2942	116	40	major	major	ADJ
ajlm-2942	116	41	cardiovascular	cardiovascular	ADJ
ajlm-2942	116	42	events	event	NOUN
ajlm-2942	116	43	.	.	PUNCT
ajlm-2942	117	1	elevated	elevate	VERB
ajlm-2942	117	2	apo	apo	PROPN
ajlm-2942	117	3	b	b	PROPN
ajlm-2942	117	4	levels	level	NOUN
ajlm-2942	117	5	in	in	ADP
ajlm-2942	117	6	ascvd	ascvd	NOUN
ajlm-2942	117	7	patients	patient	NOUN
ajlm-2942	117	8	probably	probably	ADV
ajlm-2942	117	9	indicate	indicate	VERB
ajlm-2942	117	10	an	an	DET
ajlm-2942	117	11	increased	increase	VERB
ajlm-2942	117	12	burden	burden	NOUN
ajlm-2942	117	13	of	of	ADP
ajlm-2942	117	14	atherogenic	atherogenic	ADJ
ajlm-2942	117	15	particles	particle	NOUN
ajlm-2942	117	16	,	,	PUNCT
ajlm-2942	117	17	which	which	PRON
ajlm-2942	117	18	is	be	AUX
ajlm-2942	117	19	correlated	correlate	VERB
ajlm-2942	117	20	with	with	ADP
ajlm-2942	117	21	increased	increase	VERB
ajlm-2942	117	22	cardiovascular	cardiovascular	ADJ
ajlm-2942	117	23	risk.38	risk.38	NOUN
ajlm-2942	117	24	concurrently	concurrently	ADV
ajlm-2942	117	25	,	,	PUNCT
ajlm-2942	117	26	a	a	DET
ajlm-2942	117	27	higher	high	ADJ
ajlm-2942	117	28	apo	apo	NOUN
ajlm-2942	117	29	b	b	PROPN
ajlm-2942	117	30	/	/	SYM
ajlm-2942	117	31	a1	a1	NOUN
ajlm-2942	117	32	ratio	ratio	NOUN
ajlm-2942	117	33	suggests	suggest	VERB
ajlm-2942	117	34	an	an	DET
ajlm-2942	117	35	imbalance	imbalance	NOUN
ajlm-2942	117	36	favouring	favour	VERB
ajlm-2942	117	37	atherogenic	atherogenic	ADJ
ajlm-2942	117	38	particles	particle	NOUN
ajlm-2942	117	39	over	over	ADP
ajlm-2942	117	40	antiatherogenic	antiatherogenic	ADJ
ajlm-2942	117	41	particles	particle	NOUN
ajlm-2942	117	42	,	,	PUNCT
ajlm-2942	117	43	highlighting	highlight	VERB
ajlm-2942	117	44	an	an	DET
ajlm-2942	117	45	adverse	adverse	ADJ
ajlm-2942	117	46	lipid	lipid	NOUN
ajlm-2942	117	47	profile	profile	NOUN
ajlm-2942	117	48	in	in	ADP
ajlm-2942	117	49	the	the	DET
ajlm-2942	117	50	ascvd	ascvd	NOUN
ajlm-2942	117	51	group.16	group.16	PROPN
ajlm-2942	117	52	notably	notably	ADV
ajlm-2942	117	53	,	,	PUNCT
ajlm-2942	117	54	the	the	DET
ajlm-2942	117	55	lowest	low	ADJ
ajlm-2942	117	56	reduction	reduction	NOUN
ajlm-2942	117	57	in	in	ADP
ajlm-2942	117	58	plasma	plasma	NOUN
ajlm-2942	117	59	apo	apo	PROPN
ajlm-2942	117	60	a1	a1	NOUN
ajlm-2942	117	61	levels	level	NOUN
ajlm-2942	117	62	and	and	CCONJ
ajlm-2942	117	63	the	the	DET
ajlm-2942	117	64	greatest	great	ADJ
ajlm-2942	117	65	increases	increase	NOUN
ajlm-2942	117	66	in	in	ADP
ajlm-2942	117	67	both	both	CCONJ
ajlm-2942	117	68	apo	apo	PROPN
ajlm-2942	117	69	b	b	PROPN
ajlm-2942	117	70	levels	level	NOUN
ajlm-2942	117	71	and	and	CCONJ
ajlm-2942	117	72	the	the	DET
ajlm-2942	117	73	apo	apo	PROPN
ajlm-2942	117	74	b	b	PROPN
ajlm-2942	117	75	/	/	SYM
ajlm-2942	117	76	a1	a1	NOUN
ajlm-2942	117	77	ratio	ratio	NOUN
ajlm-2942	117	78	were	be	AUX
ajlm-2942	117	79	observed	observe	VERB
ajlm-2942	117	80	in	in	ADP
ajlm-2942	117	81	patients	patient	NOUN
ajlm-2942	117	82	with	with	ADP
ajlm-2942	117	83	mi	mi	PROPN
ajlm-2942	117	84	and	and	CCONJ
ajlm-2942	117	85	ihd	ihd	ADJ
ajlm-2942	117	86	.	.	PUNCT
ajlm-2942	118	1	thus	thus	ADV
ajlm-2942	118	2	,	,	PUNCT
ajlm-2942	118	3	these	these	DET
ajlm-2942	118	4	findings	finding	NOUN
ajlm-2942	118	5	underscore	underscore	VERB
ajlm-2942	118	6	the	the	DET
ajlm-2942	118	7	critical	critical	ADJ
ajlm-2942	118	8	role	role	NOUN
ajlm-2942	118	9	of	of	ADP
ajlm-2942	118	10	apo	apo	PROPN
ajlm-2942	118	11	b	b	PROPN
ajlm-2942	118	12	in	in	ADP
ajlm-2942	118	13	the	the	DET
ajlm-2942	118	14	manifestation	manifestation	NOUN
ajlm-2942	118	15	of	of	ADP
ajlm-2942	118	16	mi	mi	PROPN
ajlm-2942	118	17	and	and	CCONJ
ajlm-2942	118	18	ihd	ihd	ADJ
ajlm-2942	118	19	,	,	PUNCT
ajlm-2942	118	20	as	as	SCONJ
ajlm-2942	118	21	elevated	elevated	ADJ
ajlm-2942	118	22	levels	level	NOUN
ajlm-2942	118	23	of	of	ADP
ajlm-2942	118	24	apo	apo	PROPN
ajlm-2942	118	25	b	b	X
ajlm-2942	118	26	-	-	PUNCT
ajlm-2942	118	27	containing	contain	VERB
ajlm-2942	118	28	lipoproteins	lipoprotein	NOUN
ajlm-2942	118	29	primarily	primarily	ADV
ajlm-2942	118	30	drive	drive	VERB
ajlm-2942	118	31	atherosclerosis.38	atherosclerosis.38	PROPN
ajlm-2942	118	32	moreover	moreover	ADV
ajlm-2942	118	33	,	,	PUNCT
ajlm-2942	118	34	reduced	reduce	VERB
ajlm-2942	118	35	apo	apo	PROPN
ajlm-2942	118	36	a1	a1	NOUN
ajlm-2942	118	37	levels	level	NOUN
ajlm-2942	118	38	in	in	ADP
ajlm-2942	118	39	these	these	DET
ajlm-2942	118	40	ascvd	ascvd	NOUN
ajlm-2942	118	41	subclasses	subclass	NOUN
ajlm-2942	118	42	(	(	PUNCT
ajlm-2942	118	43	mi	mi	NOUN
ajlm-2942	118	44	and	and	CCONJ
ajlm-2942	118	45	ihd	ihd	ADJ
ajlm-2942	118	46	)	)	PUNCT
ajlm-2942	118	47	suggest	suggest	VERB
ajlm-2942	118	48	impaired	impaired	ADJ
ajlm-2942	118	49	reverse	reverse	ADJ
ajlm-2942	118	50	cholesterol	cholesterol	NOUN
ajlm-2942	118	51	transport	transport	NOUN
ajlm-2942	118	52	,	,	PUNCT
ajlm-2942	118	53	which	which	PRON
ajlm-2942	118	54	may	may	AUX
ajlm-2942	118	55	contribute	contribute	VERB
ajlm-2942	118	56	to	to	ADP
ajlm-2942	118	57	the	the	DET
ajlm-2942	118	58	lipid	lipid	NOUN
ajlm-2942	118	59	build	build	NOUN
ajlm-2942	118	60	-	-	PUNCT
ajlm-2942	118	61	up	up	NOUN
ajlm-2942	118	62	and	and	CCONJ
ajlm-2942	118	63	instability	instability	NOUN
ajlm-2942	118	64	of	of	ADP
ajlm-2942	118	65	plaques.13	plaques.13	PROPN
ajlm-2942	118	66	plaque	plaque	NOUN
ajlm-2942	118	67	rupture	rupture	NOUN
ajlm-2942	118	68	is	be	AUX
ajlm-2942	118	69	a	a	DET
ajlm-2942	118	70	common	common	ADJ
ajlm-2942	118	71	cause	cause	NOUN
ajlm-2942	118	72	of	of	ADP
ajlm-2942	118	73	mi,41	mi,41	PROPN
ajlm-2942	118	74	making	make	VERB
ajlm-2942	118	75	apo	apo	PROPN
ajlm-2942	118	76	a1	a1	VERB
ajlm-2942	118	77	a	a	DET
ajlm-2942	118	78	crucial	crucial	ADJ
ajlm-2942	118	79	factor	factor	NOUN
ajlm-2942	118	80	in	in	ADP
ajlm-2942	118	81	these	these	DET
ajlm-2942	118	82	patients	patient	NOUN
ajlm-2942	118	83	.	.	PUNCT
ajlm-2942	119	1	furthermore	furthermore	ADV
ajlm-2942	119	2	,	,	PUNCT
ajlm-2942	119	3	the	the	DET
ajlm-2942	119	4	present	present	ADJ
ajlm-2942	119	5	study	study	NOUN
ajlm-2942	119	6	revealed	reveal	VERB
ajlm-2942	119	7	a	a	DET
ajlm-2942	119	8	marked	mark	VERB
ajlm-2942	119	9	reduction	reduction	NOUN
ajlm-2942	119	10	in	in	ADP
ajlm-2942	119	11	the	the	DET
ajlm-2942	119	12	mean	mean	ADJ
ajlm-2942	119	13	hdl	hdl	PROPN
ajlm-2942	119	14	phospholipid	phospholipid	NOUN
ajlm-2942	119	15	levels	level	NOUN
ajlm-2942	119	16	in	in	ADP
ajlm-2942	119	17	ascvd	ascvd	NOUN
ajlm-2942	119	18	patients	patient	NOUN
ajlm-2942	119	19	compared	compare	VERB
ajlm-2942	119	20	with	with	ADP
ajlm-2942	119	21	those	those	PRON
ajlm-2942	119	22	in	in	ADP
ajlm-2942	119	23	the	the	DET
ajlm-2942	119	24	controls	control	NOUN
ajlm-2942	119	25	.	.	PUNCT
ajlm-2942	120	1	this	this	DET
ajlm-2942	120	2	finding	finding	NOUN
ajlm-2942	120	3	is	be	AUX
ajlm-2942	120	4	in	in	ADP
ajlm-2942	120	5	agreement	agreement	NOUN
ajlm-2942	120	6	with	with	ADP
ajlm-2942	120	7	previous	previous	ADJ
ajlm-2942	120	8	studies	study	NOUN
ajlm-2942	120	9	that	that	PRON
ajlm-2942	120	10	reported	report	VERB
ajlm-2942	120	11	a	a	DET
ajlm-2942	120	12	reduction	reduction	NOUN
ajlm-2942	120	13	in	in	ADP
ajlm-2942	120	14	hdl	hdl	PROPN
ajlm-2942	120	15	phospholipid	phospholipid	NOUN
ajlm-2942	120	16	levels	level	NOUN
ajlm-2942	120	17	in	in	ADP
ajlm-2942	120	18	ascvd	ascvd	NOUN
ajlm-2942	120	19	patients	patient	NOUN
ajlm-2942	120	20	compared	compare	VERB
ajlm-2942	120	21	with	with	ADP
ajlm-2942	120	22	those	those	PRON
ajlm-2942	120	23	in	in	ADP
ajlm-2942	120	24	the	the	DET
ajlm-2942	120	25	control	control	NOUN
ajlm-2942	120	26	group.23,26	group.23,26	NOUN
ajlm-2942	120	27	these	these	DET
ajlm-2942	120	28	findings	finding	NOUN
ajlm-2942	120	29	suggest	suggest	VERB
ajlm-2942	120	30	a	a	DET
ajlm-2942	120	31	potential	potential	ADJ
ajlm-2942	120	32	impairment	impairment	NOUN
ajlm-2942	120	33	in	in	ADP
ajlm-2942	120	34	hdl	hdl	PROPN
ajlm-2942	120	35	functionality	functionality	PROPN
ajlm-2942	120	36	,	,	PUNCT
ajlm-2942	120	37	which	which	PRON
ajlm-2942	120	38	could	could	AUX
ajlm-2942	120	39	contribute	contribute	VERB
ajlm-2942	120	40	to	to	ADP
ajlm-2942	120	41	the	the	DET
ajlm-2942	120	42	pathophysiology	pathophysiology	NOUN
ajlm-2942	120	43	of	of	ADP
ajlm-2942	120	44	ascvd	ascvd	NOUN
ajlm-2942	120	45	.	.	PUNCT
ajlm-2942	121	1	moreover	moreover	ADV
ajlm-2942	121	2	,	,	PUNCT
ajlm-2942	121	3	the	the	DET
ajlm-2942	121	4	reduction	reduction	NOUN
ajlm-2942	121	5	in	in	ADP
ajlm-2942	121	6	hdl	hdl	PROPN
ajlm-2942	121	7	phospholipid	phospholipid	NOUN
ajlm-2942	121	8	levels	level	NOUN
ajlm-2942	121	9	was	be	AUX
ajlm-2942	121	10	particularly	particularly	ADV
ajlm-2942	121	11	pronounced	pronounce	VERB
ajlm-2942	121	12	in	in	ADP
ajlm-2942	121	13	patients	patient	NOUN
ajlm-2942	121	14	suffering	suffer	VERB
ajlm-2942	121	15	from	from	ADP
ajlm-2942	121	16	mi	mi	PROPN
ajlm-2942	121	17	and	and	CCONJ
ajlm-2942	121	18	ihd	ihd	ADJ
ajlm-2942	121	19	.	.	PUNCT
ajlm-2942	122	1	these	these	DET
ajlm-2942	122	2	findings	finding	NOUN
ajlm-2942	122	3	could	could	AUX
ajlm-2942	122	4	imply	imply	VERB
ajlm-2942	122	5	that	that	SCONJ
ajlm-2942	122	6	these	these	DET
ajlm-2942	122	7	ascvd	ascvd	NOUN
ajlm-2942	122	8	subclasses	subclass	NOUN
ajlm-2942	122	9	are	be	AUX
ajlm-2942	122	10	associated	associate	VERB
ajlm-2942	122	11	with	with	ADP
ajlm-2942	122	12	more	more	ADV
ajlm-2942	122	13	severe	severe	ADJ
ajlm-2942	122	14	alterations	alteration	NOUN
ajlm-2942	122	15	in	in	ADP
ajlm-2942	122	16	lipid	lipid	ADJ
ajlm-2942	122	17	metabolism	metabolism	NOUN
ajlm-2942	122	18	and	and	CCONJ
ajlm-2942	122	19	hdl	hdl	PROPN
ajlm-2942	122	20	function	function	PROPN
ajlm-2942	122	21	,	,	PUNCT
ajlm-2942	122	22	possibly	possibly	ADV
ajlm-2942	122	23	exacerbating	exacerbate	VERB
ajlm-2942	122	24	the	the	DET
ajlm-2942	122	25	risk	risk	NOUN
ajlm-2942	122	26	and	and	CCONJ
ajlm-2942	122	27	severity	severity	NOUN
ajlm-2942	122	28	of	of	ADP
ajlm-2942	122	29	ascvd	ascvd	NOUN
ajlm-2942	122	30	.	.	PUNCT
ajlm-2942	123	1	in	in	ADP
ajlm-2942	123	2	addition	addition	NOUN
ajlm-2942	123	3	,	,	PUNCT
ajlm-2942	123	4	the	the	DET
ajlm-2942	123	5	present	present	ADJ
ajlm-2942	123	6	study	study	NOUN
ajlm-2942	123	7	revealed	reveal	VERB
ajlm-2942	123	8	significant	significant	ADJ
ajlm-2942	123	9	inverse	inverse	NOUN
ajlm-2942	123	10	correlations	correlation	NOUN
ajlm-2942	123	11	between	between	ADP
ajlm-2942	123	12	apo	apo	PROPN
ajlm-2942	123	13	a1	a1	NOUN
ajlm-2942	123	14	levels	level	NOUN
ajlm-2942	123	15	and	and	CCONJ
ajlm-2942	123	16	atherogenic	atherogenic	ADJ
ajlm-2942	123	17	lipids	lipid	NOUN
ajlm-2942	123	18	(	(	PUNCT
ajlm-2942	123	19	tc	tc	NOUN
ajlm-2942	123	20	,	,	PUNCT
ajlm-2942	123	21	triglycerides	triglyceride	NOUN
ajlm-2942	123	22	,	,	PUNCT
ajlm-2942	123	23	ldlc	ldlc	NOUN
ajlm-2942	123	24	,	,	PUNCT
ajlm-2942	123	25	and	and	CCONJ
ajlm-2942	123	26	non	non	ADJ
ajlm-2942	123	27	-	-	NOUN
ajlm-2942	123	28	hdlc	hdlc	NOUN
ajlm-2942	123	29	)	)	PUNCT
ajlm-2942	123	30	,	,	PUNCT
ajlm-2942	123	31	and	and	CCONJ
ajlm-2942	123	32	a	a	DET
ajlm-2942	123	33	positive	positive	ADJ
ajlm-2942	123	34	association	association	NOUN
ajlm-2942	123	35	with	with	ADP
ajlm-2942	123	36	hdlc	hdlc	PROPN
ajlm-2942	123	37	,	,	PUNCT
ajlm-2942	123	38	suggesting	suggest	VERB
ajlm-2942	123	39	a	a	DET
ajlm-2942	123	40	protective	protective	ADJ
ajlm-2942	123	41	effect	effect	NOUN
ajlm-2942	123	42	against	against	ADP
ajlm-2942	123	43	atherosclerosis	atherosclerosis	NOUN
ajlm-2942	123	44	.	.	PUNCT
ajlm-2942	124	1	conversely	conversely	ADV
ajlm-2942	124	2	,	,	PUNCT
ajlm-2942	124	3	elevated	elevated	ADJ
ajlm-2942	124	4	levels	level	NOUN
ajlm-2942	124	5	of	of	ADP
ajlm-2942	124	6	apo	apo	PROPN
ajlm-2942	124	7	b	b	PROPN
ajlm-2942	124	8	correlate	correlate	VERB
ajlm-2942	124	9	with	with	ADP
ajlm-2942	124	10	increased	increase	VERB
ajlm-2942	124	11	levels	level	NOUN
ajlm-2942	124	12	of	of	ADP
ajlm-2942	124	13	atherogenic	atherogenic	ADJ
ajlm-2942	124	14	particles	particle	NOUN
ajlm-2942	124	15	,	,	PUNCT
ajlm-2942	124	16	indicating	indicate	VERB
ajlm-2942	124	17	increased	increase	VERB
ajlm-2942	124	18	cardiovascular	cardiovascular	ADJ
ajlm-2942	124	19	risk	risk	NOUN
ajlm-2942	124	20	.	.	PUNCT
ajlm-2942	125	1	this	this	DET
ajlm-2942	125	2	study	study	NOUN
ajlm-2942	125	3	also	also	ADV
ajlm-2942	125	4	identified	identify	VERB
ajlm-2942	125	5	the	the	DET
ajlm-2942	125	6	apo	apo	PROPN
ajlm-2942	125	7	b	b	PROPN
ajlm-2942	125	8	/	/	SYM
ajlm-2942	125	9	a1	a1	NOUN
ajlm-2942	125	10	ratio	ratio	NOUN
ajlm-2942	125	11	as	as	ADP
ajlm-2942	125	12	a	a	DET
ajlm-2942	125	13	comprehensive	comprehensive	ADJ
ajlm-2942	125	14	marker	marker	NOUN
ajlm-2942	125	15	for	for	ADP
ajlm-2942	125	16	lipid	lipid	NOUN
ajlm-2942	125	17	-	-	PUNCT
ajlm-2942	125	18	related	relate	VERB
ajlm-2942	125	19	ascvd	ascvd	NOUN
ajlm-2942	125	20	risk	risk	NOUN
ajlm-2942	125	21	,	,	PUNCT
ajlm-2942	125	22	indicating	indicate	VERB
ajlm-2942	125	23	that	that	SCONJ
ajlm-2942	125	24	it	it	PRON
ajlm-2942	125	25	is	be	AUX
ajlm-2942	125	26	a	a	DET
ajlm-2942	125	27	superior	superior	ADJ
ajlm-2942	125	28	marker	marker	NOUN
ajlm-2942	125	29	for	for	ADP
ajlm-2942	125	30	ascvd	ascvd	NOUN
ajlm-2942	125	31	stratification	stratification	NOUN
ajlm-2942	125	32	and	and	CCONJ
ajlm-2942	125	33	demonstrating	demonstrate	VERB
ajlm-2942	125	34	a	a	DET
ajlm-2942	125	35	strong	strong	ADJ
ajlm-2942	125	36	correlation	correlation	NOUN
ajlm-2942	125	37	with	with	ADP
ajlm-2942	125	38	traditional	traditional	ADJ
ajlm-2942	125	39	lipid	lipid	NOUN
ajlm-2942	125	40	indices	index	NOUN
ajlm-2942	125	41	.	.	PUNCT
ajlm-2942	126	1	higher	high	ADJ
ajlm-2942	126	2	ratios	ratio	NOUN
ajlm-2942	126	3	were	be	AUX
ajlm-2942	126	4	associated	associate	VERB
ajlm-2942	126	5	with	with	ADP
ajlm-2942	126	6	elevated	elevated	ADJ
ajlm-2942	126	7	levels	level	NOUN
ajlm-2942	126	8	of	of	ADP
ajlm-2942	126	9	atherogenic	atherogenic	ADJ
ajlm-2942	126	10	lipids	lipid	NOUN
ajlm-2942	126	11	and	and	CCONJ
ajlm-2942	126	12	decreased	decrease	VERB
ajlm-2942	126	13	levels	level	NOUN
ajlm-2942	126	14	of	of	ADP
ajlm-2942	126	15	hdlc	hdlc	NOUN
ajlm-2942	126	16	,	,	PUNCT
ajlm-2942	126	17	effectively	effectively	ADV
ajlm-2942	126	18	integrating	integrate	VERB
ajlm-2942	126	19	both	both	CCONJ
ajlm-2942	126	20	proatherogenic	proatherogenic	ADJ
ajlm-2942	126	21	and	and	CCONJ
ajlm-2942	126	22	antiatherogenic	antiatherogenic	ADJ
ajlm-2942	126	23	lipid	lipid	NOUN
ajlm-2942	126	24	particles	particle	NOUN
ajlm-2942	126	25	.	.	PUNCT
ajlm-2942	127	1	this	this	DET
ajlm-2942	127	2	ratio	ratio	NOUN
ajlm-2942	127	3	provides	provide	VERB
ajlm-2942	127	4	a	a	DET
ajlm-2942	127	5	more	more	ADV
ajlm-2942	127	6	complete	complete	ADJ
ajlm-2942	127	7	view	view	NOUN
ajlm-2942	127	8	of	of	ADP
ajlm-2942	127	9	an	an	DET
ajlm-2942	127	10	individual	individual	NOUN
ajlm-2942	127	11	’s	’s	PART
ajlm-2942	127	12	lipid	lipid	NOUN
ajlm-2942	127	13	profile	profile	NOUN
ajlm-2942	127	14	and	and	CCONJ
ajlm-2942	127	15	their	their	PRON
ajlm-2942	127	16	associated	associated	ADJ
ajlm-2942	127	17	cardiovascular	cardiovascular	ADJ
ajlm-2942	127	18	risk.16,17	risk.16,17	NOUN
ajlm-2942	127	19	strengths	strength	NOUN
ajlm-2942	127	20	,	,	PUNCT
ajlm-2942	127	21	contributions	contribution	NOUN
ajlm-2942	127	22	,	,	PUNCT
ajlm-2942	127	23	and	and	CCONJ
ajlm-2942	127	24	implications	implication	NOUN
ajlm-2942	127	25	for	for	ADP
ajlm-2942	127	26	future	future	ADJ
ajlm-2942	127	27	research	research	NOUN
ajlm-2942	127	28	the	the	DET
ajlm-2942	127	29	findings	finding	NOUN
ajlm-2942	127	30	of	of	ADP
ajlm-2942	127	31	this	this	DET
ajlm-2942	127	32	study	study	NOUN
ajlm-2942	127	33	carry	carry	VERB
ajlm-2942	127	34	significant	significant	ADJ
ajlm-2942	127	35	clinical	clinical	ADJ
ajlm-2942	127	36	and	and	CCONJ
ajlm-2942	127	37	public	public	ADJ
ajlm-2942	127	38	health	health	NOUN
ajlm-2942	127	39	relevance	relevance	NOUN
ajlm-2942	127	40	for	for	ADP
ajlm-2942	127	41	nigerian	nigerian	ADJ
ajlm-2942	127	42	and	and	CCONJ
ajlm-2942	127	43	sub	sub	ADJ
ajlm-2942	127	44	-	-	ADJ
ajlm-2942	127	45	saharan	saharan	ADJ
ajlm-2942	127	46	african	african	ADJ
ajlm-2942	127	47	populations	population	NOUN
ajlm-2942	127	48	.	.	PUNCT
ajlm-2942	128	1	the	the	DET
ajlm-2942	128	2	elevated	elevated	ADJ
ajlm-2942	128	3	apolipoprotein	apolipoprotein	ADJ
ajlm-2942	128	4	b	b	PROPN
ajlm-2942	128	5	/	/	SYM
ajlm-2942	128	6	a1	a1	NOUN
ajlm-2942	128	7	ratio	ratio	NOUN
ajlm-2942	128	8	,	,	PUNCT
ajlm-2942	128	9	coupled	couple	VERB
ajlm-2942	128	10	with	with	ADP
ajlm-2942	128	11	changes	change	NOUN
ajlm-2942	128	12	in	in	ADP
ajlm-2942	128	13	apolipoprotein	apolipoprotein	ADJ
ajlm-2942	128	14	a1	a1	NOUN
ajlm-2942	128	15	,	,	PUNCT
ajlm-2942	128	16	apolipoprotein	apolipoprotein	ADJ
ajlm-2942	128	17	b	b	NUM
ajlm-2942	128	18	,	,	PUNCT
ajlm-2942	128	19	and	and	CCONJ
ajlm-2942	128	20	hdl	hdl	PROPN
ajlm-2942	128	21	phospholipids	phospholipid	NOUN
ajlm-2942	128	22	,	,	PUNCT
ajlm-2942	128	23	indicates	indicate	VERB
ajlm-2942	128	24	a	a	DET
ajlm-2942	128	25	higher	high	ADJ
ajlm-2942	128	26	risk	risk	NOUN
ajlm-2942	128	27	of	of	ADP
ajlm-2942	128	28	premature	premature	ADJ
ajlm-2942	128	29	ascvd	ascvd	NOUN
ajlm-2942	128	30	.	.	PUNCT
ajlm-2942	129	1	the	the	DET
ajlm-2942	129	2	apolipoprotein	apolipoprotein	ADJ
ajlm-2942	129	3	b	b	PROPN
ajlm-2942	129	4	/	/	SYM
ajlm-2942	129	5	a1	a1	NOUN
ajlm-2942	129	6	ratio	ratio	NOUN
ajlm-2942	129	7	emerges	emerge	VERB
ajlm-2942	129	8	as	as	ADP
ajlm-2942	129	9	a	a	DET
ajlm-2942	129	10	key	key	ADJ
ajlm-2942	129	11	marker	marker	NOUN
ajlm-2942	129	12	for	for	ADP
ajlm-2942	129	13	ascvd	ascvd	NOUN
ajlm-2942	129	14	risk	risk	NOUN
ajlm-2942	129	15	,	,	PUNCT
ajlm-2942	129	16	reinforcing	reinforce	VERB
ajlm-2942	129	17	the	the	DET
ajlm-2942	129	18	need	need	NOUN
ajlm-2942	129	19	for	for	ADP
ajlm-2942	129	20	earlier	early	ADJ
ajlm-2942	129	21	diagnosis	diagnosis	NOUN
ajlm-2942	129	22	and	and	CCONJ
ajlm-2942	129	23	targeted	target	VERB
ajlm-2942	129	24	interventions	intervention	NOUN
ajlm-2942	129	25	.	.	PUNCT
ajlm-2942	130	1	the	the	DET
ajlm-2942	130	2	findings	finding	NOUN
ajlm-2942	130	3	also	also	ADV
ajlm-2942	130	4	underscore	underscore	VERB
ajlm-2942	130	5	the	the	DET
ajlm-2942	130	6	importance	importance	NOUN
ajlm-2942	130	7	of	of	ADP
ajlm-2942	130	8	early	early	ADJ
ajlm-2942	130	9	screening	screening	NOUN
ajlm-2942	130	10	and	and	CCONJ
ajlm-2942	130	11	prevention	prevention	NOUN
ajlm-2942	130	12	programmes	programme	NOUN
ajlm-2942	130	13	tailored	tailor	VERB
ajlm-2942	130	14	to	to	ADP
ajlm-2942	130	15	these	these	DET
ajlm-2942	130	16	regions	region	NOUN
ajlm-2942	130	17	.	.	PUNCT
ajlm-2942	131	1	future	future	ADJ
ajlm-2942	131	2	research	research	NOUN
ajlm-2942	131	3	should	should	AUX
ajlm-2942	131	4	focus	focus	VERB
ajlm-2942	131	5	on	on	ADP
ajlm-2942	131	6	tracking	track	VERB
ajlm-2942	131	7	changes	change	NOUN
ajlm-2942	131	8	in	in	ADP
ajlm-2942	131	9	the	the	DET
ajlm-2942	131	10	apolipoprotein	apolipoprotein	ADJ
ajlm-2942	131	11	b	b	PROPN
ajlm-2942	131	12	/	/	SYM
ajlm-2942	131	13	a1	a1	NOUN
ajlm-2942	131	14	ratio	ratio	NOUN
ajlm-2942	131	15	over	over	ADP
ajlm-2942	131	16	time	time	NOUN
ajlm-2942	131	17	and	and	CCONJ
ajlm-2942	131	18	assessing	assess	VERB
ajlm-2942	131	19	targeted	target	VERB
ajlm-2942	131	20	interventions	intervention	NOUN
ajlm-2942	131	21	for	for	ADP
ajlm-2942	131	22	ascvd	ascvd	PROPN
ajlm-2942	131	23	prevention	prevention	NOUN
ajlm-2942	131	24	in	in	ADP
ajlm-2942	131	25	sub	sub	ADJ
ajlm-2942	131	26	-	-	ADJ
ajlm-2942	131	27	saharan	saharan	ADJ
ajlm-2942	131	28	africa	africa	PROPN
ajlm-2942	131	29	.	.	PUNCT
ajlm-2942	132	1	developing	develop	VERB
ajlm-2942	132	2	tailored	tailor	VERB
ajlm-2942	132	3	screening	screen	VERB
ajlm-2942	132	4	programmes	programme	NOUN
ajlm-2942	132	5	and	and	CCONJ
ajlm-2942	132	6	investigating	investigate	VERB
ajlm-2942	132	7	genetic	genetic	ADJ
ajlm-2942	132	8	and	and	CCONJ
ajlm-2942	132	9	environmental	environmental	ADJ
ajlm-2942	132	10	factors	factor	NOUN
ajlm-2942	132	11	influencing	influence	VERB
ajlm-2942	132	12	ascvd	ascvd	NOUN
ajlm-2942	132	13	risk	risk	NOUN
ajlm-2942	132	14	are	be	AUX
ajlm-2942	132	15	crucial	crucial	ADJ
ajlm-2942	132	16	.	.	PUNCT
ajlm-2942	133	1	comparative	comparative	ADJ
ajlm-2942	133	2	studies	study	NOUN
ajlm-2942	133	3	across	across	ADP
ajlm-2942	133	4	sub	sub	ADJ
ajlm-2942	133	5	-	-	ADJ
ajlm-2942	133	6	saharan	saharan	ADJ
ajlm-2942	133	7	africa	africa	PROPN
ajlm-2942	133	8	can	can	AUX
ajlm-2942	133	9	refine	refine	VERB
ajlm-2942	133	10	risk	risk	NOUN
ajlm-2942	133	11	assessment	assessment	NOUN
ajlm-2942	133	12	,	,	PUNCT
ajlm-2942	133	13	while	while	SCONJ
ajlm-2942	133	14	public	public	ADJ
ajlm-2942	133	15	health	health	NOUN
ajlm-2942	133	16	initiatives	initiative	NOUN
ajlm-2942	133	17	and	and	CCONJ
ajlm-2942	133	18	policy	policy	NOUN
ajlm-2942	133	19	research	research	NOUN
ajlm-2942	133	20	may	may	AUX
ajlm-2942	133	21	help	help	VERB
ajlm-2942	133	22	to	to	PART
ajlm-2942	133	23	reduce	reduce	VERB
ajlm-2942	133	24	ascvd	ascvd	NOUN
ajlm-2942	133	25	mortality	mortality	NOUN
ajlm-2942	133	26	in	in	ADP
ajlm-2942	133	27	these	these	DET
ajlm-2942	133	28	regions	region	NOUN
ajlm-2942	133	29	.	.	PUNCT
ajlm-2942	134	1	limitations	limitation	NOUN
ajlm-2942	134	2	while	while	SCONJ
ajlm-2942	134	3	the	the	DET
ajlm-2942	134	4	findings	finding	NOUN
ajlm-2942	134	5	provide	provide	VERB
ajlm-2942	134	6	important	important	ADJ
ajlm-2942	134	7	insights	insight	NOUN
ajlm-2942	134	8	,	,	PUNCT
ajlm-2942	134	9	certain	certain	ADJ
ajlm-2942	134	10	factors	factor	NOUN
ajlm-2942	134	11	warrant	warrant	VERB
ajlm-2942	134	12	consideration	consideration	NOUN
ajlm-2942	134	13	.	.	PUNCT
ajlm-2942	135	1	unmeasured	unmeasured	ADJ
ajlm-2942	135	2	variables	variable	NOUN
ajlm-2942	135	3	such	such	ADJ
ajlm-2942	135	4	as	as	ADP
ajlm-2942	135	5	diet	diet	NOUN
ajlm-2942	135	6	,	,	PUNCT
ajlm-2942	135	7	physical	physical	ADJ
ajlm-2942	135	8	activity	activity	NOUN
ajlm-2942	135	9	and	and	CCONJ
ajlm-2942	135	10	genetic	genetic	ADJ
ajlm-2942	135	11	predisposition	predisposition	NOUN
ajlm-2942	135	12	may	may	AUX
ajlm-2942	135	13	have	have	AUX
ajlm-2942	135	14	influenced	influence	VERB
ajlm-2942	135	15	apolipoprotein	apolipoprotein	ADJ
ajlm-2942	135	16	and	and	CCONJ
ajlm-2942	135	17	hdl	hdl	PROPN
ajlm-2942	135	18	phospholipid	phospholipid	NOUN
ajlm-2942	135	19	levels	level	NOUN
ajlm-2942	135	20	.	.	PUNCT
ajlm-2942	136	1	the	the	DET
ajlm-2942	136	2	mean	mean	ADJ
ajlm-2942	136	3	age	age	NOUN
ajlm-2942	136	4	difference	difference	NOUN
ajlm-2942	136	5	of	of	ADP
ajlm-2942	136	6	about	about	ADV
ajlm-2942	136	7	10	10	NUM
ajlm-2942	136	8	years	year	NOUN
ajlm-2942	136	9	between	between	ADP
ajlm-2942	136	10	cases	case	NOUN
ajlm-2942	136	11	and	and	CCONJ
ajlm-2942	136	12	controls	control	NOUN
ajlm-2942	136	13	,	,	PUNCT
ajlm-2942	136	14	despite	despite	SCONJ
ajlm-2942	136	15	statistical	statistical	ADJ
ajlm-2942	136	16	adjustment	adjustment	NOUN
ajlm-2942	136	17	,	,	PUNCT
ajlm-2942	136	18	may	may	AUX
ajlm-2942	136	19	also	also	ADV
ajlm-2942	136	20	introduce	introduce	VERB
ajlm-2942	136	21	residual	residual	ADJ
ajlm-2942	136	22	confounding	confounding	NOUN
ajlm-2942	136	23	.	.	PUNCT
ajlm-2942	137	1	in	in	ADP
ajlm-2942	137	2	addition	addition	NOUN
ajlm-2942	137	3	,	,	PUNCT
ajlm-2942	137	4	the	the	DET
ajlm-2942	137	5	moderate	moderate	ADJ
ajlm-2942	137	6	areas	area	NOUN
ajlm-2942	137	7	under	under	ADP
ajlm-2942	137	8	curve	curve	NOUN
ajlm-2942	137	9	observed	observe	VERB
ajlm-2942	137	10	in	in	ADP
ajlm-2942	137	11	preliminary	preliminary	ADJ
ajlm-2942	137	12	analyses	analysis	NOUN
ajlm-2942	137	13	for	for	ADP
ajlm-2942	137	14	apo	apo	PROPN
ajlm-2942	137	15	a1	a1	PROPN
ajlm-2942	137	16	,	,	PUNCT
ajlm-2942	137	17	apo	apo	PROPN
ajlm-2942	137	18	b	b	NOUN
ajlm-2942	137	19	,	,	PUNCT
ajlm-2942	137	20	and	and	CCONJ
ajlm-2942	137	21	hdl	hdl	PROPN
ajlm-2942	137	22	phospholipids	phospholipid	NOUN
ajlm-2942	137	23	probably	probably	ADV
ajlm-2942	137	24	reflect	reflect	VERB
ajlm-2942	137	25	the	the	DET
ajlm-2942	137	26	sample	sample	NOUN
ajlm-2942	137	27	size	size	NOUN
ajlm-2942	137	28	and	and	CCONJ
ajlm-2942	137	29	exploratory	exploratory	ADJ
ajlm-2942	137	30	design	design	NOUN
ajlm-2942	137	31	of	of	ADP
ajlm-2942	137	32	the	the	DET
ajlm-2942	137	33	study	study	NOUN
ajlm-2942	137	34	.	.	PUNCT
ajlm-2942	138	1	further	further	ADJ
ajlm-2942	138	2	research	research	NOUN
ajlm-2942	138	3	with	with	ADP
ajlm-2942	138	4	larger	large	ADJ
ajlm-2942	138	5	,	,	PUNCT
ajlm-2942	138	6	diverse	diverse	ADJ
ajlm-2942	138	7	cohorts	cohort	NOUN
ajlm-2942	138	8	is	be	AUX
ajlm-2942	138	9	needed	need	VERB
ajlm-2942	138	10	to	to	PART
ajlm-2942	138	11	validate	validate	VERB
ajlm-2942	138	12	these	these	DET
ajlm-2942	138	13	findings	finding	NOUN
ajlm-2942	138	14	and	and	CCONJ
ajlm-2942	138	15	to	to	PART
ajlm-2942	138	16	refine	refine	VERB
ajlm-2942	138	17	clinically	clinically	ADV
ajlm-2942	138	18	relevant	relevant	ADJ
ajlm-2942	138	19	cut	cut	NOUN
ajlm-2942	138	20	-	-	PUNCT
ajlm-2942	138	21	off	off	ADP
ajlm-2942	138	22	values	value	NOUN
ajlm-2942	138	23	through	through	ADP
ajlm-2942	138	24	advanced	advanced	ADJ
ajlm-2942	138	25	modelling	modelling	NOUN
ajlm-2942	138	26	approaches	approach	NOUN
ajlm-2942	138	27	.	.	PUNCT
ajlm-2942	139	1	conclusion	conclusion	NOUN
ajlm-2942	139	2	this	this	DET
ajlm-2942	139	3	study	study	NOUN
ajlm-2942	139	4	identified	identify	VERB
ajlm-2942	139	5	associations	association	NOUN
ajlm-2942	139	6	between	between	ADP
ajlm-2942	139	7	lipid	lipid	NOUN
ajlm-2942	139	8	profile	profile	NOUN
ajlm-2942	139	9	disruptions	disruption	NOUN
ajlm-2942	139	10	and	and	CCONJ
ajlm-2942	139	11	ascvd	ascvd	NOUN
ajlm-2942	139	12	in	in	ADP
ajlm-2942	139	13	nigerian	nigerian	ADJ
ajlm-2942	139	14	patients	patient	NOUN
ajlm-2942	139	15	,	,	PUNCT
ajlm-2942	139	16	characterised	characterise	VERB
ajlm-2942	139	17	by	by	ADP
ajlm-2942	139	18	elevated	elevated	ADJ
ajlm-2942	139	19	atherogenic	atherogenic	ADJ
ajlm-2942	139	20	lipids	lipid	NOUN
ajlm-2942	139	21	(	(	PUNCT
ajlm-2942	139	22	triglycerides	triglyceride	NOUN
ajlm-2942	139	23	,	,	PUNCT
ajlm-2942	139	24	tc	tc	NOUN
ajlm-2942	139	25	,	,	PUNCT
ajlm-2942	139	26	ldlc	ldlc	NOUN
ajlm-2942	139	27	,	,	PUNCT
ajlm-2942	139	28	and	and	CCONJ
ajlm-2942	139	29	non	non	ADJ
ajlm-2942	139	30	-	-	NOUN
ajlm-2942	139	31	hdlc	hdlc	NOUN
ajlm-2942	139	32	)	)	PUNCT
ajlm-2942	139	33	and	and	CCONJ
ajlm-2942	139	34	reduced	reduce	VERB
ajlm-2942	139	35	hdlc	hdlc	NOUN
ajlm-2942	139	36	,	,	PUNCT
ajlm-2942	139	37	particularly	particularly	ADV
ajlm-2942	139	38	in	in	ADP
ajlm-2942	139	39	those	those	PRON
ajlm-2942	139	40	with	with	ADP
ajlm-2942	139	41	mi	mi	PROPN
ajlm-2942	139	42	and	and	CCONJ
ajlm-2942	139	43	ihd	ihd	ADJ
ajlm-2942	139	44	.	.	PUNCT
ajlm-2942	140	1	apolipoprotein	apolipoprotein	ADJ
ajlm-2942	140	2	analysis	analysis	NOUN
ajlm-2942	140	3	showed	show	VERB
ajlm-2942	140	4	decreased	decrease	VERB
ajlm-2942	140	5	apo	apo	NOUN
ajlm-2942	140	6	a1	a1	NOUN
ajlm-2942	140	7	and	and	CCONJ
ajlm-2942	140	8	increased	increase	VERB
ajlm-2942	140	9	apo	apo	PROPN
ajlm-2942	140	10	b	b	PROPN
ajlm-2942	140	11	,	,	PUNCT
ajlm-2942	140	12	leading	lead	VERB
ajlm-2942	140	13	to	to	ADP
ajlm-2942	140	14	a	a	DET
ajlm-2942	140	15	higher	high	ADJ
ajlm-2942	140	16	apo	apo	NOUN
ajlm-2942	140	17	b	b	PROPN
ajlm-2942	140	18	/	/	SYM
ajlm-2942	140	19	a1	a1	NOUN
ajlm-2942	140	20	ratio	ratio	NOUN
ajlm-2942	140	21	and	and	CCONJ
ajlm-2942	140	22	indicating	indicate	VERB
ajlm-2942	140	23	a	a	DET
ajlm-2942	140	24	greater	great	ADJ
ajlm-2942	140	25	atherogenic	atherogenic	ADJ
ajlm-2942	140	26	burden	burden	NOUN
ajlm-2942	140	27	.	.	PUNCT
ajlm-2942	141	1	reduced	reduce	VERB
ajlm-2942	141	2	hdl	hdl	PROPN
ajlm-2942	141	3	phospholipid	phospholipid	NOUN
ajlm-2942	141	4	levels	level	NOUN
ajlm-2942	141	5	further	far	ADV
ajlm-2942	141	6	suggest	suggest	VERB
ajlm-2942	141	7	impaired	impaired	ADJ
ajlm-2942	141	8	hdl	hdl	NOUN
ajlm-2942	141	9	functionality	functionality	NOUN
ajlm-2942	141	10	.	.	PUNCT
ajlm-2942	142	1	the	the	DET
ajlm-2942	142	2	apo	apo	PROPN
ajlm-2942	142	3	b	b	PROPN
ajlm-2942	142	4	/	/	SYM
ajlm-2942	142	5	a1	a1	NOUN
ajlm-2942	142	6	ratio	ratio	NOUN
ajlm-2942	142	7	emerged	emerge	VERB
ajlm-2942	142	8	as	as	ADP
ajlm-2942	142	9	a	a	DET
ajlm-2942	142	10	key	key	ADJ
ajlm-2942	142	11	marker	marker	NOUN
ajlm-2942	142	12	for	for	ADP
ajlm-2942	142	13	lipid	lipid	NOUN
ajlm-2942	142	14	-	-	PUNCT
ajlm-2942	142	15	related	relate	VERB
ajlm-2942	142	16	ascvd	ascvd	NOUN
ajlm-2942	142	17	risk	risk	NOUN
ajlm-2942	142	18	,	,	PUNCT
ajlm-2942	142	19	highlighting	highlight	VERB
ajlm-2942	142	20	its	its	PRON
ajlm-2942	142	21	potential	potential	NOUN
ajlm-2942	142	22	for	for	ADP
ajlm-2942	142	23	early	early	ADJ
ajlm-2942	142	24	diagnosis	diagnosis	NOUN
ajlm-2942	142	25	and	and	CCONJ
ajlm-2942	142	26	risk	risk	NOUN
ajlm-2942	142	27	stratification	stratification	NOUN
ajlm-2942	142	28	.	.	PUNCT
ajlm-2942	143	1	these	these	DET
ajlm-2942	143	2	findings	finding	NOUN
ajlm-2942	143	3	underscore	underscore	VERB
ajlm-2942	143	4	the	the	DET
ajlm-2942	143	5	need	need	NOUN
ajlm-2942	143	6	for	for	ADP
ajlm-2942	143	7	targeted	target	VERB
ajlm-2942	143	8	screening	screening	NOUN
ajlm-2942	143	9	and	and	CCONJ
ajlm-2942	143	10	prevention	prevention	NOUN
ajlm-2942	143	11	strategies	strategy	NOUN
ajlm-2942	143	12	to	to	PART
ajlm-2942	143	13	improve	improve	VERB
ajlm-2942	143	14	cardiovascular	cardiovascular	ADJ
ajlm-2942	143	15	outcomes	outcome	NOUN
ajlm-2942	143	16	in	in	ADP
ajlm-2942	143	17	this	this	DET
ajlm-2942	143	18	population	population	NOUN
ajlm-2942	143	19	.	.	PUNCT
ajlm-2942	144	1	acknowledgements	acknowledgement	NOUN
ajlm-2942	144	2	competing	compete	VERB
ajlm-2942	144	3	interests	interest	NOUN
ajlm-2942	144	4	the	the	DET
ajlm-2942	144	5	authors	author	NOUN
ajlm-2942	144	6	declare	declare	VERB
ajlm-2942	144	7	that	that	SCONJ
ajlm-2942	144	8	they	they	PRON
ajlm-2942	144	9	have	have	VERB
ajlm-2942	144	10	no	no	DET
ajlm-2942	144	11	financial	financial	ADJ
ajlm-2942	144	12	or	or	CCONJ
ajlm-2942	144	13	personal	personal	ADJ
ajlm-2942	144	14	relationships	relationship	NOUN
ajlm-2942	144	15	that	that	PRON
ajlm-2942	144	16	may	may	AUX
ajlm-2942	144	17	have	have	AUX
ajlm-2942	144	18	inappropriately	inappropriately	ADV
ajlm-2942	144	19	influenced	influence	VERB
ajlm-2942	144	20	them	they	PRON
ajlm-2942	144	21	in	in	ADP
ajlm-2942	144	22	writing	write	VERB
ajlm-2942	144	23	this	this	DET
ajlm-2942	144	24	article	article	NOUN
ajlm-2942	144	25	.	.	PUNCT
ajlm-2942	145	1	credit	credit	NOUN
ajlm-2942	145	2	authorship	authorship	NOUN
ajlm-2942	145	3	contribution	contribution	NOUN
ajlm-2942	145	4	promise	promise	VERB
ajlm-2942	145	5	c.	c.	PROPN
ajlm-2942	145	6	nwaejigh	nwaejigh	NOUN
ajlm-2942	145	7	:	:	PUNCT
ajlm-2942	145	8	conceptualisation	conceptualisation	NOUN
ajlm-2942	145	9	,	,	PUNCT
ajlm-2942	145	10	writing	writing	NOUN
ajlm-2942	145	11	–	–	PUNCT
ajlm-2942	145	12	original	original	ADJ
ajlm-2942	145	13	draft	draft	NOUN
ajlm-2942	145	14	,	,	PUNCT
ajlm-2942	145	15	data	data	NOUN
ajlm-2942	145	16	curation	curation	NOUN
ajlm-2942	145	17	,	,	PUNCT
ajlm-2942	145	18	writing	write	VERB
ajlm-2942	145	19	–	–	PUNCT
ajlm-2942	145	20	review	review	NOUN
ajlm-2942	145	21	&	&	CCONJ
ajlm-2942	145	22	editing	editing	NOUN
ajlm-2942	145	23	.	.	PUNCT
ajlm-2942	146	1	maria	maria	PROPN
ajlm-2942	146	2	o.	o.	PROPN
ajlm-2942	146	3	ebesunun	ebesunun	PROPN
ajlm-2942	146	4	:	:	PUNCT
ajlm-2942	146	5	conceptualisation	conceptualisation	NOUN
ajlm-2942	146	6	,	,	PUNCT
ajlm-2942	146	7	writing	writing	NOUN
ajlm-2942	146	8	–	–	PUNCT
ajlm-2942	146	9	review	review	NOUN
ajlm-2942	146	10	&	&	CCONJ
ajlm-2942	146	11	editing	editing	PROPN
ajlm-2942	146	12	.	.	PUNCT
ajlm-2942	147	1	stephen	stephen	PROPN
ajlm-2942	147	2	s.	s.	PROPN
ajlm-2942	147	3	udofia	udofia	PROPN
ajlm-2942	147	4	:	:	PUNCT
ajlm-2942	147	5	formal	formal	ADJ
ajlm-2942	147	6	analysis	analysis	NOUN
ajlm-2942	147	7	,	,	PUNCT
ajlm-2942	147	8	data	data	NOUN
ajlm-2942	147	9	curation	curation	NOUN
ajlm-2942	147	10	,	,	PUNCT
ajlm-2942	147	11	writing	write	VERB
ajlm-2942	147	12	–	–	PUNCT
ajlm-2942	147	13	review	review	NOUN
ajlm-2942	147	14	&	&	CCONJ
ajlm-2942	147	15	editing	editing	NOUN
ajlm-2942	147	16	.	.	PUNCT
ajlm-2942	148	1	adebusola	adebusola	PROPN
ajlm-2942	148	2	a.	a.	PROPN
ajlm-2942	148	3	shakunle	shakunle	PROPN
ajlm-2942	148	4	:	:	PUNCT
ajlm-2942	148	5	formal	formal	ADJ
ajlm-2942	148	6	analysis	analysis	NOUN
ajlm-2942	148	7	,	,	PUNCT
ajlm-2942	148	8	investigation	investigation	NOUN
ajlm-2942	148	9	,	,	PUNCT
ajlm-2942	148	10	writing	write	VERB
ajlm-2942	148	11	–	–	PUNCT
ajlm-2942	148	12	review	review	NOUN
ajlm-2942	148	13	&	&	CCONJ
ajlm-2942	148	14	editing	editing	NOUN
ajlm-2942	148	15	.	.	PUNCT
ajlm-2942	149	1	all	all	DET
ajlm-2942	149	2	authors	author	NOUN
ajlm-2942	149	3	reviewed	review	VERB
ajlm-2942	149	4	the	the	DET
ajlm-2942	149	5	article	article	NOUN
ajlm-2942	149	6	,	,	PUNCT
ajlm-2942	149	7	contributed	contribute	VERB
ajlm-2942	149	8	to	to	ADP
ajlm-2942	149	9	the	the	DET
ajlm-2942	149	10	discussion	discussion	NOUN
ajlm-2942	149	11	of	of	ADP
ajlm-2942	149	12	results	result	NOUN
ajlm-2942	149	13	,	,	PUNCT
ajlm-2942	149	14	approved	approve	VERB
ajlm-2942	149	15	the	the	DET
ajlm-2942	149	16	final	final	ADJ
ajlm-2942	149	17	version	version	NOUN
ajlm-2942	149	18	for	for	ADP
ajlm-2942	149	19	submission	submission	NOUN
ajlm-2942	149	20	and	and	CCONJ
ajlm-2942	149	21	publication	publication	NOUN
ajlm-2942	149	22	,	,	PUNCT
ajlm-2942	149	23	and	and	CCONJ
ajlm-2942	149	24	take	take	VERB
ajlm-2942	149	25	responsibility	responsibility	NOUN
ajlm-2942	149	26	for	for	ADP
ajlm-2942	149	27	the	the	DET
ajlm-2942	149	28	integrity	integrity	NOUN
ajlm-2942	149	29	of	of	ADP
ajlm-2942	149	30	its	its	PRON
ajlm-2942	149	31	findings	finding	NOUN
ajlm-2942	149	32	.	.	PUNCT
ajlm-2942	150	1	sources	source	NOUN
ajlm-2942	150	2	of	of	ADP
ajlm-2942	150	3	support	support	NOUN
ajlm-2942	150	4	this	this	DET
ajlm-2942	150	5	research	research	NOUN
ajlm-2942	150	6	received	receive	VERB
ajlm-2942	150	7	no	no	DET
ajlm-2942	150	8	specific	specific	ADJ
ajlm-2942	150	9	grant	grant	NOUN
ajlm-2942	150	10	from	from	ADP
ajlm-2942	150	11	any	any	DET
ajlm-2942	150	12	funding	funding	NOUN
ajlm-2942	150	13	agency	agency	NOUN
ajlm-2942	150	14	in	in	ADP
ajlm-2942	150	15	the	the	DET
ajlm-2942	150	16	public	public	ADJ
ajlm-2942	150	17	,	,	PUNCT
ajlm-2942	150	18	commercial	commercial	ADJ
ajlm-2942	150	19	,	,	PUNCT
ajlm-2942	150	20	or	or	CCONJ
ajlm-2942	150	21	not	not	PART
ajlm-2942	150	22	-	-	PUNCT
ajlm-2942	150	23	for	for	ADP
ajlm-2942	150	24	-	-	PUNCT
ajlm-2942	150	25	profit	profit	NOUN
ajlm-2942	150	26	sectors	sector	NOUN
ajlm-2942	150	27	.	.	PUNCT
ajlm-2942	151	1	data	datum	NOUN
ajlm-2942	151	2	availability	availability	NOUN
ajlm-2942	151	3	the	the	DET
ajlm-2942	151	4	authors	author	NOUN
ajlm-2942	151	5	confirm	confirm	VERB
ajlm-2942	151	6	that	that	SCONJ
ajlm-2942	151	7	the	the	DET
ajlm-2942	151	8	data	datum	NOUN
ajlm-2942	151	9	supporting	support	VERB
ajlm-2942	151	10	the	the	DET
ajlm-2942	151	11	findings	finding	NOUN
ajlm-2942	151	12	of	of	ADP
ajlm-2942	151	13	this	this	DET
ajlm-2942	151	14	study	study	NOUN
ajlm-2942	151	15	is	be	AUX
ajlm-2942	151	16	available	available	ADJ
ajlm-2942	151	17	within	within	ADP
ajlm-2942	151	18	the	the	DET
ajlm-2942	151	19	article	article	NOUN
ajlm-2942	151	20	and	and	CCONJ
ajlm-2942	151	21	its	its	PRON
ajlm-2942	151	22	supplementary	supplementary	ADJ
ajlm-2942	151	23	materials	material	NOUN
ajlm-2942	151	24	.	.	PUNCT
ajlm-2942	152	1	disclaimer	disclaimer	VERB
ajlm-2942	152	2	the	the	DET
ajlm-2942	152	3	views	view	NOUN
ajlm-2942	152	4	and	and	CCONJ
ajlm-2942	152	5	opinions	opinion	NOUN
ajlm-2942	152	6	expressed	express	VERB
ajlm-2942	152	7	in	in	ADP
ajlm-2942	152	8	this	this	DET
ajlm-2942	152	9	article	article	NOUN
ajlm-2942	152	10	are	be	AUX
ajlm-2942	152	11	those	those	PRON
ajlm-2942	152	12	of	of	ADP
ajlm-2942	152	13	the	the	DET
ajlm-2942	152	14	authors	author	NOUN
ajlm-2942	152	15	and	and	CCONJ
ajlm-2942	152	16	are	be	AUX
ajlm-2942	152	17	the	the	DET
ajlm-2942	152	18	product	product	NOUN
ajlm-2942	152	19	of	of	ADP
ajlm-2942	152	20	professional	professional	ADJ
ajlm-2942	152	21	research	research	NOUN
ajlm-2942	152	22	.	.	PUNCT
ajlm-2942	153	1	the	the	DET
ajlm-2942	153	2	article	article	NOUN
ajlm-2942	153	3	does	do	AUX
ajlm-2942	153	4	not	not	PART
ajlm-2942	153	5	necessarily	necessarily	ADV
ajlm-2942	153	6	reflect	reflect	VERB
ajlm-2942	153	7	the	the	DET
ajlm-2942	153	8	official	official	ADJ
ajlm-2942	153	9	policy	policy	NOUN
ajlm-2942	153	10	or	or	CCONJ
ajlm-2942	153	11	position	position	NOUN
ajlm-2942	153	12	of	of	ADP
ajlm-2942	153	13	any	any	DET
ajlm-2942	153	14	affiliated	affiliated	ADJ
ajlm-2942	153	15	institution	institution	NOUN
ajlm-2942	153	16	,	,	PUNCT
ajlm-2942	153	17	funder	funder	NOUN
ajlm-2942	153	18	,	,	PUNCT
ajlm-2942	153	19	agency	agency	NOUN
ajlm-2942	153	20	,	,	PUNCT
ajlm-2942	153	21	or	or	CCONJ
ajlm-2942	153	22	that	that	PRON
ajlm-2942	153	23	of	of	ADP
ajlm-2942	153	24	the	the	DET
ajlm-2942	153	25	publisher	publisher	NOUN
ajlm-2942	153	26	.	.	PUNCT
ajlm-2942	154	1	the	the	DET
ajlm-2942	154	2	authors	author	NOUN
ajlm-2942	154	3	are	be	AUX
ajlm-2942	154	4	responsible	responsible	ADJ
ajlm-2942	154	5	for	for	ADP
ajlm-2942	154	6	the	the	DET
ajlm-2942	154	7	results	result	NOUN
ajlm-2942	154	8	,	,	PUNCT
ajlm-2942	154	9	findings	finding	NOUN
ajlm-2942	154	10	,	,	PUNCT
ajlm-2942	154	11	and	and	CCONJ
ajlm-2942	154	12	content	content	NOUN
ajlm-2942	154	13	of	of	ADP
ajlm-2942	154	14	this	this	DET
ajlm-2942	154	15	article	article	NOUN
ajlm-2942	154	16	.	.	PUNCT
ajlm-2942	155	1	references	reference	NOUN
ajlm-2942	155	2	agyekum	agyekum	VERB
ajlm-2942	155	3	f	f	PROPN
ajlm-2942	155	4	,	,	PUNCT
ajlm-2942	155	5	folson	folson	PROPN
ajlm-2942	155	6	aa	aa	PROPN
ajlm-2942	155	7	,	,	PUNCT
ajlm-2942	155	8	abaidoo	abaidoo	PROPN
ajlm-2942	155	9	b	b	PROPN
ajlm-2942	155	10	,	,	PUNCT
ajlm-2942	155	11	et	et	PROPN
ajlm-2942	155	12	al	al	PROPN
ajlm-2942	155	13	.	.	PROPN
ajlm-2942	156	1	behavioural	behavioural	ADJ
ajlm-2942	156	2	and	and	CCONJ
ajlm-2942	156	3	nutritional	nutritional	ADJ
ajlm-2942	156	4	risk	risk	NOUN
ajlm-2942	156	5	factors	factor	NOUN
ajlm-2942	156	6	for	for	ADP
ajlm-2942	156	7	cardiovascular	cardiovascular	ADJ
ajlm-2942	156	8	diseases	disease	NOUN
ajlm-2942	156	9	among	among	ADP
ajlm-2942	156	10	the	the	DET
ajlm-2942	156	11	ghanaian	ghanaian	ADJ
ajlm-2942	156	12	population	population	NOUN
ajlm-2942	156	13	–	–	PUNCT
ajlm-2942	156	14	a	a	DET
ajlm-2942	156	15	cross	cross	ADJ
ajlm-2942	156	16	-	-	ADJ
ajlm-2942	156	17	sectional	sectional	ADJ
ajlm-2942	156	18	study	study	NOUN
ajlm-2942	156	19	.	.	PUNCT
ajlm-2942	157	1	bmc	bmc	ADJ
ajlm-2942	157	2	public	public	ADJ
ajlm-2942	157	3	health	health	NOUN
ajlm-2942	157	4	.	.	PUNCT
ajlm-2942	158	1	2024;24:194	2024;24:194	X
ajlm-2942	158	2	.	.	PUNCT
ajlm-2942	158	3	https://doi.org/10.1186/s12889-024-17709-5	https://doi.org/10.1186/s12889-024-17709-5	PROPN
ajlm-2942	158	4	minja	minja	PROPN
ajlm-2942	158	5	nw	nw	PROPN
ajlm-2942	158	6	,	,	PUNCT
ajlm-2942	158	7	nakagaayi	nakagaayi	PROPN
ajlm-2942	158	8	d	d	PROPN
ajlm-2942	158	9	,	,	PUNCT
ajlm-2942	158	10	aliku	aliku	PROPN
ajlm-2942	158	11	t	t	PROPN
ajlm-2942	158	12	,	,	PUNCT
ajlm-2942	158	13	et	et	PROPN
ajlm-2942	158	14	al	al	PROPN
ajlm-2942	158	15	.	.	PUNCT
ajlm-2942	159	1	cardiovascular	cardiovascular	ADJ
ajlm-2942	159	2	diseases	disease	NOUN
ajlm-2942	159	3	in	in	ADP
ajlm-2942	159	4	africa	africa	PROPN
ajlm-2942	159	5	in	in	ADP
ajlm-2942	159	6	the	the	DET
ajlm-2942	159	7	twenty	twenty	NUM
ajlm-2942	159	8	-	-	PUNCT
ajlm-2942	159	9	first	first	ADJ
ajlm-2942	159	10	century	century	NOUN
ajlm-2942	159	11	:	:	PUNCT
ajlm-2942	159	12	gaps	gap	NOUN
ajlm-2942	159	13	and	and	CCONJ
ajlm-2942	159	14	priorities	priority	NOUN
ajlm-2942	159	15	going	go	VERB
ajlm-2942	159	16	forward	forward	ADV
ajlm-2942	159	17	.	.	PUNCT
ajlm-2942	160	1	front	front	PROPN
ajlm-2942	160	2	cardiovasc	cardiovasc	PROPN
ajlm-2942	160	3	med	me	VERB
ajlm-2942	160	4	.	.	PUNCT
ajlm-2942	160	5	2022;9:1008335	2022;9:1008335	NUM
ajlm-2942	160	6	.	.	PUNCT
ajlm-2942	161	1	https://doi.org/10.3389/fcvm.2022.1008335	https://doi.org/10.3389/fcvm.2022.1008335	PROPN
ajlm-2942	161	2	duan	duan	PROPN
ajlm-2942	161	3	h	h	PROPN
ajlm-2942	161	4	,	,	PUNCT
ajlm-2942	161	5	song	song	NOUN
ajlm-2942	161	6	p	p	NOUN
ajlm-2942	161	7	,	,	PUNCT
ajlm-2942	161	8	li	li	PROPN
ajlm-2942	161	9	r	r	PROPN
ajlm-2942	161	10	,	,	PUNCT
ajlm-2942	161	11	su	su	PROPN
ajlm-2942	161	12	h	h	PROPN
ajlm-2942	161	13	,	,	PUNCT
ajlm-2942	161	14	he	he	PRON
ajlm-2942	161	15	l.	l.	NOUN
ajlm-2942	161	16	attenuating	attenuate	VERB
ajlm-2942	161	17	lipid	lipid	ADJ
ajlm-2942	161	18	metabolism	metabolism	NOUN
ajlm-2942	161	19	in	in	ADP
ajlm-2942	161	20	atherosclerosis	atherosclerosis	NOUN
ajlm-2942	161	21	:	:	PUNCT
ajlm-2942	161	22	the	the	DET
ajlm-2942	161	23	potential	potential	ADJ
ajlm-2942	161	24	role	role	NOUN
ajlm-2942	161	25	of	of	ADP
ajlm-2942	161	26	anti	anti	ADJ
ajlm-2942	161	27	-	-	ADJ
ajlm-2942	161	28	oxidative	oxidative	ADJ
ajlm-2942	161	29	effects	effect	NOUN
ajlm-2942	161	30	on	on	ADP
ajlm-2942	161	31	low	low	ADJ
ajlm-2942	161	32	-	-	PUNCT
ajlm-2942	161	33	density	density	NOUN
ajlm-2942	161	34	lipoprotein	lipoprotein	NOUN
ajlm-2942	161	35	of	of	ADP
ajlm-2942	161	36	herbal	herbal	ADJ
ajlm-2942	161	37	medicines	medicine	NOUN
ajlm-2942	161	38	.	.	PUNCT
ajlm-2942	162	1	front	front	ADJ
ajlm-2942	162	2	pharmacol	pharmacol	PROPN
ajlm-2942	162	3	.	.	PUNCT
ajlm-2942	163	1	2023;14:1161657	2023;14:1161657	NUM
ajlm-2942	163	2	.	.	PUNCT
ajlm-2942	164	1	https://doi.org/10.3389/fphar.2023.1161657	https://doi.org/10.3389/fphar.2023.1161657	PROPN
ajlm-2942	164	2	doi	doi	PROPN
ajlm-2942	164	3	t	t	PROPN
ajlm-2942	164	4	,	,	PUNCT
ajlm-2942	164	5	langsted	langste	VERB
ajlm-2942	164	6	a	a	PRON
ajlm-2942	164	7	,	,	PUNCT
ajlm-2942	164	8	nordestgaard	nordestgaard	PROPN
ajlm-2942	164	9	bg	bg	PROPN
ajlm-2942	164	10	.	.	PROPN
ajlm-2942	164	11	lipoproteins	lipoprotein	NOUN
ajlm-2942	164	12	,	,	PUNCT
ajlm-2942	164	13	cholesterol	cholesterol	NOUN
ajlm-2942	164	14	,	,	PUNCT
ajlm-2942	164	15	and	and	CCONJ
ajlm-2942	164	16	atherosclerotic	atherosclerotic	ADJ
ajlm-2942	164	17	cardiovascular	cardiovascular	ADJ
ajlm-2942	164	18	disease	disease	NOUN
ajlm-2942	164	19	in	in	ADP
ajlm-2942	164	20	east	east	PROPN
ajlm-2942	164	21	asians	asians	PROPN
ajlm-2942	164	22	and	and	CCONJ
ajlm-2942	164	23	europeans	europeans	PROPN
ajlm-2942	164	24	.	.	PUNCT
ajlm-2942	165	1	j	j	PROPN
ajlm-2942	165	2	atheroscler	atheroscler	PROPN
ajlm-2942	165	3	thromb	thromb	PROPN
ajlm-2942	165	4	.	.	PUNCT
ajlm-2942	166	1	2023;30(11):1525–1546	2023;30(11):1525–1546	X
ajlm-2942	166	2	.	.	PUNCT
ajlm-2942	167	1	https://doi.org/10.5551/jat.rv22013	https://doi.org/10.5551/jat.rv22013	PROPN
ajlm-2942	167	2	salekeen	salekeen	PROPN
ajlm-2942	167	3	r	r	PROPN
ajlm-2942	167	4	,	,	PUNCT
ajlm-2942	167	5	haider	haider	PROPN
ajlm-2942	167	6	an	an	PRON
ajlm-2942	167	7	,	,	PUNCT
ajlm-2942	167	8	akhter	akhter	NOUN
ajlm-2942	167	9	f	f	PROPN
ajlm-2942	167	10	,	,	PUNCT
ajlm-2942	167	11	billah	billah	PROPN
ajlm-2942	167	12	mm	mm	PROPN
ajlm-2942	167	13	,	,	PUNCT
ajlm-2942	167	14	islam	islam	PROPN
ajlm-2942	167	15	me	me	PROPN
ajlm-2942	167	16	,	,	PUNCT
ajlm-2942	167	17	islam	islam	PROPN
ajlm-2942	167	18	kmd	kmd	PROPN
ajlm-2942	167	19	.	.	PUNCT
ajlm-2942	168	1	lipid	lipid	PROPN
ajlm-2942	168	2	oxidation	oxidation	NOUN
ajlm-2942	168	3	in	in	ADP
ajlm-2942	168	4	pathophysiology	pathophysiology	NOUN
ajlm-2942	168	5	of	of	ADP
ajlm-2942	168	6	atherosclerosis	atherosclerosis	NOUN
ajlm-2942	168	7	:	:	PUNCT
ajlm-2942	168	8	current	current	ADJ
ajlm-2942	168	9	understanding	understanding	NOUN
ajlm-2942	168	10	and	and	CCONJ
ajlm-2942	168	11	therapeutic	therapeutic	ADJ
ajlm-2942	168	12	strategies	strategy	NOUN
ajlm-2942	168	13	.	.	PUNCT
ajlm-2942	169	1	int	int	PROPN
ajlm-2942	169	2	j	j	PROPN
ajlm-2942	169	3	cardiol	cardiol	PROPN
ajlm-2942	169	4	cardiovasc	cardiovasc	PROPN
ajlm-2942	169	5	risk	risk	NOUN
ajlm-2942	169	6	prev	prev	NOUN
ajlm-2942	169	7	.	.	PUNCT
ajlm-2942	170	1	2022;14:200143	2022;14:200143	ADJ
ajlm-2942	170	2	.	.	PUNCT
ajlm-2942	171	1	https://doi.org/10.1016/j.ijcrp.2022.200143	https://doi.org/10.1016/j.ijcrp.2022.200143	NOUN
ajlm-2942	171	2	lu	lu	PROPN
ajlm-2942	171	3	y	y	PROPN
ajlm-2942	171	4	,	,	PUNCT
ajlm-2942	171	5	cui	cui	NOUN
ajlm-2942	171	6	x	x	PROPN
ajlm-2942	171	7	,	,	PUNCT
ajlm-2942	171	8	zhang	zhang	PROPN
ajlm-2942	171	9	l	l	PROPN
ajlm-2942	171	10	,	,	PUNCT
ajlm-2942	171	11	et	et	PROPN
ajlm-2942	171	12	al	al	PROPN
ajlm-2942	171	13	.	.	PUNCT
ajlm-2942	172	1	the	the	DET
ajlm-2942	172	2	functional	functional	ADJ
ajlm-2942	172	3	role	role	NOUN
ajlm-2942	172	4	of	of	ADP
ajlm-2942	172	5	lipoproteins	lipoprotein	NOUN
ajlm-2942	172	6	in	in	ADP
ajlm-2942	172	7	atherosclerosis	atherosclerosis	NOUN
ajlm-2942	172	8	:	:	PUNCT
ajlm-2942	172	9	novel	novel	ADJ
ajlm-2942	172	10	directions	direction	NOUN
ajlm-2942	172	11	for	for	ADP
ajlm-2942	172	12	diagnosis	diagnosis	NOUN
ajlm-2942	172	13	and	and	CCONJ
ajlm-2942	172	14	targeting	target	VERB
ajlm-2942	172	15	therapy	therapy	NOUN
ajlm-2942	172	16	.	.	PUNCT
ajlm-2942	173	1	aging	age	VERB
ajlm-2942	173	2	dis	dis	PROPN
ajlm-2942	173	3	.	.	PUNCT
ajlm-2942	174	1	2022;13(2):491–520	2022;13(2):491–520	NUM
ajlm-2942	174	2	.	.	NUM
ajlm-2942	175	1	https://doi.org/10.14336/ad.2021.0929	https://doi.org/10.14336/ad.2021.0929	NOUN
ajlm-2942	175	2	mbakwem	mbakwem	AUX
ajlm-2942	175	3	ac	ac	PROPN
ajlm-2942	175	4	,	,	PUNCT
ajlm-2942	175	5	amadi	amadi	PROPN
ajlm-2942	175	6	ce	ce	PROPN
ajlm-2942	175	7	,	,	PUNCT
ajlm-2942	175	8	ajuluchukwu	ajuluchukwu	PROPN
ajlm-2942	175	9	jn	jn	PROPN
ajlm-2942	175	10	,	,	PUNCT
ajlm-2942	175	11	kushimo	kushimo	PROPN
ajlm-2942	175	12	oa	oa	INTJ
ajlm-2942	175	13	.	.	PUNCT
ajlm-2942	175	14	trends	trend	NOUN
ajlm-2942	175	15	and	and	CCONJ
ajlm-2942	175	16	outcomes	outcome	NOUN
ajlm-2942	175	17	of	of	ADP
ajlm-2942	175	18	cardiovascular	cardiovascular	ADJ
ajlm-2942	175	19	disease	disease	NOUN
ajlm-2942	175	20	admissions	admission	NOUN
ajlm-2942	175	21	in	in	ADP
ajlm-2942	175	22	lagos	lago	NOUN
ajlm-2942	175	23	,	,	PUNCT
ajlm-2942	175	24	nigeria	nigeria	PRON
ajlm-2942	175	25	:	:	PUNCT
ajlm-2942	175	26	a	a	DET
ajlm-2942	175	27	16	16	NUM
ajlm-2942	175	28	-	-	PUNCT
ajlm-2942	175	29	year	year	NOUN
ajlm-2942	175	30	review	review	NOUN
ajlm-2942	175	31	.	.	PUNCT
ajlm-2942	176	1	cardiovasc	cardiovasc	PROPN
ajlm-2942	176	2	j	j	PROPN
ajlm-2942	176	3	afr	afr	PROPN
ajlm-2942	176	4	.	.	PUNCT
ajlm-2942	177	1	2023;34(3):140–148	2023;34(3):140–148	NUM
ajlm-2942	177	2	.	.	X
ajlm-2942	177	3	https://doi.org/10.5830/cvja-2022-037	https://doi.org/10.5830/cvja-2022-037	PROPN
ajlm-2942	177	4	nwaejigh	nwaejigh	PROPN
ajlm-2942	177	5	pc	pc	PROPN
ajlm-2942	177	6	,	,	PUNCT
ajlm-2942	177	7	ebesunun	ebesunun	PROPN
ajlm-2942	177	8	mo	mo	PROPN
ajlm-2942	177	9	,	,	PUNCT
ajlm-2942	177	10	oladimeji	oladimeji	VERB
ajlm-2942	177	11	om	om	PROPN
ajlm-2942	177	12	.	.	PUNCT
ajlm-2942	178	1	lecithin	lecithin	NOUN
ajlm-2942	178	2	-	-	PUNCT
ajlm-2942	178	3	cholesterol	cholesterol	NOUN
ajlm-2942	178	4	acyltransferase	acyltransferase	NOUN
ajlm-2942	178	5	and	and	CCONJ
ajlm-2942	178	6	paraoxonase-1	paraoxonase-1	NUM
ajlm-2942	178	7	levels	level	NOUN
ajlm-2942	178	8	in	in	ADP
ajlm-2942	178	9	atherosclerotic	atherosclerotic	ADJ
ajlm-2942	178	10	cardiovascular	cardiovascular	ADJ
ajlm-2942	178	11	disease	disease	NOUN
ajlm-2942	178	12	patients	patient	NOUN
ajlm-2942	178	13	in	in	ADP
ajlm-2942	178	14	nigeria	nigeria	PROPN
ajlm-2942	178	15	.	.	PUNCT
ajlm-2942	179	1	afr	afr	PROPN
ajlm-2942	179	2	j	j	PROPN
ajlm-2942	179	3	lab	lab	PROPN
ajlm-2942	179	4	med	me	VERB
ajlm-2942	179	5	.	.	PUNCT
ajlm-2942	180	1	2024;13(1	2024;13(1	NUM
ajlm-2942	180	2	):	):	PUNCT
ajlm-2942	180	3	2286	2286	NUM
ajlm-2942	180	4	.	.	PUNCT
ajlm-2942	181	1	https://doi.org/10.4102/ajlm.v13i1.2286	https://doi.org/10.4102/ajlm.v13i1.2286	PROPN
ajlm-2942	181	2	xu	xu	PROPN
ajlm-2942	181	3	x	x	PROPN
ajlm-2942	181	4	,	,	PUNCT
ajlm-2942	181	5	song	song	NOUN
ajlm-2942	181	6	z	z	PROPN
ajlm-2942	181	7	,	,	PUNCT
ajlm-2942	181	8	mao	mao	PROPN
ajlm-2942	181	9	b	b	AUX
ajlm-2942	181	10	,	,	PUNCT
ajlm-2942	181	11	xu	xu	PROPN
ajlm-2942	181	12	g.	g.	PROPN
ajlm-2942	181	13	apolipoprotein	apolipoprotein	VERB
ajlm-2942	181	14	a1	a1	NOUN
ajlm-2942	181	15	-	-	PUNCT
ajlm-2942	181	16	related	relate	VERB
ajlm-2942	181	17	proteins	protein	NOUN
ajlm-2942	181	18	and	and	CCONJ
ajlm-2942	181	19	reverse	reverse	VERB
ajlm-2942	181	20	cholesterol	cholesterol	NOUN
ajlm-2942	181	21	transport	transport	NOUN
ajlm-2942	181	22	in	in	ADP
ajlm-2942	181	23	antiatherosclerosis	antiatherosclerosis	NOUN
ajlm-2942	181	24	therapy	therapy	NOUN
ajlm-2942	181	25	:	:	PUNCT
ajlm-2942	181	26	recent	recent	ADJ
ajlm-2942	181	27	progress	progress	NOUN
ajlm-2942	181	28	and	and	CCONJ
ajlm-2942	181	29	future	future	ADJ
ajlm-2942	181	30	perspectives	perspective	NOUN
ajlm-2942	181	31	.	.	PUNCT
ajlm-2942	182	1	cardiovasc	cardiovasc	PROPN
ajlm-2942	182	2	ther	ther	ADV
ajlm-2942	182	3	.	.	PUNCT
ajlm-2942	183	1	2022;2022:4610834	2022;2022:4610834	NUM
ajlm-2942	183	2	.	.	PUNCT
ajlm-2942	184	1	https://doi.org/10.1155/2022/4610834	https://doi.org/10.1155/2022/4610834	PROPN
ajlm-2942	184	2	bernecic	bernecic	PROPN
ajlm-2942	184	3	nc	nc	PROPN
ajlm-2942	184	4	,	,	PUNCT
ajlm-2942	184	5	de	de	PROPN
ajlm-2942	184	6	graaf	graaf	PROPN
ajlm-2942	184	7	sp	sp	PROPN
ajlm-2942	184	8	,	,	PUNCT
ajlm-2942	184	9	leahy	leahy	PROPN
ajlm-2942	184	10	t	t	PROPN
ajlm-2942	184	11	,	,	PUNCT
ajlm-2942	184	12	gadella	gadella	PROPN
ajlm-2942	184	13	bm	bm	PROPN
ajlm-2942	184	14	.	.	PROPN
ajlm-2942	184	15	hdl	hdl	PROPN
ajlm-2942	184	16	mediates	mediate	NOUN
ajlm-2942	184	17	reverse	reverse	VERB
ajlm-2942	184	18	cholesterol	cholesterol	NOUN
ajlm-2942	184	19	transport	transport	NOUN
ajlm-2942	184	20	from	from	ADP
ajlm-2942	184	21	ram	ram	NOUN
ajlm-2942	184	22	spermatozoa	spermatozoon	NOUN
ajlm-2942	184	23	and	and	CCONJ
ajlm-2942	184	24	induces	induce	NOUN
ajlm-2942	184	25	hyperactivated	hyperactivate	VERB
ajlm-2942	184	26	motility	motility	NOUN
ajlm-2942	184	27	.	.	PUNCT
ajlm-2942	185	1	biol	biol	PROPN
ajlm-2942	185	2	reprod	reprod	PROPN
ajlm-2942	185	3	.	.	PUNCT
ajlm-2942	186	1	2021;104(6):1271–1281	2021;104(6):1271–1281	NUM
ajlm-2942	186	2	.	.	PUNCT
ajlm-2942	187	1	https://doi.org/10.1093/biolre/ioab035	https://doi.org/10.1093/biolre/ioab035	PROPN
ajlm-2942	187	2	fotakis	fotakis	PROPN
ajlm-2942	188	1	p	p	X
ajlm-2942	188	2	,	,	PUNCT
ajlm-2942	188	3	kothari	kothari	PROPN
ajlm-2942	188	4	v	v	PROPN
ajlm-2942	188	5	,	,	PUNCT
ajlm-2942	188	6	thomas	thomas	PROPN
ajlm-2942	188	7	dg	dg	PROPN
ajlm-2942	188	8	,	,	PUNCT
ajlm-2942	188	9	et	et	PROPN
ajlm-2942	188	10	al	al	PROPN
ajlm-2942	188	11	.	.	PUNCT
ajlm-2942	189	1	anti	anti	ADJ
ajlm-2942	189	2	-	-	ADJ
ajlm-2942	189	3	inflammatory	inflammatory	ADJ
ajlm-2942	189	4	effects	effect	NOUN
ajlm-2942	189	5	of	of	ADP
ajlm-2942	189	6	hdl	hdl	PROPN
ajlm-2942	189	7	(	(	PUNCT
ajlm-2942	189	8	high	high	ADJ
ajlm-2942	189	9	-	-	PUNCT
ajlm-2942	189	10	density	density	NOUN
ajlm-2942	189	11	lipoprotein	lipoprotein	NOUN
ajlm-2942	189	12	)	)	PUNCT
ajlm-2942	189	13	in	in	ADP
ajlm-2942	189	14	macrophages	macrophage	NOUN
ajlm-2942	189	15	predominate	predominate	ADJ
ajlm-2942	189	16	over	over	ADP
ajlm-2942	189	17	proinflammatory	proinflammatory	ADJ
ajlm-2942	189	18	effects	effect	NOUN
ajlm-2942	189	19	in	in	ADP
ajlm-2942	189	20	atherosclerotic	atherosclerotic	ADJ
ajlm-2942	189	21	plaques	plaque	NOUN
ajlm-2942	189	22	.	.	PUNCT
ajlm-2942	190	1	arterioscler	arterioscler	PROPN
ajlm-2942	190	2	thromb	thromb	PROPN
ajlm-2942	190	3	vasc	vasc	PROPN
ajlm-2942	190	4	biol	biol	PROPN
ajlm-2942	190	5	.	.	PUNCT
ajlm-2942	191	1	2019;39(12):e253	2019;39(12):e253	NUM
ajlm-2942	191	2	–	–	PUNCT
ajlm-2942	191	3	e272	e272	PROPN
ajlm-2942	191	4	.	.	PUNCT
ajlm-2942	192	1	https://doi.org/10.1161/atvbaha.119.313737	https://doi.org/10.1161/atvbaha.119.313737	PROPN
ajlm-2942	192	2	denimal	denimal	PROPN
ajlm-2942	192	3	d.	d.	PROPN
ajlm-2942	192	4	antioxidant	antioxidant	NOUN
ajlm-2942	192	5	and	and	CCONJ
ajlm-2942	192	6	anti	anti	ADJ
ajlm-2942	192	7	-	-	ADJ
ajlm-2942	192	8	inflammatory	inflammatory	ADJ
ajlm-2942	192	9	functions	function	NOUN
ajlm-2942	192	10	of	of	ADP
ajlm-2942	192	11	high	high	ADJ
ajlm-2942	192	12	-	-	PUNCT
ajlm-2942	192	13	density	density	NOUN
ajlm-2942	192	14	lipoprotein	lipoprotein	NOUN
ajlm-2942	192	15	in	in	ADP
ajlm-2942	192	16	type	type	NOUN
ajlm-2942	192	17	1	1	NUM
ajlm-2942	192	18	and	and	CCONJ
ajlm-2942	192	19	type	type	NOUN
ajlm-2942	192	20	2	2	NUM
ajlm-2942	192	21	diabetes	diabetes	NOUN
ajlm-2942	192	22	.	.	PUNCT
ajlm-2942	193	1	antioxidants	antioxidant	NOUN
ajlm-2942	193	2	.	.	PUNCT
ajlm-2942	194	1	2024;13:57	2024;13:57	NUM
ajlm-2942	194	2	.	.	PUNCT
ajlm-2942	194	3	https://doi.org/10.3390/antiox13010057	https://doi.org/10.3390/antiox13010057	PROPN
ajlm-2942	194	4	behbodikhah	behbodikhah	PROPN
ajlm-2942	194	5	j	j	PROPN
ajlm-2942	194	6	,	,	PUNCT
ajlm-2942	194	7	ahmed	ahmed	PROPN
ajlm-2942	194	8	s	s	PROPN
ajlm-2942	194	9	,	,	PUNCT
ajlm-2942	194	10	elyasi	elyasi	NOUN
ajlm-2942	194	11	a	a	NOUN
ajlm-2942	194	12	,	,	PUNCT
ajlm-2942	194	13	et	et	PROPN
ajlm-2942	194	14	al	al	PROPN
ajlm-2942	194	15	.	.	PROPN
ajlm-2942	195	1	apolipoprotein	apolipoprotein	PROPN
ajlm-2942	195	2	b	b	PROPN
ajlm-2942	195	3	and	and	CCONJ
ajlm-2942	195	4	cardiovascular	cardiovascular	ADJ
ajlm-2942	195	5	disease	disease	NOUN
ajlm-2942	195	6	:	:	PUNCT
ajlm-2942	195	7	biomarker	biomarker	NOUN
ajlm-2942	195	8	and	and	CCONJ
ajlm-2942	195	9	potential	potential	ADJ
ajlm-2942	195	10	therapeutic	therapeutic	ADJ
ajlm-2942	195	11	target	target	NOUN
ajlm-2942	195	12	.	.	PUNCT
ajlm-2942	196	1	metabolites	metabolite	NOUN
ajlm-2942	196	2	.	.	PUNCT
ajlm-2942	197	1	2021;11(10):690	2021;11(10):690	NUM
ajlm-2942	197	2	.	.	PUNCT
ajlm-2942	198	1	https://doi.org/10.3390/metabo11100690	https://doi.org/10.3390/metabo11100690	NOUN
ajlm-2942	198	2	cole	cole	PROPN
ajlm-2942	198	3	j	j	PROPN
ajlm-2942	198	4	,	,	PUNCT
ajlm-2942	198	5	zubirán	zubirán	PROPN
ajlm-2942	198	6	r	r	PROPN
ajlm-2942	198	7	,	,	PUNCT
ajlm-2942	198	8	wolska	wolska	NOUN
ajlm-2942	198	9	a	a	NOUN
ajlm-2942	198	10	,	,	PUNCT
ajlm-2942	198	11	jialal	jialal	PROPN
ajlm-2942	198	12	i	i	PRON
ajlm-2942	198	13	,	,	PUNCT
ajlm-2942	198	14	remaley	remaley	VERB
ajlm-2942	198	15	at	at	ADP
ajlm-2942	198	16	.	.	PUNCT
ajlm-2942	199	1	use	use	NOUN
ajlm-2942	199	2	of	of	ADP
ajlm-2942	199	3	apolipoprotein	apolipoprotein	ADJ
ajlm-2942	199	4	b	b	PROPN
ajlm-2942	199	5	in	in	ADP
ajlm-2942	199	6	the	the	DET
ajlm-2942	199	7	era	era	NOUN
ajlm-2942	199	8	of	of	ADP
ajlm-2942	199	9	precision	precision	NOUN
ajlm-2942	199	10	medicine	medicine	NOUN
ajlm-2942	199	11	:	:	PUNCT
ajlm-2942	199	12	time	time	NOUN
ajlm-2942	199	13	for	for	ADP
ajlm-2942	199	14	a	a	DET
ajlm-2942	199	15	paradigm	paradigm	NOUN
ajlm-2942	199	16	change	change	NOUN
ajlm-2942	199	17	?	?	PUNCT
ajlm-2942	200	1	j	j	PROPN
ajlm-2942	200	2	clin	clin	PROPN
ajlm-2942	200	3	med	me	VERB
ajlm-2942	200	4	.	.	PUNCT
ajlm-2942	201	1	2023;12(17	2023;12(17	NUM
ajlm-2942	201	2	):	):	PUNCT
ajlm-2942	201	3	5737	5737	NUM
ajlm-2942	201	4	.	.	PUNCT
ajlm-2942	202	1	https://doi.org/10.3390/jcm12175737	https://doi.org/10.3390/jcm12175737	NOUN
ajlm-2942	202	2	glavinovic	glavinovic	PROPN
ajlm-2942	202	3	t	t	PROPN
ajlm-2942	202	4	,	,	PUNCT
ajlm-2942	202	5	thanassoulis	thanassoulis	X
ajlm-2942	202	6	g	g	NOUN
ajlm-2942	202	7	,	,	PUNCT
ajlm-2942	202	8	de	de	PROPN
ajlm-2942	202	9	graaf	graaf	PROPN
ajlm-2942	202	10	j	j	PROPN
ajlm-2942	202	11	,	,	PUNCT
ajlm-2942	202	12	couture	couture	NOUN
ajlm-2942	202	13	p	p	X
ajlm-2942	202	14	,	,	PUNCT
ajlm-2942	202	15	hegele	hegele	PROPN
ajlm-2942	202	16	ra	ra	PROPN
ajlm-2942	202	17	,	,	PUNCT
ajlm-2942	202	18	sniderman	sniderman	NOUN
ajlm-2942	202	19	ad	ad	NOUN
ajlm-2942	202	20	.	.	PUNCT
ajlm-2942	203	1	physiological	physiological	ADJ
ajlm-2942	203	2	bases	basis	NOUN
ajlm-2942	203	3	for	for	ADP
ajlm-2942	203	4	the	the	DET
ajlm-2942	203	5	superiority	superiority	NOUN
ajlm-2942	203	6	of	of	ADP
ajlm-2942	203	7	apolipoprotein	apolipoprotein	ADJ
ajlm-2942	203	8	b	b	PROPN
ajlm-2942	203	9	over	over	ADP
ajlm-2942	203	10	low	low	ADJ
ajlm-2942	203	11	-	-	PUNCT
ajlm-2942	203	12	density	density	NOUN
ajlm-2942	203	13	lipoprotein	lipoprotein	ADJ
ajlm-2942	203	14	cholesterol	cholesterol	NOUN
ajlm-2942	203	15	and	and	CCONJ
ajlm-2942	203	16	non	non	ADJ
ajlm-2942	203	17	–	–	ADJ
ajlm-2942	203	18	high	high	ADJ
ajlm-2942	203	19	-	-	PUNCT
ajlm-2942	203	20	density	density	NOUN
ajlm-2942	203	21	lipoprotein	lipoprotein	ADJ
ajlm-2942	203	22	cholesterol	cholesterol	NOUN
ajlm-2942	203	23	as	as	ADP
ajlm-2942	203	24	a	a	DET
ajlm-2942	203	25	marker	marker	NOUN
ajlm-2942	203	26	of	of	ADP
ajlm-2942	203	27	cardiovascular	cardiovascular	ADJ
ajlm-2942	203	28	risk	risk	NOUN
ajlm-2942	203	29	.	.	PUNCT
ajlm-2942	204	1	j	j	PROPN
ajlm-2942	204	2	am	be	AUX
ajlm-2942	204	3	heart	heart	NOUN
ajlm-2942	204	4	assoc	assoc	NOUN
ajlm-2942	204	5	.	.	PUNCT
ajlm-2942	205	1	2022;11(20):e025858	2022;11(20):e025858	NOUN
ajlm-2942	205	2	.	.	PUNCT
ajlm-2942	206	1	https://doi.org/10.1161/jaha.122.025858	https://doi.org/10.1161/jaha.122.025858	VERB
ajlm-2942	206	2	deng	deng	PROPN
ajlm-2942	206	3	f	f	PROPN
ajlm-2942	206	4	,	,	PUNCT
ajlm-2942	206	5	li	li	PROPN
ajlm-2942	206	6	d	d	PROPN
ajlm-2942	206	7	,	,	PUNCT
ajlm-2942	206	8	lei	lei	PROPN
ajlm-2942	206	9	l	l	NOUN
ajlm-2942	206	10	,	,	PUNCT
ajlm-2942	206	11	et	et	PROPN
ajlm-2942	206	12	al	al	PROPN
ajlm-2942	206	13	.	.	PROPN
ajlm-2942	206	14	association	association	PROPN
ajlm-2942	206	15	between	between	ADP
ajlm-2942	206	16	apolipoprotein	apolipoprotein	ADJ
ajlm-2942	206	17	b	b	PROPN
ajlm-2942	206	18	/	/	SYM
ajlm-2942	206	19	a1	a1	NOUN
ajlm-2942	206	20	ratio	ratio	NOUN
ajlm-2942	206	21	and	and	CCONJ
ajlm-2942	206	22	coronary	coronary	ADJ
ajlm-2942	206	23	plaque	plaque	NOUN
ajlm-2942	206	24	vulnerability	vulnerability	NOUN
ajlm-2942	206	25	in	in	ADP
ajlm-2942	206	26	patients	patient	NOUN
ajlm-2942	206	27	with	with	ADP
ajlm-2942	206	28	atherosclerotic	atherosclerotic	ADJ
ajlm-2942	206	29	cardiovascular	cardiovascular	ADJ
ajlm-2942	206	30	disease	disease	NOUN
ajlm-2942	206	31	:	:	PUNCT
ajlm-2942	206	32	an	an	DET
ajlm-2942	206	33	intravascular	intravascular	ADJ
ajlm-2942	206	34	optical	optical	ADJ
ajlm-2942	206	35	coherence	coherence	NOUN
ajlm-2942	206	36	tomography	tomography	NOUN
ajlm-2942	206	37	study	study	NOUN
ajlm-2942	206	38	.	.	PUNCT
ajlm-2942	207	1	cardiovasc	cardiovasc	PROPN
ajlm-2942	207	2	diabetol	diabetol	VERB
ajlm-2942	207	3	.	.	PUNCT
ajlm-2942	208	1	2021;20:188	2021;20:188	X
ajlm-2942	208	2	.	.	PUNCT
ajlm-2942	209	1	https://doi.org/10.1186/s12933-021-01381-9	https://doi.org/10.1186/s12933-021-01381-9	PROPN
ajlm-2942	209	2	jung	jung	PROPN
ajlm-2942	209	3	hw	hw	PROPN
ajlm-2942	209	4	,	,	PUNCT
ajlm-2942	209	5	hong	hong	PROPN
ajlm-2942	209	6	sp	sp	PROPN
ajlm-2942	209	7	,	,	PUNCT
ajlm-2942	209	8	kim	kim	PROPN
ajlm-2942	209	9	ks	ks	PROPN
ajlm-2942	209	10	.	.	PROPN
ajlm-2942	209	11	comparison	comparison	NOUN
ajlm-2942	209	12	of	of	ADP
ajlm-2942	209	13	apolipoprotein	apolipoprotein	ADJ
ajlm-2942	209	14	b	b	PROPN
ajlm-2942	209	15	/	/	SYM
ajlm-2942	209	16	a1	a1	NOUN
ajlm-2942	209	17	ratio	ratio	NOUN
ajlm-2942	209	18	,	,	PUNCT
ajlm-2942	209	19	tc	tc	NOUN
ajlm-2942	209	20	/	/	SYM
ajlm-2942	209	21	hdl	hdl	NOUN
ajlm-2942	209	22	-	-	PUNCT
ajlm-2942	209	23	c	c	PROPN
ajlm-2942	209	24	,	,	PUNCT
ajlm-2942	209	25	and	and	CCONJ
ajlm-2942	209	26	lipoprotein	lipoprotein	ADJ
ajlm-2942	209	27	(	(	PUNCT
ajlm-2942	209	28	a	a	NOUN
ajlm-2942	209	29	)	)	PUNCT
ajlm-2942	209	30	for	for	ADP
ajlm-2942	209	31	predicting	predict	VERB
ajlm-2942	209	32	outcomes	outcome	NOUN
ajlm-2942	209	33	after	after	ADP
ajlm-2942	209	34	pci	pci	PROPN
ajlm-2942	209	35	.	.	PUNCT
ajlm-2942	210	1	plos	plos	PROPN
ajlm-2942	210	2	one	one	NUM
ajlm-2942	210	3	.	.	PUNCT
ajlm-2942	211	1	2021;16(7):e0254677	2021;16(7):e0254677	NUM
ajlm-2942	211	2	.	.	PUNCT
ajlm-2942	212	1	https://doi.org/10.1371/journal.pone.0254677	https://doi.org/10.1371/journal.pone.0254677	PROPN
ajlm-2942	212	2	alves	alves	PROPN
ajlm-2942	212	3	de	de	PROPN
ajlm-2942	212	4	oliveira	oliveira	PROPN
ajlm-2942	212	5	h	h	PROPN
ajlm-2942	212	6	,	,	PUNCT
ajlm-2942	212	7	de	de	PROPN
ajlm-2942	212	8	menezes	menezes	PROPN
ajlm-2942	212	9	neves	neves	PROPN
ajlm-2942	212	10	pdm	pdm	PROPN
ajlm-2942	212	11	,	,	PUNCT
ajlm-2942	212	12	de	de	PROPN
ajlm-2942	212	13	figueiredo	figueiredo	PROPN
ajlm-2942	212	14	oliveira	oliveira	PROPN
ajlm-2942	212	15	gb	gb	PROPN
ajlm-2942	212	16	,	,	PUNCT
ajlm-2942	212	17	et	et	PROPN
ajlm-2942	212	18	al	al	PROPN
ajlm-2942	212	19	.	.	PROPN
ajlm-2942	212	20	impact	impact	NOUN
ajlm-2942	212	21	of	of	ADP
ajlm-2942	212	22	genetic	genetic	ADJ
ajlm-2942	212	23	background	background	NOUN
ajlm-2942	212	24	as	as	ADP
ajlm-2942	212	25	a	a	DET
ajlm-2942	212	26	risk	risk	NOUN
ajlm-2942	212	27	factor	factor	NOUN
ajlm-2942	212	28	for	for	ADP
ajlm-2942	212	29	atherosclerotic	atherosclerotic	ADJ
ajlm-2942	212	30	cardiovascular	cardiovascular	ADJ
ajlm-2942	212	31	disease	disease	NOUN
ajlm-2942	212	32	:	:	PUNCT
ajlm-2942	212	33	a	a	DET
ajlm-2942	212	34	protocol	protocol	NOUN
ajlm-2942	212	35	for	for	ADP
ajlm-2942	212	36	a	a	DET
ajlm-2942	212	37	nationwide	nationwide	ADJ
ajlm-2942	212	38	genetic	genetic	ADJ
ajlm-2942	212	39	case	case	NOUN
ajlm-2942	212	40	-	-	PUNCT
ajlm-2942	212	41	control	control	NOUN
ajlm-2942	212	42	(	(	PUNCT
ajlm-2942	212	43	cv	cv	ADJ
ajlm-2942	212	44	-	-	PUNCT
ajlm-2942	212	45	genes	gene	NOUN
ajlm-2942	212	46	)	)	PUNCT
ajlm-2942	212	47	study	study	NOUN
ajlm-2942	212	48	in	in	ADP
ajlm-2942	212	49	brazil	brazil	PROPN
ajlm-2942	212	50	.	.	PUNCT
ajlm-2942	213	1	plos	plos	PROPN
ajlm-2942	213	2	one	one	NUM
ajlm-2942	213	3	.	.	PUNCT
ajlm-2942	214	1	2024;19(3):e0289439	2024;19(3):e0289439	X
ajlm-2942	214	2	.	.	PUNCT
ajlm-2942	215	1	https://doi.org/10.1371/journal.pone.0289439	https://doi.org/10.1371/journal.pone.0289439	PROPN
ajlm-2942	215	2	tada	tada	PROPN
ajlm-2942	215	3	h	h	PROPN
ajlm-2942	215	4	,	,	PUNCT
ajlm-2942	215	5	fujino	fujino	PROPN
ajlm-2942	215	6	n	n	CCONJ
ajlm-2942	215	7	,	,	PUNCT
ajlm-2942	215	8	hayashi	hayashi	PROPN
ajlm-2942	215	9	k	k	PROPN
ajlm-2942	215	10	,	,	PUNCT
ajlm-2942	215	11	kawashiri	kawashiri	PROPN
ajlm-2942	215	12	ma	ma	PROPN
ajlm-2942	215	13	,	,	PUNCT
ajlm-2942	215	14	takamura	takamura	NOUN
ajlm-2942	215	15	m.	m.	NOUN
ajlm-2942	215	16	human	human	PROPN
ajlm-2942	215	17	genetics	genetic	NOUN
ajlm-2942	215	18	and	and	CCONJ
ajlm-2942	215	19	its	its	PRON
ajlm-2942	215	20	impact	impact	NOUN
ajlm-2942	215	21	on	on	ADP
ajlm-2942	215	22	cardiovascular	cardiovascular	ADJ
ajlm-2942	215	23	disease	disease	NOUN
ajlm-2942	215	24	.	.	PUNCT
ajlm-2942	216	1	j	j	PROPN
ajlm-2942	216	2	cardiol	cardiol	NOUN
ajlm-2942	216	3	.	.	PUNCT
ajlm-2942	217	1	2022;79(2):233–239	2022;79(2):233–239	X
ajlm-2942	217	2	.	.	PUNCT
ajlm-2942	217	3	https://doi.org/10.1016/j.jjcc.2021.09.005	https://doi.org/10.1016/j.jjcc.2021.09.005	PROPN
ajlm-2942	217	4	smith	smith	PROPN
ajlm-2942	217	5	ml	ml	PROPN
ajlm-2942	217	6	,	,	PUNCT
ajlm-2942	217	7	bull	bull	PROPN
ajlm-2942	217	8	cj	cj	NOUN
ajlm-2942	217	9	,	,	PUNCT
ajlm-2942	217	10	holmes	holmes	PROPN
ajlm-2942	217	11	mv	mv	PROPN
ajlm-2942	217	12	,	,	PUNCT
ajlm-2942	217	13	et	et	PROPN
ajlm-2942	217	14	al	al	PROPN
ajlm-2942	217	15	.	.	PROPN
ajlm-2942	218	1	distinct	distinct	ADJ
ajlm-2942	218	2	metabolic	metabolic	NOUN
ajlm-2942	218	3	features	feature	NOUN
ajlm-2942	218	4	of	of	ADP
ajlm-2942	218	5	genetic	genetic	ADJ
ajlm-2942	218	6	liability	liability	NOUN
ajlm-2942	218	7	to	to	PART
ajlm-2942	218	8	type	type	VERB
ajlm-2942	218	9	2	2	NUM
ajlm-2942	218	10	diabetes	diabetes	NOUN
ajlm-2942	218	11	and	and	CCONJ
ajlm-2942	218	12	coronary	coronary	ADJ
ajlm-2942	218	13	artery	artery	NOUN
ajlm-2942	218	14	disease	disease	NOUN
ajlm-2942	218	15	:	:	PUNCT
ajlm-2942	218	16	a	a	DET
ajlm-2942	218	17	reverse	reverse	ADJ
ajlm-2942	218	18	mendelian	mendelian	ADJ
ajlm-2942	218	19	randomization	randomization	NOUN
ajlm-2942	218	20	study	study	NOUN
ajlm-2942	218	21	.	.	PUNCT
ajlm-2942	219	1	ebiomedicine	ebiomedicine	ADJ
ajlm-2942	219	2	.	.	PUNCT
ajlm-2942	220	1	2023;90:104503	2023;90:104503	NUM
ajlm-2942	220	2	.	.	PUNCT
ajlm-2942	220	3	https://doi.org/10.1016/j.ebiom.2023.104503	https://doi.org/10.1016/j.ebiom.2023.104503	PROPN
ajlm-2942	220	4	bonacina	bonacina	PROPN
ajlm-2942	221	1	f	f	X
ajlm-2942	221	2	,	,	PUNCT
ajlm-2942	221	3	pirillo	pirillo	VERB
ajlm-2942	221	4	a	a	PRON
ajlm-2942	221	5	,	,	PUNCT
ajlm-2942	221	6	catapano	catapano	PROPN
ajlm-2942	221	7	al	al	PROPN
ajlm-2942	221	8	,	,	PUNCT
ajlm-2942	221	9	norata	norata	VERB
ajlm-2942	221	10	gd	gd	PROPN
ajlm-2942	221	11	.	.	PUNCT
ajlm-2942	222	1	hdl	hdl	PROPN
ajlm-2942	222	2	in	in	ADP
ajlm-2942	222	3	immune	immune	NOUN
ajlm-2942	222	4	-	-	PUNCT
ajlm-2942	222	5	inflammatory	inflammatory	ADJ
ajlm-2942	222	6	responses	response	NOUN
ajlm-2942	222	7	:	:	PUNCT
ajlm-2942	222	8	implications	implication	NOUN
ajlm-2942	222	9	beyond	beyond	ADP
ajlm-2942	222	10	cardiovascular	cardiovascular	ADJ
ajlm-2942	222	11	diseases	disease	NOUN
ajlm-2942	222	12	.	.	PUNCT
ajlm-2942	223	1	cells	cell	NOUN
ajlm-2942	223	2	.	.	PUNCT
ajlm-2942	224	1	2021;10(5	2021;10(5	NUM
ajlm-2942	224	2	):	):	PUNCT
ajlm-2942	224	3	1061	1061	NUM
ajlm-2942	224	4	.	.	PUNCT
ajlm-2942	225	1	https://doi.org/10.3390/cells10051061	https://doi.org/10.3390/cells10051061	PROPN
ajlm-2942	225	2	malajczuk	malajczuk	PROPN
ajlm-2942	225	3	cj	cj	PROPN
ajlm-2942	225	4	,	,	PUNCT
ajlm-2942	225	5	gandhi	gandhi	PROPN
ajlm-2942	225	6	ns	ns	NUM
ajlm-2942	225	7	,	,	PUNCT
ajlm-2942	225	8	mancera	mancera	NOUN
ajlm-2942	225	9	rl	rl	X
ajlm-2942	225	10	.	.	NOUN
ajlm-2942	225	11	structure	structure	NOUN
ajlm-2942	225	12	and	and	CCONJ
ajlm-2942	225	13	intermolecular	intermolecular	ADJ
ajlm-2942	225	14	interactions	interaction	NOUN
ajlm-2942	225	15	in	in	ADP
ajlm-2942	225	16	spheroidal	spheroidal	NOUN
ajlm-2942	225	17	high	high	ADJ
ajlm-2942	225	18	-	-	PUNCT
ajlm-2942	225	19	density	density	NOUN
ajlm-2942	225	20	lipoprotein	lipoprotein	ADJ
ajlm-2942	225	21	subpopulations	subpopulation	NOUN
ajlm-2942	225	22	.	.	PUNCT
ajlm-2942	226	1	j	j	PROPN
ajlm-2942	226	2	struct	struct	VERB
ajlm-2942	226	3	biol	biol	ADJ
ajlm-2942	226	4	x.	x.	NOUN
ajlm-2942	226	5	2021;5:100042	2021;5:100042	NOUN
ajlm-2942	226	6	.	.	PUNCT
ajlm-2942	227	1	https://doi.org/10.1016/j.yjsbx.2020.100042	https://doi.org/10.1016/j.yjsbx.2020.100042	VERB
ajlm-2942	227	2	paavola	paavola	PROPN
ajlm-2942	227	3	t	t	PROPN
ajlm-2942	227	4	,	,	PUNCT
ajlm-2942	227	5	bergmann	bergmann	PROPN
ajlm-2942	227	6	u	u	PROPN
ajlm-2942	227	7	,	,	PUNCT
ajlm-2942	227	8	kuusisto	kuusisto	PROPN
ajlm-2942	227	9	s	s	PROPN
ajlm-2942	227	10	,	,	PUNCT
ajlm-2942	227	11	kakko	kakko	PROPN
ajlm-2942	227	12	s	s	PROPN
ajlm-2942	227	13	,	,	PUNCT
ajlm-2942	227	14	savolainen	savolainen	PROPN
ajlm-2942	227	15	mj	mj	PROPN
ajlm-2942	227	16	,	,	PUNCT
ajlm-2942	227	17	salonurmi	salonurmi	VERB
ajlm-2942	227	18	t.	t.	NOUN
ajlm-2942	227	19	distinct	distinct	ADJ
ajlm-2942	227	20	fatty	fatty	NOUN
ajlm-2942	227	21	acid	acid	NOUN
ajlm-2942	227	22	compositions	composition	NOUN
ajlm-2942	227	23	of	of	ADP
ajlm-2942	227	24	hdl	hdl	PROPN
ajlm-2942	227	25	phospholipids	phospholipid	NOUN
ajlm-2942	227	26	are	be	AUX
ajlm-2942	227	27	characteristic	characteristic	ADJ
ajlm-2942	227	28	of	of	ADP
ajlm-2942	227	29	metabolic	metabolic	NOUN
ajlm-2942	227	30	syndrome	syndrome	NOUN
ajlm-2942	227	31	and	and	CCONJ
ajlm-2942	227	32	premature	premature	ADJ
ajlm-2942	227	33	coronary	coronary	ADJ
ajlm-2942	227	34	heart	heart	NOUN
ajlm-2942	227	35	disease	disease	NOUN
ajlm-2942	227	36	–	–	PUNCT
ajlm-2942	227	37	family	family	NOUN
ajlm-2942	227	38	study	study	NOUN
ajlm-2942	227	39	.	.	PUNCT
ajlm-2942	228	1	j	j	PROPN
ajlm-2942	228	2	lipid	lipid	PROPN
ajlm-2942	228	3	res	re	NOUN
ajlm-2942	228	4	.	.	PUNCT
ajlm-2942	229	1	2022;1(2):1–5	2022;1(2):1–5	NUM
ajlm-2942	229	2	.	.	PUNCT
ajlm-2942	230	1	https://doi.org/10.0000/123456789	https://doi.org/10.0000/123456789	ADV
ajlm-2942	230	2	linton	linton	PROPN
ajlm-2942	230	3	mf	mf	PROPN
ajlm-2942	230	4	,	,	PUNCT
ajlm-2942	230	5	yancey	yancey	PROPN
ajlm-2942	230	6	pg	pg	PROPN
ajlm-2942	230	7	,	,	PUNCT
ajlm-2942	230	8	tao	tao	PROPN
ajlm-2942	230	9	h	h	NOUN
ajlm-2942	230	10	,	,	PUNCT
ajlm-2942	230	11	davies	davies	PROPN
ajlm-2942	230	12	ss	ss	PROPN
ajlm-2942	230	13	.	.	PUNCT
ajlm-2942	230	14	hdl	hdl	PROPN
ajlm-2942	230	15	function	function	PROPN
ajlm-2942	230	16	and	and	CCONJ
ajlm-2942	230	17	atherosclerosis	atherosclerosis	NOUN
ajlm-2942	230	18	:	:	PUNCT
ajlm-2942	230	19	reactive	reactive	NOUN
ajlm-2942	230	20	dicarbonyls	dicarbonyls	ADJ
ajlm-2942	230	21	as	as	ADP
ajlm-2942	230	22	promising	promise	VERB
ajlm-2942	230	23	targets	target	NOUN
ajlm-2942	230	24	of	of	ADP
ajlm-2942	230	25	therapy	therapy	NOUN
ajlm-2942	230	26	.	.	PUNCT
ajlm-2942	231	1	circ	circ	PROPN
ajlm-2942	231	2	res	re	NOUN
ajlm-2942	231	3	.	.	PUNCT
ajlm-2942	232	1	2023;132(11):1521–1545	2023;132(11):1521–1545	NUM
ajlm-2942	232	2	.	.	PUNCT
ajlm-2942	233	1	https://doi.org/10.1161/circresaha.123.321563	https://doi.org/10.1161/circresaha.123.321563	PROPN
ajlm-2942	233	2	von	von	PROPN
ajlm-2942	233	3	eckardstein	eckardstein	PROPN
ajlm-2942	233	4	a	a	PRON
ajlm-2942	233	5	,	,	PUNCT
ajlm-2942	233	6	nordestgaard	nordestgaard	PROPN
ajlm-2942	233	7	bg	bg	PROPN
ajlm-2942	233	8	,	,	PUNCT
ajlm-2942	233	9	remaley	remaley	VERB
ajlm-2942	233	10	at	at	ADP
ajlm-2942	233	11	,	,	PUNCT
ajlm-2942	233	12	catapano	catapano	PROPN
ajlm-2942	233	13	al	al	PROPN
ajlm-2942	233	14	.	.	PROPN
ajlm-2942	233	15	high	high	ADJ
ajlm-2942	233	16	-	-	PUNCT
ajlm-2942	233	17	density	density	NOUN
ajlm-2942	233	18	lipoprotein	lipoprotein	NOUN
ajlm-2942	233	19	revisited	revisit	VERB
ajlm-2942	233	20	:	:	PUNCT
ajlm-2942	233	21	biological	biological	ADJ
ajlm-2942	233	22	functions	function	NOUN
ajlm-2942	233	23	and	and	CCONJ
ajlm-2942	233	24	clinical	clinical	ADJ
ajlm-2942	233	25	relevance	relevance	NOUN
ajlm-2942	233	26	.	.	PUNCT
ajlm-2942	234	1	eur	eur	PROPN
ajlm-2942	234	2	heart	heart	NOUN
ajlm-2942	234	3	j.	j.	PROPN
ajlm-2942	234	4	2023;44(16):1394–1407	2023;44(16):1394–1407	PROPN
ajlm-2942	234	5	.	.	PUNCT
ajlm-2942	235	1	https://doi.org/10.1093/eurheartj/ehac605	https://doi.org/10.1093/eurheartj/ehac605	PROPN
ajlm-2942	235	2	sato	sato	PROPN
ajlm-2942	235	3	m	m	PROPN
ajlm-2942	235	4	,	,	PUNCT
ajlm-2942	235	5	neufeld	neufeld	PROPN
ajlm-2942	235	6	eb	eb	PROPN
ajlm-2942	235	7	,	,	PUNCT
ajlm-2942	235	8	playford	playford	PROPN
ajlm-2942	235	9	mp	mp	PROPN
ajlm-2942	235	10	,	,	PUNCT
ajlm-2942	235	11	et	et	PROPN
ajlm-2942	235	12	al	al	PROPN
ajlm-2942	235	13	.	.	PUNCT
ajlm-2942	235	14	cell	cell	NOUN
ajlm-2942	235	15	-	-	PUNCT
ajlm-2942	235	16	free	free	ADJ
ajlm-2942	235	17	,	,	PUNCT
ajlm-2942	235	18	high	high	ADJ
ajlm-2942	235	19	-	-	PUNCT
ajlm-2942	235	20	density	density	NOUN
ajlm-2942	235	21	lipoprotein	lipoprotein	ADJ
ajlm-2942	235	22	-	-	PUNCT
ajlm-2942	235	23	specific	specific	ADJ
ajlm-2942	235	24	phospholipid	phospholipid	NOUN
ajlm-2942	235	25	efflux	efflux	VERB
ajlm-2942	235	26	assay	assay	NOUN
ajlm-2942	235	27	predicts	predict	NOUN
ajlm-2942	235	28	incident	incident	VERB
ajlm-2942	235	29	cardiovascular	cardiovascular	ADJ
ajlm-2942	235	30	disease	disease	NOUN
ajlm-2942	235	31	.	.	PUNCT
ajlm-2942	236	1	j	j	PROPN
ajlm-2942	236	2	clin	clin	PROPN
ajlm-2942	236	3	invest	invest	PROPN
ajlm-2942	236	4	.	.	PUNCT
ajlm-2942	237	1	2023;133(18):e165370	2023;133(18):e165370	NOUN
ajlm-2942	237	2	.	.	PUNCT
ajlm-2942	238	1	https://doi.org/10.1172/jci165370	https://doi.org/10.1172/jci165370	NOUN
ajlm-2942	238	2	ngugi	ngugi	VERB
ajlm-2942	238	3	en	en	PROPN
ajlm-2942	238	4	,	,	PUNCT
ajlm-2942	238	5	wanjiku	wanjiku	PROPN
ajlm-2942	238	6	j	j	PROPN
ajlm-2942	238	7	,	,	PUNCT
ajlm-2942	238	8	gathenu	gathenu	PROPN
ajlm-2942	238	9	j	j	PROPN
ajlm-2942	238	10	,	,	PUNCT
ajlm-2942	238	11	et	et	PROPN
ajlm-2942	238	12	al	al	PROPN
ajlm-2942	238	13	.	.	PUNCT
ajlm-2942	239	1	prevalence	prevalence	NOUN
ajlm-2942	239	2	and	and	CCONJ
ajlm-2942	239	3	determinants	determinant	NOUN
ajlm-2942	239	4	of	of	ADP
ajlm-2942	239	5	cardiovascular	cardiovascular	ADJ
ajlm-2942	239	6	disease	disease	NOUN
ajlm-2942	239	7	risk	risk	NOUN
ajlm-2942	239	8	factors	factor	NOUN
ajlm-2942	239	9	among	among	ADP
ajlm-2942	239	10	adults	adult	NOUN
ajlm-2942	239	11	in	in	ADP
ajlm-2942	239	12	nairobi	nairobi	PROPN
ajlm-2942	239	13	,	,	PUNCT
ajlm-2942	239	14	kenya	kenya	PROPN
ajlm-2942	239	15	:	:	PUNCT
ajlm-2942	239	16	a	a	DET
ajlm-2942	239	17	cross	cross	ADJ
ajlm-2942	239	18	-	-	ADJ
ajlm-2942	239	19	sectional	sectional	ADJ
ajlm-2942	239	20	study	study	NOUN
ajlm-2942	239	21	.	.	PUNCT
ajlm-2942	240	1	east	east	PROPN
ajlm-2942	240	2	afr	afr	PROPN
ajlm-2942	240	3	med	med	PROPN
ajlm-2942	240	4	j.	j.	PROPN
ajlm-2942	240	5	2021;98(5):123–134	2021;98(5):123–134	PROPN
ajlm-2942	240	6	.	.	PUNCT
ajlm-2942	241	1	mensah	mensah	PROPN
ajlm-2942	241	2	ga	ga	PROPN
ajlm-2942	241	3	,	,	PUNCT
ajlm-2942	241	4	fuster	fuster	PROPN
ajlm-2942	241	5	v	v	PROPN
ajlm-2942	241	6	,	,	PUNCT
ajlm-2942	241	7	murray	murray	PROPN
ajlm-2942	241	8	cjl	cjl	PROPN
ajlm-2942	241	9	,	,	PUNCT
ajlm-2942	241	10	et	et	PROPN
ajlm-2942	241	11	al	al	PROPN
ajlm-2942	241	12	.	.	PUNCT
ajlm-2942	242	1	global	global	ADJ
ajlm-2942	242	2	burden	burden	NOUN
ajlm-2942	242	3	of	of	ADP
ajlm-2942	242	4	cardiovascular	cardiovascular	ADJ
ajlm-2942	242	5	diseases	disease	NOUN
ajlm-2942	242	6	and	and	CCONJ
ajlm-2942	242	7	risks	risk	NOUN
ajlm-2942	242	8	,	,	PUNCT
ajlm-2942	242	9	1990–2022	1990–2022	NOUN
ajlm-2942	242	10	.	.	PUNCT
ajlm-2942	243	1	lancet	lancet	NOUN
ajlm-2942	243	2	glob	glob	PROPN
ajlm-2942	243	3	health	health	NOUN
ajlm-2942	243	4	.	.	PUNCT
ajlm-2942	244	1	2019;7(10):e1375	2019;7(10):e1375	X
ajlm-2942	244	2	–	–	PUNCT
ajlm-2942	244	3	e1387	e1387	NOUN
ajlm-2942	244	4	.	.	PROPN
ajlm-2942	244	5	https://doi.org/10.1016/s2214-109x(19)30374-2	https://doi.org/10.1016/s2214-109x(19)30374-2	PROPN
ajlm-2942	244	6	thygesen	thygesen	PROPN
ajlm-2942	244	7	k	k	PROPN
ajlm-2942	244	8	,	,	PUNCT
ajlm-2942	244	9	alpert	alpert	PROPN
ajlm-2942	244	10	js	js	PROPN
ajlm-2942	244	11	,	,	PUNCT
ajlm-2942	244	12	jaffe	jaffe	PROPN
ajlm-2942	244	13	as	as	ADP
ajlm-2942	244	14	,	,	PUNCT
ajlm-2942	244	15	et	et	PROPN
ajlm-2942	244	16	al	al	PROPN
ajlm-2942	244	17	.	.	PROPN
ajlm-2942	245	1	third	third	ADJ
ajlm-2942	245	2	universal	universal	ADJ
ajlm-2942	245	3	definition	definition	NOUN
ajlm-2942	245	4	of	of	ADP
ajlm-2942	245	5	myocardial	myocardial	ADJ
ajlm-2942	245	6	infarction	infarction	NOUN
ajlm-2942	245	7	.	.	PUNCT
ajlm-2942	246	1	circulation	circulation	NOUN
ajlm-2942	246	2	.	.	PUNCT
ajlm-2942	247	1	2012;126(16):2020–2035	2012;126(16):2020–2035	X
ajlm-2942	247	2	.	.	PUNCT
ajlm-2942	248	1	https://doi.org/10.1161/cir.0b013e31826e1058	https://doi.org/10.1161/cir.0b013e31826e1058	PROPN
ajlm-2942	248	2	allain	allain	PROPN
ajlm-2942	248	3	cc	cc	PROPN
ajlm-2942	248	4	,	,	PUNCT
ajlm-2942	248	5	poon	poon	NOUN
ajlm-2942	248	6	ls	ls	PROPN
ajlm-2942	248	7	,	,	PUNCT
ajlm-2942	248	8	chan	chan	PROPN
ajlm-2942	248	9	cs	cs	PROPN
ajlm-2942	248	10	,	,	PUNCT
ajlm-2942	248	11	richmond	richmond	PROPN
ajlm-2942	248	12	w	w	PROPN
ajlm-2942	248	13	,	,	PUNCT
ajlm-2942	248	14	fu	fu	ADJ
ajlm-2942	248	15	pc	pc	NOUN
ajlm-2942	248	16	.	.	PUNCT
ajlm-2942	249	1	enzymatic	enzymatic	ADJ
ajlm-2942	249	2	determination	determination	NOUN
ajlm-2942	249	3	of	of	ADP
ajlm-2942	249	4	total	total	ADJ
ajlm-2942	249	5	serum	serum	NOUN
ajlm-2942	249	6	cholesterol	cholesterol	PROPN
ajlm-2942	249	7	.	.	PUNCT
ajlm-2942	250	1	clin	clin	PROPN
ajlm-2942	250	2	chem	chem	NOUN
ajlm-2942	250	3	.	.	PUNCT
ajlm-2942	251	1	1974;20(4):470–475	1974;20(4):470–475	NUM
ajlm-2942	251	2	.	.	PUNCT
ajlm-2942	252	1	https://doi.org/10.1093/clinchem/20.4.470	https://doi.org/10.1093/clinchem/20.4.470	NUM
ajlm-2942	252	2	bucolo	bucolo	PROPN
ajlm-2942	252	3	g	g	PROPN
ajlm-2942	252	4	,	,	PUNCT
ajlm-2942	252	5	david	david	PROPN
ajlm-2942	252	6	h.	h.	PROPN
ajlm-2942	252	7	quantitative	quantitative	ADJ
ajlm-2942	252	8	determination	determination	NOUN
ajlm-2942	252	9	of	of	ADP
ajlm-2942	252	10	serum	serum	NOUN
ajlm-2942	252	11	triglycerides	triglyceride	NOUN
ajlm-2942	252	12	by	by	ADP
ajlm-2942	252	13	the	the	DET
ajlm-2942	252	14	use	use	NOUN
ajlm-2942	252	15	of	of	ADP
ajlm-2942	252	16	enzymes	enzyme	NOUN
ajlm-2942	252	17	.	.	PUNCT
ajlm-2942	253	1	clin	clin	PROPN
ajlm-2942	253	2	chem	chem	PROPN
ajlm-2942	253	3	.	.	PUNCT
ajlm-2942	254	1	1973;19(5):476–482	1973;19(5):476–482	NUM
ajlm-2942	254	2	.	.	PUNCT
ajlm-2942	254	3	https://doi.org/10.1093/clinchem/19.5.476	https://doi.org/10.1093/clinchem/19.5.476	NUM
ajlm-2942	254	4	friedewald	friedewald	ADJ
ajlm-2942	254	5	wt	wt	NOUN
ajlm-2942	254	6	,	,	PUNCT
ajlm-2942	254	7	levy	levy	NOUN
ajlm-2942	254	8	ri	ri	PROPN
ajlm-2942	254	9	,	,	PUNCT
ajlm-2942	254	10	fredrickson	fredrickson	PROPN
ajlm-2942	254	11	ds	ds	PROPN
ajlm-2942	254	12	.	.	PROPN
ajlm-2942	254	13	estimation	estimation	NOUN
ajlm-2942	254	14	of	of	ADP
ajlm-2942	254	15	the	the	DET
ajlm-2942	254	16	concentration	concentration	NOUN
ajlm-2942	254	17	of	of	ADP
ajlm-2942	254	18	low	low	ADJ
ajlm-2942	254	19	-	-	PUNCT
ajlm-2942	254	20	density	density	NOUN
ajlm-2942	254	21	lipoprotein	lipoprotein	ADJ
ajlm-2942	254	22	cholesterol	cholesterol	NOUN
ajlm-2942	254	23	in	in	ADP
ajlm-2942	254	24	plasma	plasma	NOUN
ajlm-2942	254	25	,	,	PUNCT
ajlm-2942	254	26	without	without	ADP
ajlm-2942	254	27	the	the	DET
ajlm-2942	254	28	use	use	NOUN
ajlm-2942	254	29	of	of	ADP
ajlm-2942	254	30	the	the	DET
ajlm-2942	254	31	preparative	preparative	ADJ
ajlm-2942	254	32	ultracentrifuge	ultracentrifuge	NOUN
ajlm-2942	254	33	.	.	PUNCT
ajlm-2942	255	1	clin	clin	PROPN
ajlm-2942	255	2	chem	chem	PROPN
ajlm-2942	255	3	.	.	PUNCT
ajlm-2942	256	1	1972;18(6):499–502	1972;18(6):499–502	NUM
ajlm-2942	256	2	.	.	PUNCT
ajlm-2942	257	1	https://doi.org/10.1093/clinchem/18.6.499	https://doi.org/10.1093/clinchem/18.6.499	PROPN
ajlm-2942	258	1	sun	sun	PROPN
ajlm-2942	258	2	cj	cj	PROPN
ajlm-2942	258	3	,	,	PUNCT
ajlm-2942	258	4	mccudden	mccudden	ADJ
ajlm-2942	258	5	c	c	NOUN
ajlm-2942	258	6	,	,	PUNCT
ajlm-2942	258	7	brisson	brisson	NOUN
ajlm-2942	258	8	d	d	PROPN
ajlm-2942	258	9	,	,	PUNCT
ajlm-2942	258	10	shaw	shaw	PROPN
ajlm-2942	258	11	j	j	PROPN
ajlm-2942	258	12	,	,	PUNCT
ajlm-2942	258	13	gaudet	gaudet	PROPN
ajlm-2942	258	14	d	d	PROPN
ajlm-2942	258	15	,	,	PUNCT
ajlm-2942	258	16	ooi	ooi	PROPN
ajlm-2942	258	17	tc	tc	PROPN
ajlm-2942	258	18	.	.	PROPN
ajlm-2942	258	19	calculated	calculate	VERB
ajlm-2942	258	20	non	non	ADJ
ajlm-2942	258	21	-	-	ADJ
ajlm-2942	258	22	hdl	hdl	ADJ
ajlm-2942	258	23	cholesterol	cholesterol	NOUN
ajlm-2942	258	24	includes	include	VERB
ajlm-2942	258	25	cholesterol	cholesterol	NOUN
ajlm-2942	258	26	in	in	ADP
ajlm-2942	258	27	larger	large	ADJ
ajlm-2942	258	28	triglyceride	triglyceride	ADJ
ajlm-2942	258	29	-	-	PUNCT
ajlm-2942	258	30	rich	rich	ADJ
ajlm-2942	258	31	lipoproteins	lipoprotein	NOUN
ajlm-2942	258	32	in	in	ADP
ajlm-2942	258	33	hypertriglyceridemia	hypertriglyceridemia	NOUN
ajlm-2942	258	34	.	.	PUNCT
ajlm-2942	259	1	j	j	PROPN
ajlm-2942	259	2	endocr	endocr	PROPN
ajlm-2942	259	3	soc	soc	PROPN
ajlm-2942	259	4	.	.	PUNCT
ajlm-2942	260	1	2019;4(1):bvz010	2019;4(1):bvz010	NUM
ajlm-2942	260	2	.	.	PUNCT
ajlm-2942	261	1	https://doi.org/10.1210/jendso/bvz010	https://doi.org/10.1210/jendso/bvz010	PROPN
ajlm-2942	261	2	olamoyegun	olamoyegun	VERB
ajlm-2942	261	3	m	m	PROPN
ajlm-2942	261	4	,	,	PUNCT
ajlm-2942	261	5	oluyombo	oluyombo	ADJ
ajlm-2942	261	6	r	r	NOUN
ajlm-2942	261	7	,	,	PUNCT
ajlm-2942	261	8	asaolu	asaolu	PROPN
ajlm-2942	261	9	s.	s.	PROPN
ajlm-2942	261	10	evaluation	evaluation	NOUN
ajlm-2942	261	11	of	of	ADP
ajlm-2942	261	12	dyslipidemia	dyslipidemia	NOUN
ajlm-2942	261	13	,	,	PUNCT
ajlm-2942	261	14	lipid	lipid	NOUN
ajlm-2942	261	15	ratios	ratio	NOUN
ajlm-2942	261	16	,	,	PUNCT
ajlm-2942	261	17	and	and	CCONJ
ajlm-2942	261	18	atherogenic	atherogenic	ADJ
ajlm-2942	261	19	index	index	NOUN
ajlm-2942	261	20	as	as	ADP
ajlm-2942	261	21	cardiovascular	cardiovascular	ADJ
ajlm-2942	261	22	risk	risk	NOUN
ajlm-2942	261	23	factors	factor	NOUN
ajlm-2942	261	24	among	among	ADP
ajlm-2942	261	25	semi	semi	ADJ
ajlm-2942	261	26	-	-	ADJ
ajlm-2942	261	27	urban	urban	ADJ
ajlm-2942	261	28	dwellers	dweller	NOUN
ajlm-2942	261	29	in	in	ADP
ajlm-2942	261	30	nigeria	nigeria	PROPN
ajlm-2942	261	31	.	.	PUNCT
ajlm-2942	262	1	ann	ann	PROPN
ajlm-2942	262	2	afr	afr	PROPN
ajlm-2942	262	3	med	med	PROPN
ajlm-2942	262	4	.	.	PUNCT
ajlm-2942	263	1	2016;15(4):194–199	2016;15(4):194–199	X
ajlm-2942	263	2	.	.	PUNCT
ajlm-2942	264	1	https://doi.org/10.4103/1596-3519.194280	https://doi.org/10.4103/1596-3519.194280	ADJ
ajlm-2942	264	2	hidaka	hidaka	ADJ
ajlm-2942	264	3	h	h	NOUN
ajlm-2942	264	4	,	,	PUNCT
ajlm-2942	264	5	yamauchi	yamauchi	PROPN
ajlm-2942	264	6	k	k	PROPN
ajlm-2942	264	7	,	,	PUNCT
ajlm-2942	264	8	ohta	ohta	VERB
ajlm-2942	264	9	h	h	NOUN
ajlm-2942	264	10	,	,	PUNCT
ajlm-2942	264	11	akamatsu	akamatsu	PROPN
ajlm-2942	264	12	t	t	PROPN
ajlm-2942	264	13	,	,	PUNCT
ajlm-2942	264	14	honda	honda	PROPN
ajlm-2942	264	15	t	t	PROPN
ajlm-2942	264	16	,	,	PUNCT
ajlm-2942	264	17	katsuyama	katsuyama	PROPN
ajlm-2942	264	18	t.	t.	PROPN
ajlm-2942	264	19	specific	specific	ADJ
ajlm-2942	264	20	,	,	PUNCT
ajlm-2942	264	21	rapid	rapid	ADJ
ajlm-2942	264	22	,	,	PUNCT
ajlm-2942	264	23	and	and	CCONJ
ajlm-2942	264	24	sensitive	sensitive	ADJ
ajlm-2942	264	25	enzymatic	enzymatic	ADJ
ajlm-2942	264	26	measurement	measurement	NOUN
ajlm-2942	264	27	of	of	ADP
ajlm-2942	264	28	sphingomyelin	sphingomyelin	NOUN
ajlm-2942	264	29	,	,	PUNCT
ajlm-2942	264	30	phosphatidylcholine	phosphatidylcholine	NOUN
ajlm-2942	264	31	and	and	CCONJ
ajlm-2942	264	32	lysophosphatidylcholine	lysophosphatidylcholine	VERB
ajlm-2942	264	33	in	in	ADP
ajlm-2942	264	34	serum	serum	NOUN
ajlm-2942	264	35	and	and	CCONJ
ajlm-2942	264	36	lipid	lipid	ADJ
ajlm-2942	264	37	extracts	extract	NOUN
ajlm-2942	264	38	.	.	PUNCT
ajlm-2942	265	1	clin	clin	PROPN
ajlm-2942	265	2	biochem	biochem	PROPN
ajlm-2942	265	3	.	.	PUNCT
ajlm-2942	266	1	2008;41(14–15):1211–1217	2008;41(14–15):1211–1217	PROPN
ajlm-2942	266	2	.	.	PUNCT
ajlm-2942	267	1	https://doi.org/10.1016/j.clinbiochem.2008.06.010	https://doi.org/10.1016/j.clinbiochem.2008.06.010	PROPN
ajlm-2942	267	2	yamaguchi	yamaguchi	PROPN
ajlm-2942	267	3	y.	y.	PROPN
ajlm-2942	267	4	determination	determination	NOUN
ajlm-2942	267	5	of	of	ADP
ajlm-2942	267	6	high	high	ADJ
ajlm-2942	267	7	-	-	PUNCT
ajlm-2942	267	8	density	density	NOUN
ajlm-2942	267	9	lipoprotein	lipoprotein	ADJ
ajlm-2942	267	10	phospholipids	phospholipid	NOUN
ajlm-2942	267	11	in	in	ADP
ajlm-2942	267	12	serum	serum	NOUN
ajlm-2942	267	13	.	.	PUNCT
ajlm-2942	268	1	clin	clin	PROPN
ajlm-2942	268	2	chem	chem	NOUN
ajlm-2942	268	3	.	.	PUNCT
ajlm-2942	269	1	1980;26(9):1275–1277	1980;26(9):1275–1277	NOUN
ajlm-2942	269	2	.	.	PUNCT
ajlm-2942	270	1	https://doi.org/10.1093/clinchem/26.9.1275	https://doi.org/10.1093/clinchem/26.9.1275	PROPN
ajlm-2942	270	2	engvall	engvall	PROPN
ajlm-2942	270	3	e	e	PROPN
ajlm-2942	270	4	,	,	PUNCT
ajlm-2942	270	5	perlmann	perlmann	NOUN
ajlm-2942	270	6	p.	p.	NOUN
ajlm-2942	270	7	enzyme	enzyme	NOUN
ajlm-2942	270	8	-	-	PUNCT
ajlm-2942	270	9	linked	link	VERB
ajlm-2942	270	10	immunosorbent	immunosorbent	NOUN
ajlm-2942	270	11	assay	assay	PROPN
ajlm-2942	270	12	(	(	PUNCT
ajlm-2942	270	13	elisa	elisa	NOUN
ajlm-2942	270	14	)	)	PUNCT
ajlm-2942	270	15	.	.	PUNCT
ajlm-2942	271	1	quantitative	quantitative	ADJ
ajlm-2942	271	2	assay	assay	PROPN
ajlm-2942	271	3	of	of	ADP
ajlm-2942	271	4	immunoglobulin	immunoglobulin	PROPN
ajlm-2942	271	5	g.	g.	PROPN
ajlm-2942	271	6	immunochemistry	immunochemistry	PROPN
ajlm-2942	271	7	.	.	PUNCT
ajlm-2942	272	1	1971;8(9):871–874	1971;8(9):871–874	X
ajlm-2942	272	2	.	.	PUNCT
ajlm-2942	273	1	https://doi.org/10.1016/0019-2791(71)90454-x	https://doi.org/10.1016/0019-2791(71)90454-x	PROPN
ajlm-2942	273	2	nacarelli	nacarelli	PROPN
ajlm-2942	273	3	gs	gs	PROPN
ajlm-2942	273	4	,	,	PUNCT
ajlm-2942	273	5	fasolino	fasolino	PROPN
ajlm-2942	273	6	t	t	PROPN
ajlm-2942	273	7	,	,	PUNCT
ajlm-2942	273	8	davis	davis	PROPN
ajlm-2942	273	9	s.	s.	PROPN
ajlm-2942	273	10	dietary	dietary	PROPN
ajlm-2942	273	11	,	,	PUNCT
ajlm-2942	273	12	macronutrient	macronutrient	NOUN
ajlm-2942	273	13	,	,	PUNCT
ajlm-2942	273	14	micronutrient	micronutrient	NOUN
ajlm-2942	273	15	,	,	PUNCT
ajlm-2942	273	16	and	and	CCONJ
ajlm-2942	273	17	nutrigenetic	nutrigenetic	ADJ
ajlm-2942	273	18	factors	factor	NOUN
ajlm-2942	273	19	impacting	impact	VERB
ajlm-2942	273	20	cardiovascular	cardiovascular	ADJ
ajlm-2942	273	21	risk	risk	NOUN
ajlm-2942	273	22	markers	marker	NOUN
ajlm-2942	273	23	apolipoprotein	apolipoprotein	ADJ
ajlm-2942	273	24	b	b	PROPN
ajlm-2942	273	25	and	and	CCONJ
ajlm-2942	273	26	apolipoprotein	apolipoprotein	ADJ
ajlm-2942	273	27	a1	a1	PROPN
ajlm-2942	273	28	:	:	PUNCT
ajlm-2942	273	29	a	a	DET
ajlm-2942	273	30	narrative	narrative	NOUN
ajlm-2942	273	31	review	review	NOUN
ajlm-2942	273	32	.	.	PUNCT
ajlm-2942	274	1	nutr	nutr	PROPN
ajlm-2942	274	2	rev	rev	PROPN
ajlm-2942	274	3	.	.	PROPN
ajlm-2942	275	1	2024;82(7):949–962	2024;82(7):949–962	NUM
ajlm-2942	275	2	.	.	PUNCT
ajlm-2942	275	3	https://doi.org/10.1093/nutrit/nuad102	https://doi.org/10.1093/nutrit/nuad102	PROPN
ajlm-2942	276	1	wan	wan	PROPN
ajlm-2942	276	2	h	h	PROPN
ajlm-2942	276	3	,	,	PUNCT
ajlm-2942	276	4	wu	wu	PROPN
ajlm-2942	276	5	h	h	PROPN
ajlm-2942	276	6	,	,	PUNCT
ajlm-2942	276	7	wei	wei	PROPN
ajlm-2942	276	8	y	y	PROPN
ajlm-2942	276	9	,	,	PUNCT
ajlm-2942	276	10	et	et	PROPN
ajlm-2942	276	11	al	al	PROPN
ajlm-2942	276	12	.	.	PROPN
ajlm-2942	276	13	novel	novel	ADJ
ajlm-2942	276	14	lipid	lipid	NOUN
ajlm-2942	276	15	profiles	profile	NOUN
ajlm-2942	276	16	and	and	CCONJ
ajlm-2942	276	17	atherosclerotic	atherosclerotic	ADJ
ajlm-2942	276	18	cardiovascular	cardiovascular	ADJ
ajlm-2942	276	19	disease	disease	NOUN
ajlm-2942	276	20	risk	risk	NOUN
ajlm-2942	276	21	:	:	PUNCT
ajlm-2942	276	22	insights	insight	NOUN
ajlm-2942	276	23	from	from	ADP
ajlm-2942	276	24	a	a	DET
ajlm-2942	276	25	latent	latent	NOUN
ajlm-2942	276	26	profile	profile	NOUN
ajlm-2942	276	27	analysis	analysis	NOUN
ajlm-2942	276	28	.	.	PUNCT
ajlm-2942	277	1	lipids	lipids	ADP
ajlm-2942	277	2	health	health	NOUN
ajlm-2942	277	3	dis	dis	PROPN
ajlm-2942	277	4	.	.	PUNCT
ajlm-2942	278	1	2025;24:71	2025;24:71	NUM
ajlm-2942	278	2	.	.	PUNCT
ajlm-2942	279	1	https://doi.org/10.1186/s12944-025-02471-3	https://doi.org/10.1186/s12944-025-02471-3	NUM
ajlm-2942	279	2	abera	abera	VERB
ajlm-2942	279	3	a	a	X
ajlm-2942	279	4	,	,	PUNCT
ajlm-2942	279	5	worede	worede	NOUN
ajlm-2942	279	6	a	a	PRON
ajlm-2942	279	7	,	,	PUNCT
ajlm-2942	279	8	hirigo	hirigo	NOUN
ajlm-2942	279	9	at	at	ADP
ajlm-2942	279	10	,	,	PUNCT
ajlm-2942	279	11	alemayehu	alemayehu	PROPN
ajlm-2942	279	12	r	r	NOUN
ajlm-2942	279	13	,	,	PUNCT
ajlm-2942	279	14	ambachew	ambachew	ADV
ajlm-2942	279	15	s.	s.	PROPN
ajlm-2942	279	16	dyslipidemia	dyslipidemia	PROPN
ajlm-2942	279	17	and	and	CCONJ
ajlm-2942	279	18	associated	associated	ADJ
ajlm-2942	279	19	factors	factor	NOUN
ajlm-2942	279	20	among	among	ADP
ajlm-2942	279	21	adult	adult	NOUN
ajlm-2942	279	22	cardiac	cardiac	ADJ
ajlm-2942	279	23	patients	patient	NOUN
ajlm-2942	279	24	:	:	PUNCT
ajlm-2942	279	25	a	a	DET
ajlm-2942	279	26	hospital	hospital	NOUN
ajlm-2942	279	27	-	-	PUNCT
ajlm-2942	279	28	based	base	VERB
ajlm-2942	279	29	comparative	comparative	ADJ
ajlm-2942	279	30	cross	cross	ADJ
ajlm-2942	279	31	-	-	ADJ
ajlm-2942	279	32	sectional	sectional	ADJ
ajlm-2942	279	33	study	study	NOUN
ajlm-2942	279	34	.	.	PUNCT
ajlm-2942	280	1	eur	eur	PROPN
ajlm-2942	280	2	j	j	PROPN
ajlm-2942	280	3	med	med	PROPN
ajlm-2942	280	4	res	re	NOUN
ajlm-2942	280	5	.	.	PUNCT
ajlm-2942	281	1	2024;29(1):237	2024;29(1):237	NUM
ajlm-2942	281	2	.	.	PUNCT
ajlm-2942	282	1	https://doi.org/10.1186/s40001-024-01802-x	https://doi.org/10.1186/s40001-024-01802-x	PROPN
ajlm-2942	282	2	palasubramaniam	palasubramaniam	PROPN
ajlm-2942	282	3	j	j	PROPN
ajlm-2942	282	4	,	,	PUNCT
ajlm-2942	282	5	wang	wang	PROPN
ajlm-2942	282	6	x	x	PROPN
ajlm-2942	282	7	,	,	PUNCT
ajlm-2942	282	8	peter	peter	PROPN
ajlm-2942	282	9	k.	k.	PROPN
ajlm-2942	282	10	myocardial	myocardial	PROPN
ajlm-2942	282	11	infarction	infarction	NOUN
ajlm-2942	282	12	–	–	PUNCT
ajlm-2942	282	13	from	from	ADP
ajlm-2942	282	14	atherosclerosis	atherosclerosis	NOUN
ajlm-2942	282	15	to	to	PART
ajlm-2942	282	16	thrombosis	thrombosis	VERB
ajlm-2942	282	17	.	.	PUNCT
ajlm-2942	283	1	arterioscler	arterioscler	PROPN
ajlm-2942	283	2	thromb	thromb	PROPN
ajlm-2942	283	3	vasc	vasc	PROPN
ajlm-2942	283	4	biol	biol	PROPN
ajlm-2942	283	5	.	.	PUNCT
ajlm-2942	284	1	2019;39(8):e176	2019;39(8):e176	NOUN
ajlm-2942	284	2	–	–	PUNCT
ajlm-2942	284	3	e185	e185	NUM
ajlm-2942	284	4	.	.	PUNCT
ajlm-2942	285	1	https://doi.org/10.1161/atvbaha.119.312578	https://doi.org/10.1161/atvbaha.119.312578	PROPN